Table of Contents
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended May 31, 2017

2022
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
15
(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For The Transition Period From
To
.

COMMISSION FILE NUMBER0-17988

NEOGEN CORPORATION

(Exact name of registrant as specified in its charter)

MICHIGAN
 
38-2367843

(State orof other jurisdiction of


incorporation or organization)


 

(I.R.S. Employer


Identification No.)


620 Lesher Place

Lansing, Michigan 48912

(Address of principal executive offices, including zip code)

517-372-9200

(Registrant’s telephone number, including area code)

SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT: NONE

Title of each Class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.16 par value per shareNEOGNASDAQ Global Select Market
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT:

COMMON STOCK, $0.16 par value per share

(Title of Class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ☒    No  ☐

Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ☐    No  ☒

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of RegulationS-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ☒    No  ☐

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
 Yes  ☒
    No  ☐

Indicate by check mark if disclosure of delinquent filerswhether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to ItemRule 405 of RegulationS-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III S-T (§ 232.405 of this Form10-K or any amendmentchapter) during the preceding 12 months (or for such shorter period that the registrant was required to this Form10-K.submit such files).
 Yes  ☒
    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or anon-accelerated filer.an emerging growth company. See definitionthe definitions of “accelerated filer and large“large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule
12b-2
of the Exchange Act.

(Check one):

Large accelerated filer

  Accelerated filer  ☐ 
Non-accelerated filer  Smaller reporting company

Emerging growth company  ☐

   Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☒
Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Act).
 Yes  ☐    No  ☒

Based on the closing sale price on November 30, 20162021 the aggregate market value of the voting stock held bynon-affiliates of the registrant was $2,403,000,000.$4,324,743,564. For these purposes, the registrant considers its Directors and executive officers to be its only affiliates.

The number of outstanding shares of the registrant’s Common Stock was 38,211,873107,837,730 on June 30, 2017.


2022.

DOCUMENTS INCORPORATED BY REFERENCE

The Registrant’s

Certain portions of the registrant’s definitive proxy statement to be prepared pursuant to Regulation 14a and filed in connection with solicitation of proxies for its October 5, 20176, 2022 annual meeting of shareholders isare incorporated by reference into part III of thisthe Form
10-K.


Table of Contents
TABLE OF CONTENTS

ITEM 1.
4
3
ITEM 1A.
13
14
ITEM 1B.
17
23
ITEM 2.
17
23
ITEM 3.
17
23
ITEM 4.
18
23
PART II
ITEM 5.
18
24
ITEM 6.
20
26
ITEM 7.
21
26
ITEM 7A.
31
38
ITEM 8.
31
38
ITEM 9.
31
38
ITEM 9A.
31
38
ITEM 9B.
33
41
PART III
ITEM 9C.
41
ITEM 10.
33
42
ITEM 11.
35
44
ITEM 12.
35
44
ITEM 13.
35
44
ITEM 14.
35
44
ITEM 15.
44
PART IV
ITEM 16.
44
ITEM 15.EXHIBITS, FINANCIAL STATEMENT SCHEDULES35
37
46
F-1
Subsidiaries
Subsidiaries
Consent of independent registered public accounting firm — BDO USA, LLP
Section 302 Certification of Principal Executive Officer
Section 302 Certification of Principal Financial Officer
Section 1350 Certification pursuant to Section 906

1

Table of Contents
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Annual Report on Form
10-K,
including statements relating to management’s expectations regarding new product introductions; the adequacy of the Company’sour sources for certain components, raw materials and finished products; and the Company’sour ability to utilize certain inventory. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may differ materially from those described in the forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, effects of the ongoing
COVID-19
pandemic on our business, global business disruption caused by the Russian invasion in Ukraine and related sanctions, results of operations, liquidity, financial condition and stock price, inflation, supply chain, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation, risks related to completion of the 3M transaction, and other risks detailed in item 1A. RISK FACTORS in this Form
10-K
and from time to time in the Company’s reports on file at the Securities and Exchange Commission (SEC), that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in ITEM 1A. RISK FACTORS and under the captions “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” “Critical Accounting Policies and Estimates,” and “Future Operating Results.”

statements.

In addition, any forward-looking statements represent management’s views only as of the day this Annual Report on Form
10-K
was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

As used in this Annual Report on Form
10-K,
the terms “Neogen,” “the Company,” “we,” “us,” and “our” refer to Neogen Corporation and, where appropriate, its consolidated subsidiaries, unless the context indicates otherwise.
2

Table of Contents
PART I

ITEM 1.
BUSINESS

Neogen Corporation and subsidiaries (Neogen or the Company) develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. The Company’sOur Food Safety segment consists primarily of diagnostic test kits and complementary products (e.g., dehydrated culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant
by-products,
meat speciation, drug residues, pesticide residues and general sanitation concerns. TheOur diagnostic test kits are generally less expensive, easier to use and provide greater accuracy and speed than conventional diagnostic methods. The majority of the teststest kits are disposable,
single-use,
immunoassay and DNA detection products that rely on the Company’s proprietary antibodies and RNA and DNA testing methodologies to produce rapid and accurate test results. The Company’sOur expanding line of food safety products also includes bioluminescence-basedgenomics-based diagnostic technology.

technology, and advanced software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

On December 13, 2021, Neogen and 3M announced plans to merge 3M’s Food Safety business with Neogen in a Reverse Morris Trust transaction. The transaction is expected to close by the end of the third calendar quarter of 2022. See Note 3, Business Combinations, to the consolidated financial statements for further discussion.
Neogen’s Animal Safety segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the worldwide animal safety market. The majority of these consumable products are marketed through a network of nationalveterinarians, retailers, livestock producers and international distributors, as well as a number of large farm supply retail chains in the United States and Canada. The Company’s USDA-licensed facility in Lansing, Michigan, produces immunostimulant products for horses and dogs, and a unique equine botulism vaccine. The Company’sanimal health product distributors. Our line of drug detection products is sold worldwide for the detection of abused and therapeutic drugs in animals and animal products, and has expanded into the workplace and human forensic market.

markets.

Neogen’s products are marketed by Companyour sales personnel in the U.S., Canada, Mexico, Central America, Brazil, Argentina, Uruguay, Chile, the United Kingdom, and other parts of Europe, Brazil,the European Union, China, India and Australia, and by distributors throughout the rest of the world.

Neogen’s

Our mission is to be the leading company in the development and marketing of solutions for food and animal safety. To meet this vision,mission, a growth strategy consisting of the following elements has been developed: (i) increasing sales of existing products; (ii) introducing newinnovative products and product lines;services; (iii) expandinggrowing international sales; and (iv) acquiring businesses and forming strategic alliances. The Company hasWe have historically been successful at increasing product sales organically, including international growth, and maintainsmaintain an active acquisition program to identify and capitalize on opportunities to acquire new products, and/businesses, or businesses.

technology.

Neogen Corporation was formed as a Michigan corporation in June 1981 and actual operations began in 1982. The Company’sOur principal executive offices are located at 620 Lesher Place, Lansing, Michigan 48912-1595 and itsour telephone number is
(517) 372-9200.

Neogen’s Annual Report on Form
10-K,
Quarterly Reports on Form
10-Q,
Current Reports on Form
8-K,
and amendments to those reports are available free of charge via our website (
www.neogen.com
) as soon as reasonably practicable after such information is filed with, or furnished to, the United States Securities and Exchange Commission.

The content of our website or the website of any third party that may be noted herein is not incorporated by reference in this Form

10-K.
PRODUCTS

Product trademarks and registered trademarks owned by Neogen include:
CORPORATE:
Neogen
®
, Neogen flask logo(logo)
®;
, Neogen and flask (logo)
®
, NeoCenter
FOOD SAFETY:
AccuClean
®
, AccuPoint
®
, AccuScan
®
, Acumedia
®
, Agri-Screen
®
, Alert
®
, ANSR
®
, BetaStar
®
, BioLumix
®
, Ceralpha
®
, Colitag
, F.A.S.T.
®
, GeneQuence
®
, GENE-TRAK
®
, HarlequinTM
®
,
ISO-GRID
®
, Lab M
®
,
Listeria
Right Now
, NeoCare™Megazyme
®
, NeoColumn™Megazyme (design)
®
NeoFilm®MPNPlate
, NeoNet™MPNTray
, NeoSeek™NeoCare
, NeoColumn
, NeoNet
®
, NeoSeek
,
NEO-GRID
®
, Penzyme
®
, Raptor™Raptor
®
, Reveal
®
, Soleris
®
, µPREP
®
, Veratox
®
, Simple. Accurate. Supported. Food Safety Solutions
SM;
LIFE SCIENCES:
Alert
®
,
K-Blue
®
,K-Blue Substrate
K-Gold
®, K-Gold®
, NeoSal
®;
ANIMAL SAFETY:Acid-A-Foam™
Acid-A-Foam
, Aero-ssault™,
Ag-Tek
®
, AluShield™AluShield
, AquaPrime
®
, Assault
®
, Barnstorm™Barnstorm
®
, BioCres™ BioCres
50, BioPhene™BioPhene
, BioQuat™BioQuat
, BotVax
®
, Breeder-Sleeve
®, Bromethalin One Meal Is All It Takes(design)®
, Calf Eze™Eze
, Chem-Tech, Ltd.
, Chem-Tech’s CT logo (with circle)
,Chlor-A-Foam™, COMPANION™
Chlor-A-Foam
, Cowboy SyringeCOMPANION
,
CT-511
®,CT-511®
, Cykill™Cykill
, D3™ D3
Needles, DC&R
®
, DeciMax
®
,
Di-Kill
®
, Dr. Frank’s
®
,
Dy-Fly
®,Dyne-O-Might®
, Earth City Resources (design)DX3
,
Dyne-O-Might
®
, ElectroJac
®
, ELISA Technologies (design)
®
, EqStim
®
, EquiSleeve
®
,
E-Z Bond™
Bond
,
E-Z
Catch
®
, Farm-Foam
, Farmphene
®
,
Final-Fly-T
®
,
Fly-Die Defense™
Defense
,
Fly-Die
Ultra
, Fura-Zone
®
, GenQuat™GenQuat
, Horse Sense
®
, Ideal
®
, ImmunoRegulin
®, Insectrin®, Insight™
, Iodis
®
, Jolt
®
,
LD-44
®
,LD-44T™
LD-44T
,
MACLEOD
®
, Maxi Sleeve
®
, MaxKlor
®
, MegaShot™MegaShot
,
®
Viroxide Super
, MycAseptic™Neogen
®
Viroxide Super and flask (design)
®
, NeedleGard™, NFZ™NFZ
, Nu Dyne
®
, PanaKare™PanaKare
, Pantek™Pantek
, ParlorMint™Paradefense
®
, ParlorMint
, Parvosol
®
, Peraside
, Place Pack
®
, PolyPetite™PolyPetite
, PolyShield™PolyShield
, PolySleeve
®
, Preserve™Preserve
®
, Preserve International™International
®
, Preserve International(design)
®
, Prima
®
, Prima Marc™Marc
, Prima®
3

Table of Contents
Prima-Shot
, Prima Tech
®
,
Pro-Fix
®
,
Pro-Flex
®
, Prima Tech logo®Promar
,Pro-Fix®
Pro-Shot
,Pro-Flex®, Promar™,Pro-Shot™,
PRO-TECT
6 MIL
®
,PRO-TECT 6 MIL logo Protectus
, Provecta Advanced
®
, Prozap
®
, Prozap (stylized mark w/fancy Z)
,PY-75™, Quat-Chem™
PY-75
, Ramik
®
, Rat &Mouse-A-Rest II®RenaKare
, RenaKare™Rodex
,
Safe-T-Flex
, Rodent Elimination Station™Siloxycide
®
, Rodex™,Rot-Not™,Safe-T-Flex™, Siloxycide®, Spectrasol™, Spec-Tuss™Spectrasol
, Squire
®
, Standguard
®
, Starlicide
®
,
Stress-Dex
®
, SureBond
®
, SureKill
®
,Swine-O-Dyne™, Synergize
Swine-O-Dyne
®
, SyrVetSynergize
®
, Tetrabase™Tetrabase
®
, Tetracid
®,Tetradyne™
, ThyroKare™Tetradyne
®
, TopHoof™ThyroKare
,
Tri-Hist
®
,Tri-Seal™, Tryad Paradefense
®
, Turbocide
®
, Turbocide Gold
®
, Uniprim
®
, UriKare™
VAP-5
,VAP-5™
VAP-20
,VAP-20™
Vet-Tie
,Vet-Tie™
Vita-15
,Vita-15™,
War Paint
®
,
X-185
GENOMICS:
Deoxi
, We keep ‘em movin’®,X-185™, Zipcide®;GENOMICS: Deoxi™Envigor
, GeneSeek
®
, Genomic Profiler™Profiler
, Genomic SolutionsInsight for Food Security®Personalized Care
, Igenity
®
, SeekGain™Infiniseek
, SeekSire™SeekGain
, SeekTrace™SeekSire
,Tru-Polled®;LOGOTYPES: Skimseek
, Early Warning
LOGOTYPES:
BioSentry barn logo
®
, BioSentry chicken logo
®
, BioSentry pig logo
®
, Circular design
®
, TurboCide
®
(stylized).

, D3 color mark – red

®
Neogen operates in two business areas: the Food Safety and the Animal Safety segments. See Notesthe “Notes to Consolidated Financial Statements elsewhere inStatements” section of this Form
10-K
for financial information about the Company’sour business segments and international operations.

FOOD SAFETY SEGMENT

Neogen’s Food Safety segment is primarily engaged in the production and marketing of diagnostic test kits and complementary products marketed to food and feed producers and processors to detect dangerous and/or unintended substances in food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant
by-products,
meat speciation, drug residues, pesticide residues and general sanitation concerns.

Our test kits are used to detect potential hazards or unintended substances in food and animal feed by testers ranging from small local grain elevators to the largest, best-known food and feed processors in the world, and numerous regulatory agencies. Neogen’s products include tests for:

Mycotoxins.
Grain producers and processors of all types and sizes use the Company’sour Veratox, Agri-Screen, Reveal, Reveal Q+ and Reveal Q+ MAX tests to detect the presence of mycotoxins, including aflatoxin, aflatoxin M1, deoxynivalenol, fumonisin, ochratoxin, zearalenone,
T-2/HT-2
toxin andT-2/HT-2 toxin, ergot alkaloid, to help ensure product safety and quality in food and animal feed.

Food allergens.
The world’s largest producers of cookies, crackers, candy, ice cream and many other processed foods use the Company’sour Veratox, Alert, Reveal, Reveal
3-D
and BioKits testing products for food allergens to help protect their food-allergic customers from the inadvertent contamination of products with food allergens, such asincluding but not limited to peanut, milk, egg, almond, gliadin (gluten), soy, hazelnut and hazelnutcoconut residues.

Dairy antibiotics. Dairies
Dairy processors are the primary users of Neogen’s BetaStar BetaStar Combo, BetaStar 4D and Penzyme diagnostic tests to detect the presence of beta-lactam and tetracyclineveterinary antibiotics in milk. The presence of these drugs above a certain level in milk is a public health hazard and an economic risk to processorsproducers as it limits the milk’s further processing.

Foodborne pathogens.
Meat and poultry processors, seafood processors, fruit and vegetable producers and many other market segments are the primary users of Neogen’s ANSR and Reveal tests for foodborne bacteria, including
E. coli
O157:H7,
Salmonella
,
Listeria
and
Campylobacter
. Neogen’s ANSR pathogen detection system is an isothermal amplification reaction test method whichthat exponentially amplifies the DNA of any bacteria present in food and environmental samples to detectable levels in 10 minutes. Combined with ANSR’s single enrichment step, Neogen’s pathogen detection method provides
DNA-definitive
results in a fraction of the time of other molecular detection methods. Our
Listeria
Right Now test detects the pathogen in less than 60 minutes without sample enrichment. Reveal’s lateral flow device combines an immunoassay with chromatography for a rapid and accurate
one-step
result.

Spoilage microorganisms.
Neogen’s Soleris and BioLumix products are used by food processors to identify the presence of spoilage organisms (e.g., yeast and mold) and other microbiological contamination in food. The systems measure microbial growth by monitoring biochemical reactions that generate a color change in the media as microorganisms grow. The sensitivity of the system allows detection in a fraction of the time needed for traditional methods, with less labor and handling time.

In July 2020, we launched Soleris NG, a next generation version of the platform, which features enhanced hardware and software for results that are easier to analyze and audit. Our NeoSeek genomics services utilize a novel application of metagenomics to determine all bacteria in a sample, without introducing biases from culture media, and without the need to generate a bacterial isolate for each possible microbe in a sample.

Sanitation monitoring.
Neogen manufactures and markets itsour AccuPoint Advanced rapid sanitation test forto detect the presence of adenosine triphosphate (ATP), a chemical found in all living cells. This
easy-to-use
and inexpensive test uses bioluminescence to quickly determine if a contact surface has been completely sanitized. When ATP comes into contact with the reagents contained in the test device, a reaction takes place that produces light. More light is indicative of higher levels of ATP and a need for more thorough sanitation. The Company’sIn May 2021, we launched AccuPoint Advanced NG, a next generation version, designed to be simpler to use, and provide results that are easier to analyze. Our worldwide customer base for its ATP sanitation testing products includes food and beverage processors, the food service and healthcare industries, as well as many other users.

Dehydrated culture media.Neogen’s Acumedia and Lab M products offer dehydrated culture media for varied purposes, including traditional bacterial testing and the growth of beneficial bacteria, such as cultures for sausages and beer. The Company’s customers for dehydrated culture media also include commercial and research laboratories and producers of pharmaceuticals, cosmetics and veterinary vaccines.

Seafood contaminants.
Neogen’s specialty products for the seafood market include tests for histamine, a highly allergenic substance that occurs when certain species of fish begin to decay; chloramphenicol, a banned antibiotic in most of the world, but still used by some shrimp farmers to improve the yield of their products; sulfite, an effective but potentially allergenic shrimp preservative; and shellfish toxins.

Neogen’s Reveal lateral

4

Table of Contents
flow tests for shellfish toxins include rapid tests to detect the toxins that cause amnesic shellfish poisoning (ASP), diarrhetic shellfish poisoning (DSP) and paralytic shellfish poisoning (PSP).
Waterborne microorganisms.
Neogen offers the food and beverage industries, including water companies, several platforms for performing the microbial analysis of water. This includes Neogen’s filter tests, which are a combination of Neogen Filter membrane filtration and Neogen Culture Media ampouled media, and an
easy-to-use
Colitag product. With Colitag, after an incubation period, the sample changes color in the presence of coliforms and fluoresces in the presence of
E. coli
.
Culture media.
Neogen Culture Media, formerly Neogen’s Acumedia and Lab M products, offers culture media and prepared media for varied purposes, including traditional bacterial testing and the growth of beneficial bacteria, such as cultures for sausages and beer. Our customers for culture media also include commercial and research laboratories and producers of pharmaceuticals, cosmetics and veterinary vaccines.
Food quality diagnostics.
Through the December 2020 acquisition of Ireland-based Megazyme, Ltd., Neogen supplies diagnostic kits and specialty enzymes used worldwide by quality control laboratories in the food, animal feed and beverage industries. Megazyme’s validated assays and reagents are used across various food industries such as the grain, wine and dairy markets, to measure dietary fibers, complex carbohydrates, simple sugars and organic acids, such as lactose.
Digital services.
Our food safety and risk management
software-as-a-service,
Neogen Analytics, delivers a comprehensive Environmental Monitoring Program (EMP) automation solution for food companies. The software reduces risk by increasing visibility to food safety testing results, elevating the ability to enforce and improve food safety standards. Neogen Analytics builds upon innovative technologies like our AccuPoint Advanced Next Generation and ANSR systems, offering floor plan mapping, smart test scheduling, easily filtered and auditable data management, and corrective actions.
Laboratory services.
Neogen offers food safety analysis services in the U.S., United Kingdom (U.K.) and India. These
ISO-accredited
laboratories offer a variety of
fee-for-service
tests for the food and feed industries.
The majority of Neogen’s food safety test kits use immunoassay technology to rapidly detect target substances. The Company’sOur ability to produce high quality antibodies sets itsour products apart from immunoassay test kits produced and sold by other companies. The Company’sOur kits are available in microwell formats, which allow for automated and rapid processing of a large number of samples, and lateral flow and other similar devices that provide distinct visual results. Typically, test kits use antibody-coated test devices and chemical reagents to indicate a positive or negative result for the presence of a target substance in a test sample; the simplicity of the tests makes them accessible to all levels of food producers, processors and handlers. Neogen also offers other testtesting methods and products to complement its immunoassay tests.

The Company’s

Our test kits are generally based on internally developed technology, licensed technology, or technology that is acquired in connection withas a result of acquisitions. In fiscal 2017,2022, the Food Safety segment incurred royalty expense totaling $1,710,000$1,779,000 for licenses and royalties for licensed technology used in the Company’sour products, including expense of $863,000$800,000 for allergen products $199,000and $494,000 for the pathogen product line and $375,000 for licenses related to the dairy antibiotics product line. Generally, the Company’s royalty rates are in the range of 2% to 10% of revenues on products containing the licensed technology. Some licenses involve technology that is exclusive to Neogen’s use, while others are
non-exclusive
and involve technology licensed to multiple licensees.

Neogen’s international operations in the United Kingdom,U.K., Mexico, Guatemala, Brazil, Argentina, Uruguay, Chile, China and India originally focused on the Company’s Food Safetyfood safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer the Company’sour complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management at our international operations, and are reportedreport through the Food Safety segment.

Revenues from Neogen’s Food Safety segment accounted for 47.4%49.3%, 45.6%50.0%, and 46.5%50.9% of the Company’sour total revenues for fiscal years ended May 31, 2017, 20162022, 2021 and 2015,2020, respectively.

ANIMAL SAFETY SEGMENT

Neogen’s Animal Safety segment is primarily engaged in the development, manufacture, marketing and marketingdistribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, a full suite of agricultural biosecurity products such as rodenticides, cleaners, disinfectants and insecticides, and genomics services.

Veterinary instruments.
Neogen markets a broad line of veterinary instruments and animal health delivery systems under the Ideal brand name. Approximately 250 different products are offered, many of which are used to deliver animal health products, such as antibiotics and vaccines. Ideal’s D3 Needles are stronger than conventional veterinary needles and are uniquely detectable by metal detectors at meat processing facilities — a potential market advantage in the safety-conscious beef and swine industries. Neogen’s Prima Tech product line consists of highly accurate devices used by farmers, ranchers and veterinarians to inject animals, provide topical applications and to use for oral administration. The Prima Tech isline also a supplier ofincludes products used in artificial insemination in the swine industry. Other products includeindustry, animal identification products and handling equipment.

5

Table of Contents
Veterinary pharmaceuticals.
Animal Safety’s NeogenVet product line provides innovative, value-added, high quality products to the veterinary market. Top NeogenVet products include PanaKare, a digestive aid that serves as a replacement therapy where digestion of protein, carbohydrate and fat is inadequate due to exocrine pancreatic insufficiency; Natural Vitamin
E-AD,
which aids in the prevention and treatment of vitamin deficiencies in swine, cattle and sheep; and RenaKare, a supplement for potassium deficiency in cats and dogs.dogs; and ThryroKare, a supplement used as replacement therapy for dogs with diminished thyroid function. Other products sold under the NeogenVet brand include
Vita-15
and Liver 7, which are used in the treatment and prevention of nutritional deficiencies. The CompanyNeogen also manufactures and markets Uniprim, a leading veterinary antibiotic.

antibiotic, and, through the Company’s September 2021 acquisition of CAPInnoVet, Inc., several companion animal parasiticides.

Veterinary biologics.
Neogen’s BotVax B vaccine has successfully protected thousands of high-value horses and foals against Type B botulism, commonly known as Shaker Foal Syndrome. The Company’sOur product is the only USDA-approved vaccine for the prevention of Type B botulism in horses. Years of research and many thousands of doses have proven Neogen’s EqStim immunostimulant to be safe and effective as a veterinarian-administered adjunct to conventional treatment of equine bacterial and viral respiratory infections. The Company’s ImmunoRegulin product uses similar immunostimulant technology to aid in the treatment of pyoderma (a bacterial skin inflammation) in dogs.

Veterinary OTC products.
Animal Safety products offered by Neogen to the retail
over-the-counter
(OTC) market include Ideal brand veterinary instruments packaged for the retail market. OTC products also include
Stress-Dex,
an oral electrolyte replacer for performance horses, and Fura-Zone, for the prevention and treatment of surface bacterial infections in wounds, burns and cutaneous ulcers.Ag-Tek and other hoof Hoof care, disposables and artificial insemination supplies are marketed to the dairy and veterinary industries.

Rodenticides.
Neogen’s comprehensive line of proven rodenticides, sold under brand names such as Ramik and Havoc, effectively address rodent problems of any size and serve as a critical component of an overall biosecurity plan for animal protein production operations. Neogen offers several rodenticide active ingredients including diphacinone, bromethalin, brodifacoum and zinc phosphide, formulated with food grade ingredients to generate the highest acceptance and most palatable bait possible.

Cleaners and disinfectants.
Used in animal and food production facilities, Neogen’s cleaners and disinfectants, including DC&R, 904 Disinfectant,
Acid-A-Foam, Preserve, Tetradyne
Synergize, BioPhene, Neogen Viroxide Super, and FarmFluid S, can stop aCompanion, prevent disease outbreak before it starts.outbreaks. The products are also are used in the veterinary clinic market to maintain sanitary conditions and limit the potential hazards of bacteria, fungi and viruses.

Neogen’s water line cleaner and disinfectant products, including Peraside, NeoKlor, AquaPrime and Siloxycide, are used to clean water lines and provide continuous disinfection of a livestock facility’s water supply.

Insecticides.
Neogen’s highly effective insecticides utilize environmentally friendly technical formulas, and several are approved for use in food establishments.establishments and by pest control professionals in a wide range of environments. The company’sCompany’s Prozap insecticide brand is well knownused in the large animal production industry, particularly with dairy and equine producers.

Neogen’s SureKill line of products is used by professionals to control a variety of insects and the Company’s StandGuard

Pour-on
solution, acquired in July 2020, is used for horn fly and lice control in beef cattle.
Animal genomics services. Neogen’s animal genomics businesses,
Neogen Genomics, formerly known as GeneSeek, and Igenity, provideprovides value-added services to leading agricultural genetics providers, large national cattle associations, companion animal breed registries and direct to consumer canine genetic test providers, university researchers, and numerous commercial beef and dairy cattle, swine, sheep and poultry producers. With
state-of-the-art genetics
genomics laboratories and the comprehensive bioinformatics to interpret geneticgenomics test results, Neogen Genomics offers identity and trait determination and analysis. GeneSeek’sOur technology employs high-resolutionhigh-density DNA genotyping and genomic sequencing for identity and trait analysis in a variety of important animal and agricultural plant species. Igenity’sOur extensive bioinformatics database identifies and predicts an animal’s positive or negative traits based on DNA test results. This information has helped livestock producers make significant improvementsincrease the speed of genetic improvement in the genomic makeuptheir herds and overall performance and quality of their animals.

Neogen’s December 2021 acquisition of Genetic Veterinary Sciences, Inc. expanded the Company’s portfolio through the addition of a number of genetic tests for companion animals, including dogs, cats and birds.

Life sciences.
Neogen’s line of approximately 100 drug detection immunoassay test kits is sold worldwide for the detection of approximately 300 abused and therapeutic drugs in farm animals and racing animals, and for the detection of drug residues in meat and meat products. The test kits are also used for human forensic toxicology drug screening applications. This line includes tests for narcotics, analgesics, stimulants, depressants, tranquilizers, anesthetics, steroids and diuretics. Neogen also has several products used by researchers for the detection of biologically active substances.

6

Table of Contents
Many of the products and services in the Animal Safety segment use licensed technology. In fiscal 2022, the Animal Safety segment incurred royalty expense totaling $949,000$220,000 for licenses and royalties in fiscal 2017 for licensed technology used in the segment’sour products and services, including expense of $410,000 for licenses$122,000 related to thegenomics services.
Neogen’s operation in Australia originally focused on providing genomics services line.

and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, our Australian operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.

Revenues from Neogen’s Animal Safety segment accounted for 52.6%50.7%, 54.4%50.0%, and 53.5%49.1% of the Company’sour total revenues for fiscal years ended May 31, 2017, 20162022, 2021 and 2015,2020, respectively.

GENERAL SALES AND MARKETING

Neogen is organized under two segments — Food Safety and Animal Safety. Within these segments, the Company’sour sales efforts are generally organized by specific markets, rather than by products and/or geography. During the fiscal year that ended May 31, 2017, the Company2022, we had approximately 23,00032,000 customers for itsour products. SinceAs many of our customers for animal safety products are distributors and certain animal safety products are offered to the general retail market, the total number of end users of the Company’sour products is considerably greater than 23,000.32,000. As of May 31, 2017,2022, a total of 375573 employees were assigned to sales and marketing functions, within the Company, compared to 348494 at the end of May 2016.2021. During the fiscal years ended May 31, 2017, 20162022, 2021 and 2015,2020, no single customer or distributor accounted for 10% or more of the Company’sour revenues.

DOMESTIC SALES AND MARKETING

FOOD SAFETY

To reach each customer and prospect with expertise and experience, Neogen has a staff of specialized food safety sales and technical service representatives assigned to specific markets.markets or geographies. This staff sells Companyour products directly to end users, and also handles technical support issues that arise with customers in the United States and Canada.

customers.

Neogen’s food safety markets are primarily comprised of: milling
Milling and grain
, including grain elevators, feed mills, pet food manufacturers and grain inspection companies; meat
Meat and poultry
, including meat and poultry processors, producers of
ready-to-eat
meat and poultry products, and the USDA’s Food Safety Inspection Service (FSIS); grocery products,
Prepared foods and ingredients
, including flour millers, malters, bakeries, candy and confection manufacturers, manufacturers of prepared meals, nuts, spices, cookies, crackers and other snack foods; fruits
Fruits and vegetables
, including growers and processors of juice and packaged fresh cut grocery items; seafood,
Seafood
, including harvesters and processors of a wide variety of seafood products; dairy,
Dairy
, including milk and yogurt processors; beverage,
Beverage
, including soft drink bottlers and beer and wine producers; healthcare,
Water,
including food producers, water bottlers and municipal water departments;
Healthcare
, including hospitals and distributors to the healthcare industry; traditional
Traditional culture media markets
, including commercial and research laboratories and producers of pharmaceuticals, cosmetics and veterinary vaccines; food
Food service
, including fast food service establishments and retail grocery market chains,chains; and nutraceuticals,
Dietary supplements
, including producers and marketers of a wide variety of nutritional and holistic consumer products.

ANIMAL SAFETY

Neogen markets a broad range

Neogen’s staff of pharmaceuticals, vitamin injectables, wound carespecialized animal safety sales, marketing, customer and technical service representatives sell our products topicals, instruments, genomicsand services directly to consumers, dealers, veterinarians, distributors and biologicals to the veterinary market. The product range is focused on the food (e.g., cattle, swineother manufacturers and poultry) and companion (e.g., horses, dogs and cats) animal markets. Neogen’s sales group works directly with veterinarians, clinics and universities, and markets through established ethical distributors by supporting the efforts of over 1,000 domestic distributor sales representatives calling on 35,000 plus veterinarians.also handle technical support issues. Neogen further supports its veterinary distribution channelchannels through product training, field support, promotions and technical service.

The Company believes the animal health market offers growth opportunities for Neogen and its products. Neogen offers a broad range of products including well-recognized brands of rodenticides, cleaners and disinfectants, insecticides, instruments and horse care products. To reach the OTC market, Neogen’s sales team works with a large network of animal health distributors including marketing groups, traditionaltwo-step distributors, catalogers and large retail chains. Support includes product training, field support, planogram solutions,various promotions and advertising.

As

7

Table of Contents
Neogen’s animal safety markets are primarily comprised of:
Companion animal veterinarians.
Neogen has a commercial laboratory, GeneSeek providesdedicated sales group that sells and technically supports the Company’s animal care, biosecurity and disposable products to the companion animal veterinary market.
Livestock producers, veterinarians and breed associations.
Neogen has a dedicated group of sales professionals that sells the Company’s comprehensive suite of biosecurity and husbandry products and genomics services directdirectly to large-herd beeflivestock producers, and livestock veterinarians and veterinary clinics.
Distributors.
To expand the reach of its animal safety OTC and veterinary products, Neogen has a dedicated sales team that sells the Company’s products to animal health product distributors.
Retailers.
Neogen offers select animal care and biosecurity products directly to large farm and ranch retailers for sale to consumers.
Breeding and genetics companies.
Neogen has sales professionals who sell directly to the large dairy cattle, swine,artificial insemination providers, poultry and sheep producers, universitiesswine genetics companies and the aquaculture industry.
Diagnostic labs and universities.
Neogen has a dedicated lab, manufacturing, sales and technical service group that calls on large commercial and forensic testing laboratories and universities.
Other manufacturers and government agencies.
Neogen has an experienced group of professionals who work directly with other research organizations,manufacturers and various livestockgovernment agencies to provide custom solution products and canine breed associations.

services for their needs.

INTERNATIONAL SALES AND MARKETING

Neogen maintains 10 Company-owned locations outside of the United States in 14 countries to provide a direct presence in regions of particular importance to the Company, and maintainsus; we maintain an extensive network of distributors to reach countries where the Company doeswe do not have a direct presence.

Neogen Europe.Europe and subsidiaries.
Neogen Europe, Ltd., locatedheadquartered in Ayr, Scotland, provides the Company access to the European Union (E.U.), and sells products and services to itsour network of customers and distributors throughout the E.U.United Kingdom (U.K.), Europe, the Middle East and Africa. Customers in the United Kingdom,U.K., France, Germany, Italy, the Netherlands and the NetherlandsUnited Arab Emirates (U.A.E.) are served by Companyour employees. In other European regions, customers are generally serviced by distributors managed by Neogen Europe personnel. Neogen Europe’s research and development team continues to be a strong asset in the development of products tailored to meet the unique requirements of the European market.
Neogen Europe management is also responsible for sales and marketing for the Company’s England-based Lab M and Quat-Chem businesses. In August 2015, Neogen acquired the stock of Lab M Holdings (Lab M), a developer, manufacturer and supplier of microbiological culture media and diagnostic systems located in Heywood, England. Lab M’s extensive range of microbiological culture media, supplements, immunomagnetic separation techniques and proficiency testing systems are used in laboratories around the world. In December 2016, Neogen acquired Neogen’s other European operations, which include:
Quat-Chem, Ltd.,
a Rochdale, England-based chemical company specializingthat specializes in the development, manufacture and sale of agricultural, industrial and food processing biocidal hygiene products, including cleaners and disinfectants. Quat-Chem sells its products on a global basis, with a focus on markets in the United Kingdom, European Union,U.K., Europe, Middle East, Africa and Asia.

Neogen Latinoamérica. The Company’s subsidiaryItalia
, a Milan, Italy-based business, which directly markets Neogen’s products in Mexico, Italy.
Megazyme, Ltd
., a Bray, Ireland-based food quality diagnostics company, acquired in December 2020, which develops and refines the analytical methods used to measure the carbohydrates and enzymes in food and feed products that affect quality.
Delf, Ltd
., a Liverpool, England-based manufacturer and supplier of animal hygiene and industrial cleaning products, acquired in November 2021.
Abbott Analytical, Ltd.
, a Liverpool, England-based service provider, acquired in November 2021.
Neogen Europe has two additional manufacturing locations in:
Heywood, England, which manufactures an extensive range of microbiological culture media, supplements and immunomagnetic separation techniques.
Liverpool, England, which manufacturers culture media supplements and microbiology technologies.
Neogen Latinoam
é
rica and Neogen Guatemala.
Neogen Latinoamérica is headquartered near Mexico City and distributesNeogen Guatemala is located in Guatemala City. Combined, the two businesses distribute Neogen’s products throughout Mexico and Central America. Neogen Latinoamérica manages the Company’sour business activities throughout the region by marketing to animal and crop producers and food processors, utilizing itsour direct sales representatives to sell Food Safetyfood safety products and genomics services, while marketing cleaners, disinfectants, rodenticides and other Animal Safetyanimal safety products primarily through distributors.

8

Table of Contents
Neogen Argentina, Neogen Uruguay and Neogen Chile.
These three countries provide Neogen with a physical presence in the important agricultural Southern Cone region of South America, which has large beef and dairy populations with significant export markets. The operations are managed through Neogen’s Latin American operations and offer direct sales of Neogen food safety, animal safety and genomics products into Argentina, Uruguay and Chile.
Neogen do Brasil.
Neogen do Brasil, (translated as Neogen of Brazil), headquartered near São Paulo, distributes Neogen’s products throughout Brazil. Brazil is one of thea world leadersleader in the export of numerous food commodities, including beef, poultry, soybeans, coffee, corn, sugar and orange juice, and this operation gives the Companyus direct sales representation to these important markets. Neogen do Brasil management is also responsible for manufacturing, marketing and sales and marketing for the Company’sBrazil-based Deoxi and Rogama, businesses. Neogen owns Deoxi Biotecnologia Ltda,located in Pindamonhangaba, Brazil. This company operates a genomics testing laboratory located in Aracatuba, Brazil, which it purchased in April 2016. In December 2016, Neogen acquiredBrazil-based Rogama Indústria e Comércio Ltda., a company which(formerly named Deoxi) and develops, manufactures and markets rodenticides and insecticides. Rogama was founded in 1979 and offers more than 70 registered pest control products to Brazil’s agronomic, professional and retail markets.

Neogen China. Neogen’s
Our Chinese subsidiary, with officeslocated in Shanghai, and Beijing, employs sales representatives who sell directly to Chinese customers. China’s burgeoning middle class, with its rapidly growing demand for higher quality meat and dairy products, makes the country a substantial growth opportunity for NeogenNeogen’s products and services — both for animal production on the country’s farms, and in processing plants throughout China’s food production and distribution channels. The Company utilizesbusiness also operates a genomics testing laboratory. We utilize both direct sales representatives and distributors to market itssell our complete portfolio.

portfolio in this growing market.

Neogen India. In June 2015, Neogen acquired the assets of Sterling Test House, a leading commercial food testing
This business operates an accredited laboratory based in southwest India, to serve as a base for the Company’s operations in India. Sterling Test House was incorporated in 1990, and its business includeswhich performs food safety and water quality testing for food producers, major hotels and restaurants in its home region, as well as safety and quality analysis for the country’s expanding nutraceutical market, and growing food export businesses. The laboratory is located in Kochi, in the state of Kerala, which is India’s leading region for the export of spices, tea, and fresh fruits and vegetables. In late fiscal 2016, Neogen transferredIndia is also responsible for sales responsibility for its Food Safetyof our food safety and animal safety products directly to sales representatives at Neogen India.

Neogen Canada. In September 2015, Neogen opened a Canadian location in Guelph, Ontario. Currently, this office is used for genomics sales and sample reception, and reports through the Animal Safety segment.

Dairy antibiotics distributor. Neogen’s dairy antibiotics diagnostic products are marketed directly to customers and distributors in North America, BrazilIndia and China,nearby countries.

Neogen Australasia.
Neogen Australasia operates a genomics testing laboratory, focusing on the sheep and distributed elsewhere internationally by Denmark based Chr. Hansen, an international supplier of natural ingredient solutions for thecattle markets in Australia and New Zealand, and also directly markets and sells our food health and nutritional industries.

animal safety products in those countries.

Neogen Canada.
This business operates a genomics testing laboratory in Edmonton, Alberta.
Other distributor partners.
Outside of the Companyour physical locations, and dairy antibiotics distributor mentioned above, Neogen uses itsour own sales managers in both the Food Safety and Animal Safety segments to work closely with and coordinate the efforts of a network of approximately 150600 distributors in more than 100 countries. The distributors provide local training and technical support, perform market research and promote Company products within designated countries around the world.

Sales to customers outside the United States accounted for 35.8%39.7%, 33.5%39.1%, and 36.7%39.4% of the Company’sour total revenues for fiscal years ended May 31, 2017, 20162022, 2021 and 2015,2020, respectively.

No individual foreign country contributed 10% or more of our revenues for those same periods.

RESEARCH AND DEVELOPMENT

Management maintains a strong commitment to Neogen’s research and development activities. The Company’sOur product development efforts are focused on the enhancement of existing products and inon the development of new products that fit itsour business strategy. As of May 31, 2017, the Company2022, we employed 92 individuals121 scientists and support staff in itsour worldwide research and development group, including immunologists, chemists and microbiologists. Research and development costs were approximately $10.4$17.0 million, $9.9$16.2 million, and $9.6$14.8 million representing 2.9%3.2%, 3.1%3.5%, and 3.4%3.5% of total revenues in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively. Management currently expects the Company’sour future research and development expenditures to approximate 3% to 4% of total revenues.

revenues annually.

Neogen has ongoing development projects for a number ofseveral new and improved diagnostic tests and other complementary products for both the food safetyFood Safety and animal safetyAnimal Safety markets. Management expects that a number of these products will be commercially available at various times during fiscal years 2018 to 2020.

Portions of certain2023 and 2024.

Certain technologies utilizedused in some products manufactured and marketed by Neogen were acquired from or developed in collaboration with affiliated partnerships,partners, independent scientists, governmental units,agencies, universities and other third parties. The Company hasWe have entered into agreements with these parties that provide for the payment of license fees and royalties based upon sales of products that utilizeuse the pertinent licensed technology. License fees and royalties,Royalties, expensed to sales and marketing, under these agreements amounted to $2,659,000, $1,969,000$1,999,000, $2,129,000, and $2,189,000$2,524,000 in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively.

9

Table of Contents
PROPRIETARY PROTECTION AND APPROVALS

Neogen uses trade secrets as proprietary protection in many of its food and animal safety products. In many cases, the Company haswe have developed unique antibodies capable of detecting microorganisms and residues at minute levels. The supply of these antibodies, and the proprietary techniques utilized for their development, may offer better protection than the filing of patents. Such proprietary reagents are maintained in secure facilities and stored in more than one location to reduce exposure to complete destruction by natural disaster or other means.

Patent and trademark applications are submitted whenever appropriate. Since its inception, Neogen has acquired and receivedbeen granted numerous patents and trademarks and has severalnumerous pending patents and trademarks.trademark applications. The patents expire at various times over the next 2220 years.

A summary of patents by product categories follows:

   USA   International   Expiration 

Natural Toxins, Allergens, & Drug Residues

   6    31    2018-2038 

Bacterial & General Sanitation

   17    18    2017-2030 

Life Sciences

   0    7    2024 

Veterinary Instruments & Other

   14    32    2017-2039 

Genomics Services

   7    1    2021-2029 

The Company does

   
USA
   
International
   
Expiration
Natural Toxins, Allergens, & Drug Residues
   18    57   2023-2042
Life Sciences
   0    3   2024
Vaccine
   1    0   2028
Veterinary Instruments & Other
   10    28   2023-2042
Genomics Services
   18    3   2024-2029
We do not expect the near-term expiration of any single patent to have a significant effect on future results of operations.

Management believes that Neogen has adequate protection regarding proprietary rights for itsto commercialize our products. However, it iswe are aware that substantial research has taken placeis conducted at universities, governmental agencies and other companies throughout the world and that numerousit is always possible that patents have been applied for and issued forcould be granted that are relevant to technologies whichthat may be used in the Company’sour products. To the extent some of the Company’sour products may now, or in the future, embody technologies protected by patents copyrights or trade secrets of others, we may need to obtain licenses to use such technologies may need to be obtained in order to continue to sell the products. These licenses may not be available on commercially reasonable terms. Failure to obtain any such licenses maycould delay or prevent the sale of certain new or existing products. In addition, patent litigation is not uncommon. Accordingly, there can be no assurance that the Company’s existing patentswe will be sufficientcontinue to completely protect its proprietary rights.

have adequate rights to commercialize our new products or that we will avoid litigation.

One of the major areas affecting the success of biotechnology development involves the time, cost and uncertainty surrounding regulatory approvals. Neogen products requiring regulatory approval, which the Companywe currently hashave in place, include BotVax B, EqStim, ImmunoRegulin, Uniprim and BetaStar. The Company’sOur general strategy is to selectfocus on technical and proprietary products that do not require mandatory approval by regulatory bodies to be marketed. Neogen’s rodenticide, disinfectant and insecticide products are subject to registration in the United States and internationally.

Neogen utilizes third-party validations on many of itsour disposable test kits as a marketing tool to provide itsour customers with assurances that the Company’sour products perform to specified levels. These include validation by the AOAC International, independently administered third-party, multi-laboratory collaborative studies and approvals by the U.S. Federal Grain Inspection Service and the USDA Food Safety Inspection Service for the use of Companyour products in their operations.

PRODUCTION AND SUPPLY

Neogen manufactures itsour products in Michigan, Kentucky, Wisconsin, North Carolina, Iowa, Tennessee, California, Ireland, the United Kingdom and Brazil and provides genomics services in Nebraska, Washington, Scotland, Brazil, Australia, China and Brazil.Canada. As of May 31, 2017,2022, there were approximately 6801,039 full-time employees assigned to manufacturing operations and providing of services in these locations, operating on one or two shifts;multiple shift schedules; with occasional 24/7 production during high demand periods. Future demand increases could be accommodated by adding shifts. Management believes itwe could increase the current output of itsour primary product lines by more than 50%30% using the current space available; however, to do so would require investment in additional capital equipment.

Food safety diagnostics.
Manufacturing of diagnostic tests for the detection of natural toxins, pathogens, food allergens, dairy antibiotics, spoilage organisms and pesticides, final kit assembly, quality assurance and shipping takes place in the Company’sat our facilities in Lansing, Michigan. Proprietary monoclonal and polyclonal antibodies for Neogen’s diagnostic kits are produced on a regular schedule in the Company’sour immunology laboratories in Lansing. Generally, final assembly and shipment of diagnostic test kits to customers in Europe is performed in the Company’sour Ayr, Scotland facility. Assembly and shipmentMost of electronic readers and disposablesingle-use samplers takes place in the Company’s facilities in Lansing. Solerisfood safety
10

Table of Contents
diagnostic instruments and BioLumix instrument readers are produced by third partythird-party vendors to the Company’sour specifications, quality tested in Lansing, and then shipped to customers. Dehydrated cultureCulture media products are manufactured in aFDA-registeredan
ISO-approved
facility in Lansing and also in Heywood and Liverpool, England. Products are blended following strict formulations or custom blended to customer specificationspecifications and shipped directly to customers from Lansing and Heywood.

the United Kingdom. The Heywood location produces prepared media plates, sterile liquid media, and other related products in ready to use format for food testing laboratories across the U.K. and western Europe. Enzyme substrates are manufactured at Megazyme in Bray, Ireland.

Animal health products.
Manufacturing of animal health products, pharmacological diagnostic test kits and test kits for drug residues takes place in the Company’sour
FDA-registered
facilities in Lexington, Kentucky. In general, manufacturing operations including reagent manufacturing, quality assurance, final kit assembly and packaging are performed by Neogen personnel. Certain animal health products and veterinary instruments that are purchased finished or that are toll manufactured by third party vendors are warehoused and shipped from the Company’sour Lexington facilities. OtherSome veterinary instruments are produced in the Company’sour facilities in Lansing, and are generally then shipped to Lexington for distribution to customers. Manufacturing and shipment of devices used for animal injections, topical applications and oral administration takes place in a Company-owned facilityoccurs in Kenansville, North Carolina.

Veterinary biologics.
Neogen maintains a Lansing-based USDA-approved manufacturing facility devoted to the production of the biologic products EqStim and ImmunoRegulin.P. acnes
P.acnes
seed cultures are added to media and then subjected to several stages of further processing resulting in a finished product that is filled and packaged within the facility. The Company’sOur BotVax B vaccine is also produced in the Lansing facility utilizing Type B botulism seed cultures and a traditional fermentation process. All completed biologic products are then shipped to Neogen’s Lexington facilities for inventory andwhere they are inventoried prior to distribution to customers.

Agricultural genomics services.
Neogen offers agricultural genomics laboratory services and bioinformatics at itsour locations in Lincoln, Nebraska; Ayr, Scotland;Nebraska, Washington, Scotland, Brazil, Australia, China and Aracatuba, Brazil.Canada. Through itsour laboratory services and bioinformatics (primarily in beef and dairy cattle, pigs, sheep, poultry, horses and dogs), GeneSeek empowers itsNeogen Genomics allows our customers to speed genetic improvement efforts, as well as identify economically important diseases. In fiscal 2016, the Company added to its processing capabilities in Scotland, while also purchasing a genomics business in Brazil to enhance its presence there.

Cleaners, disinfectants and rodenticides.
Manufacturing of rodenticides and/or cleaners and disinfectants takes place in the following locations: Randolph, Wisconsin; Memphis, Tennessee; Turlock, California; Rochdale, England;Wisconsin, Tennessee, California, England and Pindamonhangaba, Brazil. Manufacturing of rodenticides consists of blending technical material (active ingredient) with bait consisting principally of various grains. Certain cleaners and disinfectants are manufactured in Neogen facilities, while others are purchased from other manufacturers for resale, or toll manufactured by third parties.

Pesticides.

Insecticides.
Neogen manufactures insecticides and other pesticides at its facilities in Pleasantville, Iowa and Pindamonhangaba, Brazil.

Neogen purchases component parts and raw materials from more than 9001,000 suppliers. Though many of these items are purchased from a single source in order to achieve the greatest volume discounts, the Company believes it haswe believe we have identified acceptable alternative suppliers for most of itsour key components and raw materials where it is economically feasible to do so. There can be no assurance that the Companywe would avoid a disruption of supply in the event a supplier discontinues shipment of product. Shipments of higher volume products are generally accomplished within a
48-hour
turnaround time. As a result of this quick response time, Neogen’sOur backlog of unshipped orders at any given time has historically not been significant.

COMPETITION

Although competitors vary in individual markets, management knows of no single competitor that is pursuing Neogen’s fundamental strategy of developing and marketing a broad line of products, ranging from disposable tests and dehydrated culture media to veterinary pharmaceuticals and instruments for a large number of food safety and animal safety concerns. For each of itsour individual products the Company facesor product lines, we face intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the Company. Neogen competesNeogen. We compete primarily on the basis of ease of use, speed, accuracy and other similar performance characteristics of itsour products. The breadth of the Company’sour product line, the effectiveness of itsour sales and customer service organizations, and pricing are also components in management’s competitive plan.

strategy.

Future competition may become even more intense, and could result from the development of new technologies, which could affect the marketability and profitability of Neogen’s products. The Company’sOur competitive position will also depend on management’sour ability to continue to develop proprietary products, attract and retain qualified scientific and other personnel, develop and implement production and marketing plans and obtain patent protection.protection for new products. Additionally, the Companywe must continue to generate or have access to adequate capital resources to execute itsour strategy.

11

Table of Contents
FOOD SAFETY:

With a large professional sales organization offering a comprehensive catalog of food safety solutions, management believes the Company maintainswe maintain a general advantage over competitors offering only limited product lines. In most cases, Neogen sales and technical service personnel can offer unique insight into a customer’s numerous safety and quality challenges, and offer testing and other solutions to help the customer overcome those challenges.

Competition for pathogen detection products includes traditional methods and antibody and genetic-based platforms; competition for natural toxins and allergen detection products include instrumentation and antibody-based tests. While the Company’sour offerings will not always compete on all platforms in all markets, the products that are offeredwe offer provide tests that can be utilized by most customers to meet their testing needs.

Besides its

In addition to our extensive product offerings and robust distribution network, the Company focuses itswe focus our competitive advantage in the areas of customer service, product performance, speed, and ease of use of itsour products. Additionally, by aggressively maintaining itself as alow-cost producer, Neogen believesNeogen’s ability to produce at low cost, we believe that itwe can be competitive with new market entrants that may choose a low pricing strategy in an attempt to gain market share.

ANIMAL SAFETY:

Neogen’s Animal Safety segment faces no onesingle competitor across the products and markets it serves.we serve. In the racing industry market, the Company believes it holdswe believe we hold a leading market share position. In the life sciences and forensicforensics markets, the Company competeswe compete against several other diagnostic and reagent companies with similar product offerings.

In the veterinary market, Neogen markets BotVax B, the only USDA-approved vaccine for the prevention of botulism Type B in horses. The Company competesWe compete on other key products through differentiated product performance and superior customer and technical support. With some of itsour products, the Company provideswe provide solutions as a lower cost alternative and offersalso offer a private label option for itsour distributors.

Competition in the rodenticide market includes several companies of comparable size that offer products into similar market segments. The retail rodenticide market is not dominated by a single brand. While the technical materials used by competing companies are similar, Neogen uses manufacturing and bait formula techniques which the Company believeswe believe may better attract rodents to the product and thereby improves overall product performance.

Within the insecticide market, the Company’sChem-Tech products specifically focus on the area of insect control for food and animal safety applications. There are several competitors offering similar products, however, the Company haswe have a proprietary formulation chemistry that optimizes the delivery and safe application of insecticides at the customer’s location. These products are currently only sold in the U.S. through a combination of direct sales and distributors.

Numerous companies, including a number of large multinationals, compete for sales in the cleaner and disinfectant product segment. Neogen’s broad line of products are sold through itsour distributor network around the world, primarily to assist in the cleaning and disinfecting of animal production facilities.

In addition to the Company’sour extensive portfolio of Animal Safetyanimal safety products, Neogen also competes in the retail market by providing solutions to common retail problems, such as stock outs, wasted floor space and inconsistent brand identity. The Company differentiates itselfWe differentiate ourselves by offering planograms and convenient reordering systems to maximize turns and profitability for itsour retail customers.

GeneSeek,

Neogen Genomics, the leading worldwide commercial agricultural genomics laboratory in the U.S., employs cutting-edge technology in the area of genomics. The result of this technology allows the acceleration of natural selection through parentage testing and selective breeding of traits such as disease resistance, yield improvement and meat quality. Competition comes mainly from a number of service providers, whose primary focus are the human and pharmaceutical industries,some significantly larger than us as well as several smaller companies offering genomics services. GeneSeekNeogen Genomics is not involved in cloning or the development of transgenic animals.

GOVERNMENT REGULATION

A significant portion of Neogen’s products and revenues are affected by the regulations of various domestic and foreign government agencies, including the U.S. Department of Agriculture (USDA), the Environmental Protection Agency (EPA), and the U.S. Food and Drug Administration (FDA). Changes in these regulations could affect revenues and/or costs of production and distribution.

12

Table of Contents
Neogen’s development and manufacturing processes involve the use of certain hazardous materials, chemicals and compounds. Management believes that the Company’sour safety procedures for handling and disposing of such commodities comply with the standards prescribed by federal, state and local regulations; however, changes in such regulations or rules could involve significant costs to the Companyus and could be materially adverse to itsour business.

The rodenticides, insecticides, cleaners, disinfectants and sanitizers manufactured and distributed by Neogen are subject to EPA and various state regulations. In general, any international sale of the productour products must also comply with similar regulatory requirements in the country of destination. Each country has its own individual regulatory construct with specific requirements (e.g., label in the language of the importing country). To the best of the Company’sour knowledge, Neogen products are in compliancecompliant with applicable regulations in the countries where such products are sold.

Dairy

Many of the food safety diagnostic products used in National Conference on Interstate Milk Shipments (NCIMS) and other milk monitoring programs are regulated by the FDA. Beforedo not require direct government approval. However, we have pursued AOAC approval for a number of these products requiring FDA approval can be sold in the U.S., extensive product performance data must be submitted in accordance with theFDA-approved protocol administered by the AOAC Research Institute (AOAC RI). Following approval of a product by the FDA, the product must also be approved by NCIMS, an oversight body that includes federal, state and industry representatives. The Company’sto enhance their marketability. Our BetaStar Advanced U.S. dairy antibiotic residue testing product has been reviewed and/or approved by the FDA, NCIMS, and AOAC RI. While some foreign countries accept AOAC RI approval as part of theirappropriate regulatory approval processes, many countries have their own regulatory requirements.

Many of the food safety diagnostic products to detect allergens and spoilage organisms do not require direct government approval. However, the Company has pursued AOAC approval for many of these products to enhance their marketability. Products for mycotoxin detection, which are used by federal inspectors, must be approved by the USDA. Neogen has obtained and retained the necessary approvals to conduct its current operations.

bodies.

Neogen’s veterinary vaccine products and some pharmaceutical products require government approval to allow for lawful sales. The vaccine products are approved by the U.S. Department of Agriculture, Center for Veterinary Biologics
(USDA-CVB)
and the pharmaceutical products are approved by the FDA. The products, and the facilities in which they are manufactured, are in a position of good standing with both agencies. The Company has hadWe have no warning letters based on any review of these products or facility inspection,inspections, no recalls on any of these products, and knowsare not aware of noany reason why itwe could not manufacture and market such products in the future.

Other animal safety and food safety products generally do not require additional registrations or approvals. However, Neogen’s regulatory staff routinely monitors amendments to current regulatory requirements to ensure compliance.

EMPLOYEES

HUMAN CAPITAL MANAGEMENT
Our people are a critical component in our continued success. As a team, they put Neogen’s core values into action, while executing on key growth initiatives to maintain long-term sustainable growth. We strive to create a workplace of choice to attract, retain and develop top talent to achieve our vision and deliver shareholder results. As of May 31, 2017,2022, we employed 2,108 people worldwide, with 1,264 located in the Company employed 1,413 full-time persons worldwide.U.S. and 844 international. None of thethese employees are covered by collective bargaining agreements. There have been no work stoppages or slowdowns due
The Company is committed to labor-related problems,fostering a diverse and management believesinclusive workplace that its relationship withattracts and retains exceptional talent. Through ongoing employee development, comprehensive compensation and benefits, and a focus on health, safety and employee wellbeing, the Company strives to help its employees is generally good. Employees having accessin all aspects of their lives so they can do their best work.
Workplace Culture and Employee Engagement
. We have established our One Neogen Pillars of Trust which are the principles that guide our decision making every day: • Openness • Honesty • Credibility • Respect • Service. We value responsibility, consistency and integrity. Our Code of Conduct contains general guidelines for conducting business ethically.
Inclusion, Diversity, Equity and Belonging (IDEB)
.
We strive to proprietarycreate an environment where colleagues feel valued and cared for and understand the important role we play in embracing diversity to improve the quality of our innovation, collaboration and relationships. We are dedicated to executing on our diversity, equity and inclusion initiatives.
Talent Recruitment, Development and Retention
.
We employ a variety of career development, employee benefits, policies and compensation programs designed to attract, develop and retain our colleagues. Employee benefits and policies are designed for diverse needs. We have internal programs designed to develop and retain talent, including career planning, leadership development programs, performance management and training programs.
Compensation and Benefits
. We strive to support our colleagues’ well-being and enable them to achieve their best at work and at home. Our compensation and benefits programs are designed to be competitive and support colleague well-being including physical and mental health, financial wellness, and family resources.
Employee Health and Safety
. We are committed to ensuring a safe working environment for our colleagues. Our sites have injury prevention programs, and we strive to build on our safety culture. Our procedures emphasize the need for the cause of injuries to be investigated and for action plans to be implemented to mitigate potential recurrence. Our safety programs have resulted in strong safety performance.
13

Table of Contents
ITEM 1A.
RISK FACTORS
Investing in our securities involves a variety of risks and uncertainties, known and unknown, including, among others, those discussed below. Each of the following risks should be carefully considered, together with all the other information have executed confidentiality agreementsincluded in this Annual Report on Form
10-K,
including our consolidated financial statements and the related notes and in our other filings with the Company.

ITEM 1A.RISK FACTORS

An investment in Neogen Corporation’s common shares involves a high degree of risk. TheSEC. Furthermore, additional risks described below areand uncertainty not the only ones that an investor faces. Additional risks that are not yetpresently known to us or that we currently think arebelieve to be immaterial may also adversely affect our business. Our business, results of operations, financial condition and cash flow could be materially and adversely affected by any of these risks or uncertainties.

RISKS RELATING TO REVERSE MORRIS TRUST TRANSACTION WITH 3M CORPORATION
The pending Reverse Morris Trust transaction with 3M may not be completed on the terms or timeline currently contemplated, or at all, and the failure to complete the transaction could adversely impact the market price of Neogen common stock, as well as its business and operating results.
On December 13, 2021, Neogen, 3M and Garden SpinCo, a newly formed subsidiary of 3M created to carve out 3M’s Food Safety business, entered into a number of agreements pursuant to which, among other things, 3M’s Food Safety business will combine with Neogen in a Reverse Morris Trust transaction, intended to be
tax-efficient to
3M and its shareholders for U.S. federal income tax purposes. Immediately following the transaction, Garden SpinCo stockholders will own, in the aggregate, approximately 50.1% of the issued and outstanding shares of Neogen common stock and
pre-merger
Neogen shareholders will own, in the aggregate, approximately 49.9% of the issued and outstanding shares of Neogen common stock. The transaction implies an enterprise value for 3M’s Food Safety business of approximately $3.4 billion based on Neogen’s stock price at July 22, 2022, including $1 billion in new debt to be incurred by 3M’s Food Safety business. 3M’s Food Safety business will fund to 3M consideration valued at approximately $1 billion, subject to closing and other adjustments.
The consummation of the transaction is subject to certain conditions, including: (i) the effectiveness of Neogen’s registration statement registering the Neogen common stock to be issued pursuant to the merger agreement, and of Garden SpinCo’s registration statement registering the shares of Garden SpinCo common stock in connection with the distribution; (ii) the approval for listing on NASDAQ of the shares of Neogen common stock to be issued in the merger; and (iii) approval of the share issuance and certain Neogen charter and bylaw amendments by the requisite vote of Neogen’s shareholders. There is no assurance that these conditions will be met or that the transaction will be completed on the terms or timeline currently contemplated, or at all.
If the transaction is not completed for any reason, the price of Neogen common stock could decline. Neogen also impair ourcould experience negative reactions from employees, customers, suppliers or other third parties if the transaction is not completed.
Neogen and 3M have expended and will continue to expend significant management time and resources and have incurred and will continue to incur significant expenses related to the transaction, including legal, advisory, printing and financial services fees. Even if the transaction is completed, any delay in the completion of the transaction could diminish the anticipated benefits of the transaction or result in additional transaction expenses, loss of revenue or other effects associated with uncertainty about the transaction. If the transaction is not consummated because the merger agreement is terminated, Neogen may be required under certain circumstances to pay 3M a termination fee of $140 million or may be required to reimburse 3M for expenses incurred in connection with the transaction.
If the transaction is completed, Neogen may not realize the anticipated financial and other benefits, including growth opportunities, expected from the transaction.
Neogen expects that it will realize synergies, growth opportunities and other financial and operating benefits as a result of the transaction. Neogen’s success in realizing these benefits, and the timing of their realization, depends, among other things, on the successful integration of the business operations of the 3M Food Safety business with Neogen. Even if Neogen is able to integrate the 3M Food Safety business successfully, Neogen cannot predict with certainty if or when these synergies, growth opportunities and other benefits will be realized, or the extent to which they will actually be achieved. For example, the benefits from the transaction could be offset by costs incurred in integrating the 3M Food Safety business or in otherwise consummating the transaction. Realization of any synergies, growth opportunities or other benefits could be affected by the factors described in other risk factors and a number of factors beyond Neogen’s control, including, without limitation, general economic conditions, increased operating costs and regulatory developments.
14

Table of Contents
The integration of the 3M Food Safety business with Neogen following the transaction could present significant challenges, and the failure to successfully integrate the 3M Food Safety business could have a material adverse effect on the combined company’s business, financial condition or results of operations. If any
There is a significant degree of difficulty inherent in the process of integrating the 3M Food Safety business with Neogen. These difficulties include:
the integration of the 3M Food Safety business with Neogen’s current businesses while carrying on the ongoing operations of all businesses;
managing a significantly larger company than before the consummation of the transaction;
integrating the business cultures of the 3M Food Safety business and Neogen, which could prove to be incompatible;
creating uniform standards, controls, procedures, policies and information systems and controlling the costs associated with such matters;
the ability to ensure the effectiveness of internal control over financial reporting across the combined company;
integrating certain information technology, purchasing, accounting, finance, sales, billing, human resources, payroll and regulatory compliance systems; and
the potential difficulty in retaining key officers and personnel of Neogen and the 3M Food Safety business.
The process of integrating operations could result in significant costs and cause an interruption of, or loss of momentum in, the activities of Neogen’s business. Members of Neogen’s senior management following risks actually occurs, ourthe transaction may be required to devote considerable amounts of time to this integration process, which could decrease the time they will have to manage the combined company’s business, serve the existing business or operations of Neogen or develop new products or strategies. If Neogen’s senior management is not able to effectively manage the integration process, or if any significant business activities are interrupted as a result of the integration process, the existing business of Neogen or the 3M Food Safety business could be materially adversely affected.
Neogen’s successful integration of the 3M Food Safety business cannot be assured. The failure to do so could have a material adverse effect on Neogen’s business, financial condition or results of operations after the transaction.
Pursuant to the terms of the transaction, Neogen and Garden SpinCo will be restricted from taking certain actions that could adversely affect the intended tax treatment of the transaction, and such restrictions could significantly impair Neogen’s and Garden SpinCo’s ability to implement strategic initiatives that otherwise would be beneficial.
The Tax Matters Agreement executed in connection with the Transaction generally restricts Neogen, Garden SpinCo and their affiliates from taking certain actions after the distribution of Neogen shares that could adversely affect the intended tax treatment of the transaction. In particular:
for a
two-year
period following the distribution date, except as described below:
Garden SpinCo will continue the active conduct of its trade or business and the trade or business of certain Garden SpinCo subsidiaries;
Garden SpinCo will not voluntarily dissolve or liquidate or permit certain Garden SpinCo subsidiaries to voluntarily dissolve or liquidate;
Neogen and Garden SpinCo will not enter into any transaction or series of transactions (or any agreement, understanding or arrangement) as a result of which one or more persons would acquire (directly or indirectly) stock comprising 50% or more of the vote or value of Garden SpinCo or Neogen (taking into account the stock acquired pursuant to the merger);
15

Table of Contents
Neogen and Garden SpinCo will not engage in certain mergers or consolidations;
Garden SpinCo will not, and will not permit certain Garden SpinCo subsidiaries to, sell, transfer or otherwise dispose of 30% or more of the gross assets of Garden SpinCo, such subsidiaries, the Garden SpinCo group or the active trade or business of Garden SpinCo or certain Garden SpinCo subsidiaries, subject to certain exceptions;
Neogen and Garden SpinCo will not, and will not permit certain Garden SpinCo subsidiaries to, redeem or repurchase stock or rights to acquire stock, unless certain requirements are met;
Neogen and Garden SpinCo will not, and will not permit certain Garden SpinCo subsidiaries to, amend their certificates of incorporation (or other organizational documents) or take any other action affecting the voting rights of any stock or stock rights of Neogen or Garden SpinCo; and
Neogen and Garden SpinCo will not, and will not permit any member of the Garden SpinCo group or Neogen to, take any other action that would, when combined with any other direct or indirect changes in ownership of Garden SpinCo and Neogen stock (including pursuant to the merger), have the effect of causing one or more persons to acquire stock representing 50% or more of the vote or value of Garden SpinCo or Neogen, or otherwise jeopardize the
tax-free
status of the transaction;
during the time period ending three years after the date of the distribution, Garden SpinCo and Neogen also will be subject to certain restrictions relating to the SpinCo Business in Switzerland; and
additionally, none of Garden SpinCo, Neogen or any member of Garden SpinCo group or Neogen may:
take, or permit to be taken, any action that could reasonably be expected to jeopardize the qualification of certain Garden SpinCo debt as a security under Section 361(a) of the Code (other than making any payment permitted or required by the terms of the Garden SpinCo debt);
within 90 days of the distribution date, refinance or repay (other than in the ordinary course of business) any third-party debt of any member of the Garden SpinCo group, except as required by the transaction documents; or
permit any portion of certain nonqualified preferred stock to cease to be outstanding or modify the terms of such stock;
unless, in each case, prior to taking any such action, Neogen and Garden SpinCo shall have requested that 3M obtain, or request and receive 3M’s prior written consent to obtain, an IRS ruling satisfactory to 3M in its reasonable discretion or provide 3M with an unqualified tax opinion satisfactory to 3M in its sole and absolute discretion to the effect that such action would not jeopardize the intended tax treatment of the transaction, unless 3M waives such requirement. Failure to adhere to these requirements could result in tax being imposed on 3M for which Neogen and Garden SpinCo could bear responsibility and for which Neogen and Garden SpinCo could be obligated to indemnify 3M. Any such indemnification obligation would likely be substantial and would likely have a material adverse effect on Neogen. These restrictions could have a material adverse effect on Neogen’s liquidity and financial condition, and otherwise could impair Neogen’s and Garden SpinCo’s ability to implement strategic initiatives and Garden SpinCo’s and Neogen’s indemnity obligation to 3M might discourage, delay or prevent a change of control that shareholders of Neogen may consider favorable.
Current Neogen shareholders’ percentage ownership interest in Neogen will be substantially diluted in the transaction.
Immediately following the merger with Garden SpinCo, the
pre-merger
Neogen shareholders will own, in the aggregate, approximately 49.9% of the issued and outstanding shares of Neogen common stock. Consequently, Neogen’s
pre-merger
shareholders, as a group, will be substantially diluted in the transaction and have less ability to exercise influence over the management and policies of Neogen following the merger than immediately prior to the transaction.
RISKS RELATING TO
COVID-19
The ongoing effects of the
COVID-19
pandemic could adversely affected.

Risks Relatingaffect our business, results of operations and financial condition.

Since March 2020, the
COVID-19
pandemic has negatively impacted the global economy, disrupted global supply chains, and created significant volatility and disruption of financial markets.
16

Table of Contents
The extent of the impact of the
COVID-19
pandemic on our operational and financial performance, including our ability to Our Business

execute our business strategies and initiatives in the expected time frame, continues to depend on many factors outside our control, including, without limitation, the timing, extent, trajectory and duration of the pandemic, related restrictions on travel and transports, the development and availability of effective treatments and vaccines, the imposition of protective public safety measures including lockdowns, and the impact of the pandemic on the global economy and consumer demand.

During the course of the pandemic, we modified our business practices to comply with safety measures required by federal, state and local governments, as well as those we determine to be in the best interests of our employees and customers, including implementing social distancing, remote work, reducing employee travel, restricting building access and more. In taking such precautionary actions, we may experience disruptions in our supply chain, operations, facilities and workforce, which could negatively affect efficiency and productivity, cause delays in developing new products, our ability to market products and services, and, ultimately, our stock price and financial performance.
Additional future impacts to us may include, but are not limited to, material adverse effects on the demand for our products and services, our supply chain and sales and distribution channels, our cost structure and profitability. An extended period of global supply chain and economic disruption could materially affect our business, results of operations and financial condition.
The situation regarding the pandemic continues to evolve, and future strains of the
COVID-19
virus may impact us. To the extent the
COVID-19
pandemic adversely affects our business, results of operations, financial condition and stock price, it may also have the effect of heightening many of the other risks described in this section.
RISKS RELATING TO OUR BUSINESS AND INDUSTRY
Our business strategy is dependent on successfully promoting internal growth and identifying and integrating acquisitions.

Our business has grown significantly over the past several years as a result of both internal growth and acquisitions of existing businesses and their products. Management initiatives may be attempted to augment internal growth, such as strengthening our presence in select markets, reallocating research and development funds to products with higher growth potential, products, development of new applications for our technologies, enhancing our service offerings, continuing key customer efforts, and finding new markets for our products. Failure of these management initiatives may have a material adverse effect on our operating results and financial condition.

Identifying and pursuing acquisition opportunities, integrating these acquisitions into our business and managing their growth requires a significant amount of management’s time and skill. We cannot assure that we will be effective in identifying, integrating or managing future acquisition targets. Our failure to successfully integrate and manage a future acquisition may have a material adverse effect on our operating results and financial condition.

In addition, if we continue to experience growth in our business, such growth could place a significant strain on our management, customer service, operations, sales and administrative personnel, and other resources. To serve the needs of our existing and future customers we will be required to recruit, train, motivate and manage qualified employees. We have incurred and will continue to incur significant costs to retain qualified management, sales and marketing, engineering, production, manufacturing and administrative personnel, as well as expenses for marketing and promotional activities. Our ability to manage our planned growth depends upon our success in expanding our operating, management, information and financial systems, which might significantly increase our operating expenses.

We may not be able to effectively manage our future growth, and if we fail to do so, our business, financial condition and results of operations could be adversely affected.

We are subject to risks relating to existing international operations and expansion into new geographical markets.
We focus on expanding sales globally as part of our overall growth strategy and expect sales from outside the United States to continue to represent a significant portion of our revenue. In fiscal 2022, sales to customers outside of the U.S. accounted for 39.7% of our total revenue. Neogen’s international operations are subject to general risks related to such operations, including:
political, social and economic instability and disruptions, including social unrest, geopolitical tensions, currency, inflation and interest rate uncertainties;
government export controls, economic sanctions, embargoes or trade restrictions;
the imposition of duties and tariffs and other trade barriers;
17

Table of Contents
limitations on ownership and on repatriation or dividend of earnings;
transportation delays and interruptions;
labor unrest and current and changing regulatory environments;
increased compliance costs, including costs associated with disclosure requirements and related due diligence;
difficulties in staffing and managing multi-national operations;
limitations on Neogen’s ability to enforce legal rights and remedies;
current products may not comply with product standards established by foreign regulatory bodies;
access to or control of networks and confidential information due to local government controls and vulnerability of local networks to cyber risks; and
fluctuations in foreign currency exchange rates.
If Neogen is unable to successfully manage the risks associated with expanding our global business or adequately manage operational risks of our existing international operations, these risks could have a material adverse effect on our growth strategy into new geographical markets, our reputation, our business, results of operations, financial condition and cash flows. In addition, the impact of such risks may be outside of Neogen’s control and could decrease our ability to sell products internationally, which could adversely affect our business, financial condition, results of operations or cash flows. For example, as a result of the ongoing military conflict between Russia and Ukraine and resulting heightened economic sanctions from the United States and the international community, Neogen has discontinued sales into Russia and Belarus. The United States and other countries have imposed significant sanctions and could impose even wider sanctions and take other actions should the conflict further escalate. While it is difficult to anticipate the effect the sanctions announced to date may have on Neogen, any further sanctions imposed or actions taken by the United States or other countries, including any expansion of sanctions beyond Russia and Belarus, could affect the global price and availability of raw materials, reduce our sales and earnings or otherwise have an adverse effect on our business and results of operations.
We rely significantly on our information systemssystems’ infrastructure to support our operations and a failure of these systems and infrastructure and/or a security breach of the Company’sour information systems could damage the Company’sour reputation and have an adverse effect on operations and results.

We rely on our information systemssystems’ infrastructure to integrate departments and functions, to enhance our ability to service customers, to improve our control environment and to manage our cost reduction initiatives. If a security breach or cyberattack of our IT networks and systems occurs, our operations could be interrupted. Any issues involving our critical business applications and infrastructure may adversely impact our ability to manage our operations and the customers we serve. Although we have controls and security measures in place to prevent such attacks, experienced computer hackers are increasingly organized and sophisticated. Malicious attack efforts operate on a large scale and sometimes offer targeted attacks as a
paid-for
service. In addition, if the Company’stechniques used to access or sabotage networks change frequently and generally are not recognized until launched against a target.
We rely on several information systems throughout our company, as well as those of our third-party business partners, to provide access to our
web-based
products and services, keep financial records, analyze results of operations, process customer orders, manage inventory, process shipments to customers, store confidential or proprietary information and operate other critical functions. Although Neogen employs system backup measures and engages in information system redundancy planning and processes, such measures, as well as our current disaster recovery plan, may be ineffective or inadequate to address all vulnerabilities. Further, our information systems and our business partners’ and suppliers’ information systems may be vulnerable to attacks by hackers and other security breaches, including computer viruses and malware, through the internet (including via devices and applications connected to the internet), email attachments and persons with access to these information systems, such as our employees or third parties with whom we do business. As information systems and the use of software and related applications by us, our business partners, suppliers and customers become more cloud-based, there has been an increase in global cybersecurity vulnerabilities and threats, including more sophisticated and targeted cyber-related attacks that pose a risk to the security of our information systems and networks and the confidentiality, availability and integrity of data and information.
While we have implemented network security and internal control measures, especially for the purpose of protecting our connected products and services from cyberattacks, and invested in our data and information technology infrastructure, there can be no assurance that these efforts will prevent a system disruption, attack, or security breach and, as such, the risk of system disruptions and security breaches from a cyberattack remains.
18

Table of Contents
If our security and information systems are compromised, or employees fail to comply with the applicable laws and regulations, andor this information is obtained by unauthorized persons or used inappropriately, it could adversely affect the Company’sour reputation, as well as results of operations, and could result in litigation, the imposition of penalties, or significant expenditures to remediate any damage to persons whose personal information has been compromised.

Disruption of our manufacturing and service operations could have an adverse effect on our financial condition and results of operations.

We manufacture our products at several manufacturing facilities located in the following locations: Lansing, Michigan; Lexington, Kentucky; Randolph, Wisconsin; Kenansville, North Carolina; Pleasantville, Iowa; Memphis, Tennessee; Turlock, California; Heywood, England; Ayr, Scotland; Rochdale, England; and Pindamonhangaba, Brazil. We offer genomics services from facilities located in: Lincoln, Nebraska; Ayr, Scotland; and Aracatuba, Brazil. These

Our facilities and our distribution systems are subject to catastrophic loss due to fire, flood, terrorism or other natural or
man-made
disasters. If any of theseour facilities were to experience a catastrophic loss, it could disrupt our operations, delay production, shipments and revenue and result in significant expenses to repair or replace the facility and/or distribution system. If such a disruption were to occur, we could breach agreements, our reputation could be harmed, and our business and operating results could be adversely affected. Although we carry insurance for property damage and business interruption, we do not carry insurance or financial reserves for interruptions or potential losses arising from terrorism. Economic conditions and uncertainties in global markets may adversely affect the cost and other terms upon which we are able to obtain third party insurance. If our third partywe are unable to obtain sufficient and cost-effective third-party insurance coverage, is adversely affected, or to the extent we have elected to self-insure, we may be at greater risk that our operations will be harmed by a catastrophic loss.

Our dependence on suppliers could limit our ability to sell certain products or negatively affect our operating results.

We rely on third partythird-party suppliers to provide raw materials and other components in our products, manufacture products that we do not manufacture ourselves and perform services that we do not provide ourselves, including package delivery services.ourselves. Because these suppliers are independent third parties with their own financial objectives, actions taken by them could have a negative effect on our results of operations. The risks of relying on suppliers include our inability to enter into contracts with third party suppliers on reasonable terms, inconsistent or inadequate quality control, relocation of supplier facilities, supplier work stoppages and suppliers’ failure to comply with their contractual obligations. In addition, we currently purchase some raw materials and products from sole or single sources. Some of the products that we purchase from these sources are proprietary and, therefore, cannot be readily or easily replaced by alternative sources. Problems with suppliers and the supply chain could negatively impact our ability to supply the market, substantially decrease sales, lead to higher costs or damage our reputation with our customers.

We rely heavily on third partythird-party package delivery services, and a significant disruption in these services or significant increases in prices may disrupt our ability to ship products, increase our costs and lower our profitability.

We ship a significant portion of our products to our customers through independent package delivery companies, such as UPS, Federal Express and DHL. We also ship our products through other carriers, including national and regional trucking firms, overnight carrier services and the U.S. Postal Service. If one or more of these third partythird-party package delivery providers were to experience a major work stoppage, preventing our products from being delivered in a timely fashion or causing us to incur additional shipping costs we could not pass on to our customers, our costs could increase and our relationships with some of our customers could be adversely affected. In addition, if one or more of our third partythird-party package delivery providers were to increase prices, and we were not able to find comparable alternatives or make adjustments inwithin our delivery network, our profitability could be adversely affected.

Our business sells many products through distributors, which present risks that could negatively affect our operating results.

We sell many of our products, both within and outside of the U.S., through distributors.distribution. As a result, we are dependent on these distributors to sell our products and assist us in promoting and creating a demand for our products. Our distributors sometimes offer products from several different companies, and those distributors may carry our competitors’ products and promote our competitors’ products over our own. We have limited ability, if any, to cause our distributors to devote adequate resources to promoting, marketing, selling and supporting our products. We cannot assure that we will be successful in maintaining and strengthening our relationships with our distributors or establishing relationships with new distributors who have the ability to market, sell and support our products effectively. We may rely on one or more key distributors for a product or region, and the loss of one or more of these distributors could reduce our revenue. Distributors maycould face financial difficulties, including bankruptcy, which could harmimpact our collection ofability to collect our accounts receivable and negatively impact our financial results. In addition, violations of anti-bribery and anti-corruption laws or similar laws by our distributors could have a material impact on our business, and anybusiness. Further, termination of a distributor relationship maycould result in increased competition in the applicable jurisdiction. Failing to manage the risks associated with our use of distributors maycould reduce sales, increase expenses and weaken our competitive position, which could have a negative impact on our operating results.

19

Table of Contents
The development of new products entails substantial risk of failure due to the production of
non-viable
products, lack of properly identifying market potential, and competitors better serving the marketplace.

Our growth strategy includes significant investment in and expenditures for product development. To execute this strategy, we are continually developing new products for which we believe there should be significant market demand. We cannot assure that we will successfully develop commercially viable products, that the products will be developed on a timely basis to meet market demand or that the relevant market will be properly identified. Our competitors may also adapt more quickly, and deliver superior technologies, price and/or service to better fit our customers’ requirements. If we expend substantial resources in developing an unsuccessful product, whether that lack of success is the result of our production of a
non-viable
product, a misidentified market, or a competitor’s superior ability to meet our customers’ requirements, operating results could be adversely affected.

Our international operations are subject to different product standards as well as other operational risks.

In fiscal 2017, sales to customers outside of the U.S. accounted for 35.8% of the Company’s total revenue. We expect that our international business will continue to account for a significant portion of our total revenue. Foreign regulatory bodies may establish product standards different from those in the U.S. and with which the Company’s current products do not comply. Our potential inability to design products that comply with foreign standards could have a material adverse effect on our future growth. Other risks related to our sales to customers outside of the U.S. include possible disruptions in transportation, difficulties in building and managing foreign distribution, fluctuation in the value of foreign currencies, changes in import duties and quotas and unexpected economic and political changes in foreign markets. These factors could adversely affect international sales and our overall financial performance.

The markets for our products are extremely competitive, and our competitors may be able to utilizecould use existing resource advantages to our detriment.

The markets in which the Company competeswe compete are subject to rapid and substantial changes in technology and are characterized by extensive research and development and intense competition. Many of ourOur competitors and potential competitors may have greater financial, technical, manufacturing, marketing, research and development and management resources than we do. These competitors might be able tocould use their resources, reputations and ability to leverage existing customer relationships to give them a competitive advantage over us. They might also succeed in developing products that are more reliable and effective than our products, make additional measurements, are less costly than our products or provide alternatives to our products.

We are dependent on the agricultural marketplace, which is affected by factors beyond our control.

Our primary customers are in the agricultural and food production industries. Economic conditions affecting agricultural industries are cyclical and are dependent upon many factors outside of our control, including weather conditions, changes in consumption patterns or commodity prices. Any of these factors in the agricultural marketplace could affect our sales and overall financial performance.

RISKS RELATED TO AN INVESTMENT IN OUR SECURITIES
Our quarterly or annual operating results are subject to significant fluctuations.

We have experienced, and may experience in the future, significant fluctuations in our quarterly or annual operating results. The mix of products sold and the acceptance of new products, in addition to other factors such as cost increases, could contribute to this quarterly variability. We operate with relatively little backlog and have few long-term customer contracts. Substantially all of our product revenue in each quarterperiod results from orders received in that quarter.period. In addition, our expense levels are based, in part, on our expectation of future revenue levels. ATherefore, a shortfall in expected revenue could therefore, result in a disproportionate decrease in our net income.

The market price of our common stock may be highly volatile.
The trading price of our common stock may be volatile. Securities markets worldwide experience significant price and volume fluctuations. This market volatility, as well as other general economic, market or political conditions, could reduce the market price of our common stock rapidly and unexpectedly, despite our operating performance. Factors that may impact the market price of our common stock include the factors described in this “Risk Factors” section and elsewhere in this Form
10-K,
as well as:
Public announcements (including the timing of these announcements) regarding our business, financial performance, acquisitions and prospects or new products or services, product enhancements or technological advances by our competitors or us;
Trading activity in our stock, including transactions by us, our executive officers and directors, and significant stockholders; trading activity that results from the ordinary course rebalancing of stock indices in which we may be included, such as the S&P
Mid-Cap
400 Index; trading activity related to our inclusion in, or removal from, any stock indices; and short-interest in our common stock, which could be significant from time to time;
Investor perception of us and the industry and markets in which we operate, including changes in earnings estimates or buy/sell recommendations by securities analysts; and whether or not we meet earnings estimates of securities analysts who follow us; and
General financial, domestic, international, economic and market conditions, including overall fluctuations in the U.S. equity markets, which may experience extreme volatility that, in some cases, is unrelated or disproportionate to the operating performance of particular companies.
20

Table of Contents
GENERAL RISK FACTORS
Our success is highly dependent on our ability to obtain protection for the intellectual property utilized in our products.

products; these products could be the subject of patent infringement challenges.

Our success and ability to compete depends in part uponon our ability to obtain protection in the United StatesU.S. and other countries for our products by establishing and maintaining intellectual property rights relating to or incorporated intocapable of protecting our technology and products. Patent applications filed by the Companyus may not result in the issuance of patents or, if issued,granted, may not be issuedgranted in a form that will be commercially advantageous to us. Even if issued,granted, patents maycan be challenged, narrowed, invalidated or circumvented, which could limit our ability to stop competitors from marketing similar products or limit the length of time we may have patent protection for our products. We also cannot assure that our nondisclosure agreements, together with trade secrets and other common law rights, will provide meaningful protection for the Company’sour trade secrets and other proprietary information. Moreover, the laws of some foreign jurisdictions may not protect intellectual property rights to the same extent as in the United States,U.S., and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights domestically or in foreign jurisdictions, we maycould incur substantial costs and our business, including our business prospects, could be substantially harmed.

From time to time, the Company haswe have received notices alleging that the Company’sour products infringe third partythird-party proprietary rights. Whether the manufacture, sale or use of current products, or whether any products under development would, upon commercialization, infringe any patent claim will notcannot be known with certainty unless and until a court interprets the patent claim in the context of litigation. When an infringement allegation is made against us, we may seek to invalidate the asserted patent claim and/or to allege
non-infringement
of the asserted patent claim. In order forFor us to invalidate a U.S. patent claim, we would need to rebut the presumption of validity afforded to issued patents in the United StatesU.S. with clear and convincing evidence of invalidity, which is a high burden of proof. The outcome of infringement litigation is subject to substantial uncertainties, and also the testimony of experts as to technical facts upon which experts may reasonably disagree. Our defense of an infringement litigation lawsuit could result in significant expense. Regardless of the outcome, infringement litigation could significantly disrupt our marketing, development and commercialization efforts, divert management’s attention and consume our financial resources. In the event that we are found to infringe any valid claim in a patent held by a third party, we may,could, among other things, be required to:

Pay damages, including up to treble damages and the other party’s attorneys’ fees, which may be substantial;

Cease the development, manufacture, importation, use and sale of products that infringe the patent rights of others, through a court-imposed injunction;

Expend significant resources to redesign our technology so that it does not infringe others’ patent rights, or develop or acquire
non-infringing
intellectual property, which may not be possible;

Discontinue manufacturing or other processes incorporating infringing technology; and/or

Obtain licenses to the infringed intellectual property, which may not be available to us on acceptable terms, or at all.

Any development or acquisition of
non-infringing
products, technology or licenses could require the expenditure of substantial time and other resources and could have a material adverse effect on our business and financial results. If we are required to, but cannot, obtain a license to valid patent rights held by a third party, we would likely be prevented from commercializing the relevant product, or from further manufacture, sale or use of the relevant product.

We are subject to substantial governmental regulation.

A portion of our products and facilities are regulated by various domestic and foreign government agencies including, but not limited to, the U.S. Department of Agriculture, the U.S. Food and Drug Administration and the Environmental Protection Agency. A significant portion of our revenue is derived from products used to monitor and detect the presence of residues that are regulated by various government agencies. Furthermore, the Company’sour growth may be adversely affected by the implementation of new regulations. The Company is not aware of any failures to comply with applicable laws and regulations; the costs of compliance or failure to comply with any obligations related to these laws or regulations could adversely impact theour business.

We are dependent on key employees.

Our success depends, in large part, on members of our management team. Our loss of any of these, or other key employees could have a material adverse effect on the Company.us. We maintain certain incentive plans for key employees, and most of these employees have been with the Company in excess of five years. However, we have not executed long-term employment agreements with any of these employees and do not expect to do so in the foreseeable future. Our success depends, significantly, on our ability to continue to attract and retain such personnel. We cannot assure that we will be able to retain our existing personnel or attract additional qualified persons when required and on acceptable terms.

Our business may be subject to product or service liability claims.

The manufacturing and distribution of the Company’sour products involveor performance of our services involves an inherent risk of product liability claims being asserted against us. Regardless of whether we are ultimately determined to be liable or our products are determined to be defective, we might incur significant legal
21

Table of Contents
expenses not covered by insurance. In addition, product or service liability litigation could damage our reputation and impair our ability to market our products and services, regardless of the outcome. Litigation could also impair our ability to retain product liability insurance or make our insurance more expensive. Although the Companywe currently maintainsmaintain liability insurance, we cannot assure that we will be able to continue to obtain such insurance on acceptable terms, or that such insurance will provide adequate coverage against all potential claims. If we are subject to an uninsured or inadequately insured product or services liability claim, our business, financial condition and results of operations could be adversely affected.

Market prices for securities of technology companies are highly volatile.

The market prices for securities of technology companies have been volatile

Changing political conditions could adversely impact our business and financial results.
Changes in the past and could continue to be volatilepolitical conditions in the future. Fluctuations in our financial performance from period to period could have a significant impact on the market price of our common shares.

Operating results could be negatively impacted by economic, political or other developments in countriesmarkets in which we do business.

Future operatingmanufacture, sell or distribute our products may be difficult to predict and may adversely affect our business and financial results. In addition, results of elections, referendums or other political processes in certain markets in which our products are manufactured, sold or distributed could be negatively impacted by unstable economic, political and social conditions, including but not limited to fluctuations in foreign currency exchange rates, political instability, or changes in the creation or interpretation ofcreate uncertainty regarding how existing governmental policies, laws and regulations may change, including with respect to sanctions, taxes, the movement of goods, services, capital and people between countries and other matters. The potential implications of such uncertainty, which include, among others, exchange rate fluctuations, trade barriers and market contraction, could adversely affect the Company’s business and financial results.

Climate change, or administrative actionslegal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations.
Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in each of the countries where the Company conducts business, including the United States.

These potential negative impacts include, but are not limited to: reduction of demand for someatmosphere could present risks to our future operations from natural disasters and extreme weather conditions, such as hurricanes, tornadoes, earthquakes, wildfires or flooding. Such extreme weather conditions could pose physical risks to our facilities and disrupt operation of our products, increasesupply chain and may impact operational costs. The impacts of climate change on global water resources may result in water scarcity, which could in the future impact our ability to access sufficient quantities of water in certain locations and result in increased costs. Concern over climate change could result in new legal or regulatory requirements designed to mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory requirements, we may experience increased compliance burdens and costs to meet the regulatory obligations and may adversely affect raw material sourcing, manufacturing operations and the distribution of our products.

Tax legislation could materially adversely affect our financial results and tax liabilities.
The Company’s business is subject to
tax-related
external conditions, such as tax rates, tax laws and regulations, changing political environments in the U.S. and foreign jurisdictions that impact tax examination, assessment and enforcement approaches. In addition, changes in tax laws including further regulatory developments arising from U.S. tax reform legislation and/or regulations around the world could result in a tax expense or benefit recorded to the Company’s consolidated statement of earnings. In connection with guidance such as the Base Erosion and Profit Shifting (BEPS) Integrated Framework provided by Organization for Economic Cooperation and Development (OECD), determination of multi-jurisdictional taxation rights and the rate of order cancellations or delays, increased risk of excess and obsolete inventories, increased pressure on the prices for our products and services, and longer sales cycles and greater difficulty in collecting accounts receivable.

Additionally, the Company operates in multiple income tax jurisdictions and must determine the appropriate allocationapplicable to certain types of income may be subject to eachpotential change. Due to uncertainty of the regulation changes and other

tax-related
factors stated above, it is currently not possible to assess the ultimate impact of these jurisdictions basedactions on current interpretations of complex incomeour financial statements.
Although we believe that our historical tax regulations.positions are sound and consistent with applicable laws, regulations and existing precedent, there can be no assurance that our tax positions will not be challenged by relevant tax authorities or that we would be successful in any such challenge. Income tax audits associated with the allocation of income and other complex issues may result in significant income tax adjustments that could negatively impact the Company’sour future operating results.

22

Table of Contents
ITEM 1B.
UNRESOLVED STAFF COMMENTS – NONE

ITEM 2.
PROPERTIES

Principal Manufacturing, Distribution and Administrative locations

Location

Approximate Square
Feet

Operations

Ownership

Lansing, Michigan

300,000Corporate, Food Safety, Animal SafetyOwned

Lexington, Kentucky

210,000Animal SafetyOwned

Kenansville, North Carolina

26,000Animal SafetyLeased, expires 12/2017

St Joseph, Michigan

7,000Animal SafetyLeased, month to month

Randolph, Wisconsin

113,000Animal SafetyOwned

Pleasantville, Iowa

59,000Animal SafetyLeased, expires 12/2018

Lincoln, Nebraska

26,000Animal SafetyOwned

Memphis, Tennessee

66,100Animal SafetyOwned

Turlock, California

29,500Animal SafetyLeased, expires 9/2022

Guelph, Ontario, Canada

700Animal SafetyLeased, expires 7/2019

Ayr, Scotland, United Kingdom

74,000Food SafetyOwned

Heywood, England, United Kingdom

24,800Food SafetyOwned

Rochdale, England, United Kingdom

60,000Food SafetyOwned

Indaiatuba, Brazil

6,800Food SafetyLeased, expires 5/2021

Aracatuba, Brazil

2,000Food SafetyLeased, expires 10/2017

Pindamonhangaba, Brazil

55,300Food SafetyOwned

Naucalpan, Mexico

27,000Food SafetyLeased, expires 10/2018

Shanghai, China

4,900Food SafetyLeased, expires 2/2019

Beijing, China

1,100Food SafetyLeased, expires 12/2017

Kochi, India

5,500Food SafetyLeased, expires 4/2018

The Company’slocations:

Location
  
Square Feet
   
Owned
   
Leased
   
Segment
U.S.
   1,146,100    6    5   Corporate, Food Safety, Animal Safety
Canada
   4,800    1    0   Animal Safety
United Kingdom
   190,800    3    2   Food Safety
Ireland
   39,000    1    0   Food Safety
Italy
   1,000    0    1   Food Safety
UAE
   1,100    0    1   Food Safety
Brazil
   82,800    1    1   Food Safety
Mexico
   33,580    0    4   Food Safety
Guatemala
   1,700    0    1   Food Safety
Argentina
   7,500    0    1   Food Safety
Uruguay
   3,200    0    1   Food Safety
Chile
   3,200    0    1   Food Safety
China
   7,900    0    1   Food Safety
India
   9,500    1    1   Food Safety
Australia
   34,600    1    1   Animal Safety
  
 
 
   
 
 
   
 
 
   
Total
  
 
1,566,780
 
  
 
14
 
  
 
21
 
  
  
 
 
   
 
 
   
 
 
   
Our corporate headquarters are located in Lansing, Michigan, with administrative, sales, manufacturing and warehousing in other locations domestically and globally. These properties are in good condition, well-maintained, and generally suitable and adequate to carry on the Company’ssupport our business.

For leased properties, we do not anticipate difficulty in renewing existing leases or in finding alternative facilities.
ITEM 3.
LEGAL PROCEEDINGS

Neogen is subject to certain legal proceedings in the normal course of business that, in the opinion of management, should not have a material effect on itsour future results of operations or financial position.

On March 6, 2020, the Company received an administrative subpoena from the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran. The Company subsequently conducted an internal investigation under the direction of outside legal counsel and disclosed information concerning certain genomic testing services provided to an unrelated U.S.-based party engaged in veterinary activities involving an Iranian party. The Company continues to cooperate with OFAC’s investigation and is currently examining whether certain of these activities may be eligible for OFAC General Licenses authorizing agricultural and veterinary activities. In addition to responding to the administrative subpoena, the Company has implemented additional compliance measures to prevent inadvertent dealings with restricted countries or parties. These measures further enhance the Company’s international trade compliance program, which is designed to assure that the Company does not conduct business directly or indirectly with any countries or parties subject to economic sanctions and export control laws of the U.S. and other applicable jurisdictions. Although it is too early to predict what action, if any, that OFAC will take, the Company does not currently have any reason to believe that OFAC’s pending investigation will have a meaningful impact on its operations, the results of operations for any future period, or its overall financial condition. In fiscal 2020, the Company took a charge to expense and recorded a reserve of $600,000 to provide for potential fines or penalties on this matter. At this time, the Company believes that it is adequately reserved for this issue.

ITEM 4.
MINE SAFETY DISCLOSURES NOT APPLICABLE

23

Table of Contents
PART II

ITEM 5.
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

MARKET INFORMATION:

Market Information
Neogen Common Stock is traded on the NASDAQ Global Select Market under the symbol “NEOG”. The following table sets forth, for the fiscal periods indicated, the high and low sales prices for the Common Stock as reported on the NASDAQ Stock Market.

   High   Low 

Year ended May 31, 2017

    

First Quarter

  $60.56   $49.30 

Second Quarter

  $63.57   $50.53 

Third Quarter

  $69.09   $61.25 

Fourth Quarter

  $68.98   $59.51 

Year ended May 31, 2016

    

First Quarter

  $62.70   $44.90 

Second Quarter

  $59.76   $43.00 

Third Quarter

  $60.38   $45.00 

Fourth Quarter

  $53.02   $43.79 

HOLDERS:

NEOG.

Holders
As of June 30, 2017,2022, there were approximately 281215 stockholders of record of Common Stockour common stock. The actual number of holders is greater than this number of holders and management believes thereincludes stockholders who are a total of approximately 12,000 beneficial holders.

DIVIDENDS:

owners but whose shares are held in street name by brokers and other nominees.

Dividends
Neogen has never paid cash dividends on its Common Stock and does not anticipate paying cashexpect to pay dividends in the foreseeable future.

Securities Authorized for Issuance under Equity Compensation Plan
 
   Equity Compensation Plan Information 
(shares in thousands)
  Number of shares to be issued upon
exercise of outstanding options and
RSUs (1)
   Weighted average
price of
outstanding options
and RSUs
   Number of securities remaining available for future
issuance under equity compensation plans (excluding
securities reflected in first column) (2)
 
Equity compensation plans approved by shareholders
   3,501   $32.42    5,386 
Equity compensation plans not approved by shareholders
   —     
 
 
    —   
   3,501   $32.42    5,386 
(1)
Outstanding options and RSUs as of May 31, 2022.
(2)
Reflects shares available for future issuance as May 31, 2022 under our 2018 Omnibus Incentive Plan dated August 28, 2018 and approved by shareholders on October 4, 2018.
For additional information, see Note 5, Equity Compensation Plans, in the consolidated financial statements.
The graph below matches Neogen Corporation’s cumulative5-year
5-Year
total shareholder return on common stock with the cumulative total returns of the NASDAQ Composite index and the NASDAQ Medical Equipment index. The graph tracks the performance of a $100 investment in our common stock and in each index (with the reinvestment of all dividends) from May 31, 20125/31/2017 to May 31, 2017.

   5/12   5/13   5/14   5/15   5/16   5/17 

Neogen Corporation

   100.00    139.88    145.57    180.05    190.18    243.80 

NASDAQ Composite

   100.00    123.46    155.08    186.71    183.49    231.19 

NASDAQ Medical Equipment

   100.00    110.10    114.40    146.23    155.20    204.07 

5/31/2022.

24

Table of Contents

   
5/17
   
5/18
   
5/19
   
5/20
   
5/21
   
5/22
 
Neogen Corporation
  
 
100.00
 
  
 
159.50
 
  
 
118.71
 
  
 
150.04
 
  
 
194.47
 
  
 
111.49
 
NASDAQ Composite
  
 
100.00
 
  
 
121.34
 
  
 
122.84
 
  
 
158.05
 
  
 
230.68
 
  
 
204.09
 
NASDAQ Medical Equipment
  
 
100.00
 
  
 
127.47
 
  
 
113.54
 
  
 
125.55
 
  
 
180.52
 
  
 
123.62
 
S&P Life Sciences Tools & Services
  
 
100.00
 
  
 
119.37
 
  
 
145.59
 
  
 
178.60
 
  
 
247.39
 
  
 
247.97
 
The stock price performance included in this graph is not necessarily indicative of future stock price performance.

Issuer Purchases

25

Table of Equity Securities

In December 2008, the Board of Directors authorized management to repurchase up to a total of 1,125,000 shares of its common stock in open market transactions. This authorization remains in effect; however, the Company made no purchases of common stock in fiscal years 2017, 2016 and 2015.

Contents

ITEM 6.
SELECTED FINANCIAL DATA
RESERVED

ITEM 7.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following tables set forth selected consolidateddiscussion and analysis of our financial datacondition and results of Neogen for the year ended May 31, 2017, and each of the four preceding fiscal years. The selected consolidated financial data presented below have been derived from the Company’s consolidated financial statements. This financial dataoperations should be read in conjunction with the consolidated financial statements and related notes and other financial information appearing elsewhere in this Form10-K.

   Years Ended May 31 
(in thousands, except per share data)  2017  2016  2015  2014  2013 

Income Statement Data:

      

Food Safety Revenues

  $171,325  $146,421  $131,479  $116,290  $106,158 

Animal Safety Revenues

   190,269   174,854   151,595   131,115   101,370 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Total Revenues

   361,594   321,275   283,074   247,405   207,528 

Cost of Revenues

   189,626   168,211   143,389   124,807   98,034 

Sales and Marketing

   62,424   57,599   51,757   46,432   40,791 

General and Administrative

   34,214   29,189   25,233   24,449   20,216 

Research and Development

   10,385   9,890   9,577   8,326   7,781 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Operating Income

   64,945   56,386   53,118   43,391   40,706 

Other Income (Expense)

   1,728   (873  (1,042  (360  435 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Income Before Income Taxes

   66,673   55,513   52,076   43,031   41,141 

Provision for Income Taxes

   22,700   18,975   18,500   15,000   14,100 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net Income

   43,973   36,538   33,576   28,031   27,041 

Net (Income) Loss Attibutable toNon-Controlling Interest

   (180  26   (50  127   149 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net Income Attributable to Neogen

  $43,793  $36,564  $33,526  $28,158  $27,190 
  

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

Net Income per Share (basic) (1)

  $1.16  $0.98  $0.91  $0.77  $0.76 

Net Income per Share (diluted) (1)

  $1.14  $0.97  $0.90  $0.76  $0.75 

Weighted Average Shares Outstanding (diluted) (1)

   38,374   37,875   37,444   37,267   36,491 
   2017  2016  2015  2014  2013 

Balance Sheet Data:

      

Cash and Cash Equivalents and Marketable Securities

  $143,635  $107,796  $114,164  $76,496  $85,369 

Working Capital (2)

   256,959   219,628   205,739   163,779   150,728 

Total Assets

   528,409   449,940   392,181   345,301   290,558 

Long-Term Debt

   —     —     —     —     —   

Total Equity

   471,757   404,161   350,963   306,300   258,287 

(1)On October 30, 2013, the Company paid a3-for-2 stock split affected in the form of a dividend of its common stock. All share and per share amounts have been adjusted to reflect the stock split as if it had taken place at the beginning of the period presented.

(2)Defined as current assets less current liabilities.

ITEM 7.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The information in this Management’s Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen Corporation management does not provide forecasts of future financial performance. While management is optimistic about the Company’s long-term prospects, historical financial information may not be indicative of future financial results.

Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “seeks,” “estimates,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependenceAnnual Report on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company’s reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation’s results to differ materially from those indicated by such forward-looking statements, including those detailed in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Form

10-K.
In addition, any forward-looking statements represent management’s views only as of the day this Report on Form
10-K
was first filed with the Securities and Exchange Commission and should not be relied upon as representing management’s views as of any subsequent date. While managementwe may elect to update forward-looking statements at some point in the future, itwe specifically disclaimsdisclaim any obligation to do so, even if itsour views change.

TRENDS AND UNCERTAINTIES
During fiscal 2022, we experienced higher than expected input cost inflation, including higher transportation, supply chain and labor costs, that negatively impacted operating results. Pricing actions taken during fiscal 2022 mitigated some, but not all, of the inflationary pressures. Ongoing inflation may also have an impact on our customer’s purchasing decisions and order patterns. We estimate inflation will continue to affect us in fiscal 2023, although at this time it is impracticable to quantify the impact.
Although we have no operations in or direct exposure to Russia, Belarus and Ukraine, we have experienced intermittent shortages in materials and increased costs for transportation, energy and raw materials due, in part, to the negative impact of the Russia-Ukraine military conflict on the global economy. To date, our European operations and customer base have not been materially impacted by the conflict, however, as the conflict continues or worsens, it may impact our business, financial condition or results of operations in fiscal 2023.
As we continue to monitor the ongoing
COVID-19
pandemic, our top priority remains protecting the health and safety of our employees, their families, and those in our communities. Safety guidelines and procedures have been developed for
on-site
employees and these policies are regularly monitored and updated by our internal Emergency Response Team.
In fiscal 2022,
COVID-19,
including new strains of the virus such as Delta and Omicron, continued to impact our business operations and financial results. A number of our food safety diagnostic product lines have been negatively impacted due to decreased demand in many of our customers’ businesses around the world, particularly those serving restaurants, bars and other institutional food service markets. Many of our markets across the world are recovering, but the pandemic has continued to adversely impact our customers and ultimately, our revenues. We have also experienced supply chain difficulties including vendor disruptions, border closures, shipping issues and significantly increased shipping costs; labor shortages and higher labor costs, as we have had to use staffing agencies and increase our base pay in many areas of the Company to fill open positions; and restricted travel, which hinders our ability to connect with customers.
Overall, the impact of
COVID-19
remains uncertain and ultimately depends on the length and severity of the pandemic, inclusive of the introduction of new strains of the virus; government actions taken in response; vaccination rates and effectiveness; the impact of vaccination requirements; extent of protection provided by prior viral infection; and the macroeconomic environment. We will continue to evaluate the nature and extent to which
COVID-19
will impact our business, supply chain, including labor availability and attrition, consolidated results of operations, financial condition, and liquidity; we expect it to impact us through at least the end of our fiscal year ending May 31, 2023.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The discussion and analysis of the Company’sour financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including but not limited to, those related to receivable allowances, inventories and intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Though the impact of the
COVID-19
pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. Actual results may differ from these estimates under different assumptions or conditions.

The following critical accounting policies reflect management’s more significant judgments and estimates used in the preparation of the consolidated financial statements.

Revenue Recognition

Revenue from products and services is recognized when the product has been shipped or the service performed, the sales price is fixed and determinable, and collection

26

Table of any receivable is probable. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred and later recognized in the period that all recognition criteria have been met. Customer credits for sales returns, pricing and other disputes, and other related matters (including volume rebates offered to certain distributors as marketing support) represent approximately 3% of reported net revenue for each period presented.

Accounts Receivable Allowance

Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, that amount is charged against the allowance for doubtful accounts.

Inventory

A reserve for obsolete and slow moving inventory has been established and is reviewed at least quarterly based on an analysis of the inventory, taking into account the current condition of the asset as well as other known facts and future plans. The reserve required to record inventory at lower of cost or market may be adjusted as conditions change. Product obsolescence may be caused by shelf-life expiration, discontinuance of a product line, replacement products in the marketplace or other competitive situations.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenantsnot-to-compete and patents. Amortizable intangible assets are amortized on either an accelerated or a straight-line basis, generally over 5 to 25 years. The Company reviews the carrying amounts of goodwill and othernon-amortizable intangible assets annually, or when indications of impairment exist, to determine if such assets may be impaired by performing a quantitative assessment. If the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysis and comparison to comparable EBITDA multiples of peer companies, such assets are reduced to their estimated fair value and a charge is made to operations.

Long-lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset indicate that the carrying amount of the asset may not be recoverable. In such an event, fair value is determined using discounted cash flows and, if lower than the carrying value, impairment is recognized through a charge to operations.

Equity Compensation Plans

Share options awarded to employees and shares of stock awarded to employees under certain stock purchase plans are recognized as compensation expense based on their fair value at grant date. The fair market value of options granted under the Company’s stock option plans was estimated on the date of grant using the Black-Scholes option-pricing model using assumptions for inputs such as interest rates, expected dividends, volatility measures and specific employee exercise behavior patterns based on statistical data. Some of the inputs used are not market-observable and have to be estimated or derived from available data. Use of different estimates would produce different option values, which in turn would result in higher or lower compensation expense recognized.

To value options, several recognized valuation models exist. None of these models can be singled out as being the best or most correct one. The model applied by the Company is able to handle most of the specific features included in the options granted, which is the reason for its use. If a different model were used, the option values could differ despite using the same inputs. Accordingly, using different assumptions coupled with using a different valuation model could have a significant impact on the fair value of employee stock options. Fair value could be either higher or lower than the number provided by the model applied and the inputs used. Further information on the Company’s equity compensation plans, including inputs used to determine the fair value of options, is disclosed in Notes 1 and 5 to the consolidated financial statements.

Contents

Income Taxes

The Company accounts

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carry forwardscarryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

The Company’s wholly-owneddetermination of income subject to income tax in each tax paying jurisdiction requires us to apply transfer pricing guidelines for certain intercompany transactions.

Our tax rate is subject to adjustment over the balance of the year due to, among other things, income tax rate changes by governments; the jurisdictions in which our profits are determined to be earned and taxed; changes in the valuation of our deferred tax assets and liabilities; adjustments to our interpretation of transfer pricing standards; changes in available tax credits or other incentives; changes in stock-based compensation expense; changes in tax laws or the interpretation of such tax laws; and changes in U.S. generally accepted accounting principles.
Although we believe our tax estimates are reasonable and we prepare our tax filings in accordance with all applicable tax laws, the final determination with respect to any audit, and any related litigation, could be materially different from our estimates or from our historical income tax provisions and accruals. The results of an audit or litigation could have a material effect on operating results and/or cash flows in the periods for which that determination is made. In addition, future period earnings may be adversely impacted by litigation costs, settlements, penalties, and/or interest assessments.
Our wholly owned foreign subsidiaries are comprised of Neogen Europe, Lab M Holdings, Quat-Chem Ltd, Abbott Analytical Limited, Delf (UK) Limited, Delf-Chem Solutions Limited, Megazyme Ltd, Megazyme IP, Neogen Italia S.r.l., Neogen do Brasil, Rogama Industria e Comercio Ltda, Neogen Latinoamérica, Neogen Guatemala, Neogen Argentina, Neogen Uruguay, Neogen Chile SpA, Neogen
Bio-Scientific
Technology Co (Shanghai), Neogen Food and Animal Security (India), Neogen Canada, Acumedia do Brasil, Deoxi Biotecnologia Ltda,Neogen Canada Properties LLC and Rogama Industria e Comercio, Ltda; Neogen owns 90% of Neogen Latinoamerica.Australasia Pty Limited. Based on historical experience, as well as the Company’smanagement’s future plans, earnings from these subsidiaries are expected to be
re-invested
indefinitely for future expansion and working capital needs. Furthermore, the Company’sour domestic operations have historically produced sufficient operating cash flow to mitigate the need to remit foreign earnings. On an annual basis, the Company evaluateswe evaluate the current business environment and whether any new events or other external changes might require a
re-evaluation
of the decision to indefinitely
re-invest
foreign earnings. At May 31, 2017, unremittedIt is not practicable to determine the income tax liability that would be payable if such earnings were not reinvested indefinitely.
Business Combinations and Contingent Consideration
We allocate the purchase price of acquired companies to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The estimates used to value the net assets acquired are based in part on historical experience and information obtained from management of the foreign subsidiaries were $35,281,000.

acquired company. We generally value the identifiable intangible assets acquired using a discounted cash flow model. The significant estimates used in valuing certain of the intangible assets include, but are not limited to: future expected cash flows of the asset, discount rates to determine the present value of the future cash flows, attrition rates of customers, royalty rates and expected technology life cycles. We also estimate the useful lives of the intangible assets based on the expected period over which we anticipate generating economic benefit from the asset.

Our estimates of fair value are based on assumptions believed to be reasonable at that time. If we made different estimates or judgments, it may result in material differences in the fair values of the net assets acquired.
Certain business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. We record contingent consideration at fair value at the date of acquisition based on the consideration expected to be transferred, estimated as the probability weighted future cash flows, discounted back to present value. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment and projected revenues (for revenue-based considerations); various methodologies can be used to determine fair value of contingent consideration, including Monte Carlo simulations, among others. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. The discount rate used is determined at the time of measurement in accordance with accepted valuation methodologies. Changes in projected revenues, probabilities of payment, discount rates and projected payment dates may result in adjustments to the fair value measurements. Contingent consideration is remeasured each reporting period using Level 3 inputs, and the change in fair value, including accretion for the passage of time, is recognized in other income (expense) in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows.
27

Table of Contents
RESULTS OF OPERATIONS

Executive Overview

Total consolidated revenue

(in thousands, except earnings per share)
  
2022
  
2021
  
%
 
Consolidated
    
Revenues
  $ 527,159  $ 468,459   13
Organic Sales Growth
    
 
9
Food Safety
    
Revenues
  $259,979  $234,244   11
Organic Sales Growth
    
 
7
Animal Safety
    
Revenues
  $267,180  $234,215   14
Organic Sales Growth
    
 
12
% of International Sales
   40  39 
Effective Tax Rate
   19.8  19.1 
Net Income
  $48,307  $60,882   (21)% 
Earnings per Diluted Share
  $0.45  $0.57  
Cash from Operations
  $68,038   81,089  
Food Safety organic sales exclude revenues from the acquisitions of Megazyme (December 2020) and Delf/Abbott Analytical (November 2021).
Animal Safety organic sales exclude revenues from the acquisitions of StandGuard (July 2020), CAPInnoVet (September 2021) and Genetic Veterinary Sciences (December 2021).
Net income was negatively impacted by $25.6 million in the current fiscal year due to legal and consulting expenses for Neogen Corporationdue diligence related to our recently announced agreement to combine with 3M’s Food Safety business.
Neogen’s international revenues were $209.3 million in fiscal 2017 was $361.62022, compared to $183.2 million in fiscal 2021, an increase of 13% compared to revenue of $321.3 million14%. Currency translation had a negligible impact on revenues for the full year, with gains in the U.K., Italy, Mexico, Brazil, China, and Canada partially offset by negative impact in Argentina, Chile, India and Australia. In a neutral currency environment, sales would have been $844,000 lower than reported in fiscal 2016. Net income attributable to Neogen rose 20% to $43.8 million, or $1.14 per fully diluted share, compared to $36.6 million, or $0.97 per fully diluted share, in fiscal 2016. Cash flow from operations2022.
28

Table of Contents
Sales results for fiscal 2017 was $60.3 million compared to $35.3 million in fiscal 2016.

The Company’s Food Safety segment revenues were $171.3 million in fiscal 2017, an increase of 17%, and Animal Safety segment revenues were $190.3 million, an increase of 9%, each2022 compared to the prior fiscal year. Recent acquisitionsyear are as follows for each of Lab M (August 2015), Virbac (December 2015), Deoxi (April 2016), Preserve (May 2016), Quat-Chem (December 2016) and Rogama (December 2016) contributed $27.7 million ofour international locations:

   
Revenue
Change
USD
  
Revenue
Change
Local Currency
 
U.K. Operations (including Neogen Italia)
   13  12
Brazil Operations
   1  (2)% 
Neogen Latinoamerica
   11  9
Neogen Argentina
   34  71
Neogen Uruguay
   9  9
Neogen Chile
   33  43
Neogen China
   0  (3)% 
Neogen India
   19  21
Neogen Canada
   37  35
Neogen Australasia
   25  27
The 13% revenue increase at our combined U.K. operations in fiscal 2017; overall organic2022 was led by a 25% increase in sales of cleaners and disinfectants, primarily from strong sales in the U.K. and Asia, and new culture media business with commercial laboratories in the U.K. that have adopted our recently launched One Broth One Plate workflow. Revenues in Brazil increased 1% in USD in fiscal 2022 but decreased 2% in local currency; market gains in genomics services in the beef market were offset by lower sales of dairy drug residue test kits, due to competitive pressures.
Neogen Latinoamerica revenues rose by 11% in USD in fiscal 2022, led by growth was 4%.

Internationalin natural toxins test kits, environmental sanitation products and culture media. China’s sales were $129.3flat, as growth in the first half of the fiscal year was offset by lower sales in the last six months due to lockdowns and restrictions resulting from China’s “Zero COVID” strategy. Sales at Neogen Australasia increased 25% for fiscal 2022, led by new genomics service business in the bovine, sheep and companion animal markets.

Service revenue, which consists primarily of genomics services sales to animal protein and companion animal markets, was $102.5 million in fiscal 2017, or 35.8%2022, an increase of total revenues, compared11% over prior fiscal year sales of $92.2 million. The growth was led by the previously mentioned strength in Australia and Brazil, and was partially offset by lower volumes of domestic companion animal samples, the result of a difficult comparison due to $107.7 million, or 33.5% of total revenues,large increases in the prior year. The
29

Table of Contents
REVENUES
   
Year Ended
 
(dollars in thousands)
  
May 31, 2022
   
Change
  
May 31, 2021
   
Change
  
May 31, 2020
 
Food Safety:
        
Natural Toxins, Allergens & Drug Residues
  $79,395    4 $76,614    1 $76,207 
Bacterial & General Sanitation
   47,282    7  44,009    5  41,780 
Culture Media & Other
   75,278    23  61,245    28  47,847 
Rodenticides, Insecticides & Disinfectants
   35,691    11  32,219    12  28,890 
Genomics Services
   22,333    11  20,157    12  17,967 
  
 
 
    
 
 
    
 
 
 
  $ 259,979    11 $ 234,244    10 $ 212,691 
Animal Safety:
        
Life Sciences
   5,685    (1%)   5,715    (10%)   6,322 
Veterinary Instruments & Disposables
   63,938    33  48,128    12  42,941 
Animal Care & Other
   39,805    11  35,897    26  28,389 
Rodenticides, Insecticides & Disinfectants
   83,610    8  77,458    13  68,815 
Genomics Services
   74,142    11  67,017    14  59,012 
  
 
 
    
 
 
    
 
 
 
  $267,180    14 $234,215    14 $205,479 
  
 
 
    
 
 
    
 
 
 
Total Revenue
  $527,159    13 $468,459    12 $418,170 
  
 
 
    
 
 
    
 
 
 
Year Ended May 31, 2022 Compared to Year Ended May 31, 2021
Food Safety:
Natural Toxins, Allergens
 & Drug Residues –
Sales in this category increased 4% in fiscal 2022, with a 6% increase in international sales of natural toxin test kits and a 9% increase in sales of our allergens product line partially offset by a 33% decrease in sales of drug residue test kits, as a percentagewe are discontinuing sales of total sales wascertain lower margin products due to recent international acquisitions and strengthcompetitive market pressure.
Bacterial
 & General Sanitation –
Sales in thepre-existing international operations. Forthis category increased 7% in fiscal 2022 compared to the year, revenues at Neogen Europeprior year. Sales of our AccuPoint
®
sanitation monitoring product line increased 13% (32% increase in local currency) due primarily to12% aided by strong sales of deoxynivalenol (DON) test kits resulting from outbreaksour new reader. Sales of contaminated corn crops in western Europe, and increases in genomics revenues resulting from strong demand for these services in Europe and the addition of anin-house genomics lab in Ayr. Neogen do Brasil revenuesour Listeria Right Now
product increased 65% for the year (46% increase in local currency)25%, withwhile sales of forensic and diagnostic test kits leading the growth. Revenues at Neogen Latinoamerica declined by 7% (6% increaseproducts to detect spoilage organisms in local currency) due to adverse currency translations and the termination of a distribution agreement for certain of its cleaners and disinfectantsprocessed foods increased 4%.
Culture Media
 & Other –
Sales in the 4th quarter of fiscal 2017. Neogen China revenues rose 24% (32% increase in local currency) and Neogen India salesthis category increased 67% (70% increase in local currency), each off of small bases.

Service revenue was $55.1 million23% in fiscal 2017, an increase of $7.4 million, or 15%,2022 compared to fiscal 2016.2021; excluding sales from the December 2020 acquisition of Megazyme, sales increased 11%. Sales of Neogen Culture Media products rose 16% as our new workflow, One Broth One Plate, continued to drive growth and increased sales to commercial labs in the U.K.; a large

non-recurring
sale to a domestic vaccine manufacturer in the first quarter also contributed to the current year growth.
Rodenticides, Insecticides
 & Disinfectants –
Revenues of products in this category sold through our Food Safety operations increased 11% in fiscal 2022 compared to fiscal 2021. Excluding revenues from the November 2020 acquisition of Delf and Abbott Analytical, the growth was 3%. The increase was primarily due to higher genomics revenues duecontinued strength in sales of cleaners and disinfectants to continued market penetration in U.S. beef and dairy cattle markets, strong demand in Europe and additional genomics capacity resulting from laboratory facilities constructed at our Scotland-based operation, and incremental ongoing business with a large customer in the poultry industry. Revenues were also enhanced, to a lesser extent, by the April 2016 acquisition of Deoxi Laboratories, an agricultural genomics lab in Brazil.

Gross margin was 47.6% in both fiscal years 2017 and 2016. In the current year, acquisitions of businesses with gross margins which are lower than the Company’s historical average, and the adverse margin impact resulting from currency translation, were entirely offset by favorable product mix shifts on existing products and higher genomics margins, resulting in gross margins that were flat compared to the prior year.

Sales and marketing expenses were $62.4 million, an increase of $4.8 million, or 8%, compared to the prior fiscal year. Increases in this category were primarily the result of increased personnel related costs such as salaries, commissions and travel; shipping and royalty expenses also rose due to the increased volume. General and administrative expenses were $34.2 million, an increase of $5.0 million, or 17%. Incremental ongoing operating expenses from the most recent four acquisitions, which continued to operate from their existing locations, and related amortization expense accounted for $2.6 million of the increase. Other increases in this category resulted from investments in information technology personnel and infrastructure and increased salary and benefit expenses across the organization. Research and development expenses increased 5% to $10.4 million, primarily due to increased personnel related expenses and new product development activities, partially offset by lower contracted outside services.

Operating margin in fiscal 2017 was 18.0% compared to 17.6% in the prior fiscal year. The improvement in operating margin resulted from the revenue increases, flat gross margins, and growth in operating expenses which was less than the rate of the revenue increase.

Other income of $1.7 million in fiscal 2017 included $838,000 of net interest income, a $660,000 gain recorded as the result of the settlement of a licensing agreement, $171,000 of royalty income, and a loss of $40,000 from currency translations. Fiscal 2016 other expense of $873,000 included a $1,338,000 loss from currency translations, partially offset by interest income of $322,000 and royalty income of $217,000.

The effective income tax rate for fiscal 2017 was 34.0%, compared to 34.2% in the prior fiscal year.

REVENUES

   Year Ended 

(dollars in thousands)

  May 31, 2017   Increase/
(Decrease)
  May 31, 2016   Increase/
(Decrease)
  May 31, 2015 

Food Safety:

        

Natural Toxins, Allergens & Drug Residues

  $70,926    12 $63,269    4 $60,561 

Bacterial & General Sanitation

   34,706    2  33,899    15  29,492 

Dehydrated Culture Media & Other

   40,658    9  37,285    27  29,423 

Rodenticides, Insecticides & Disinfectants

   13,620    223  4,213    (8%)   4,568 

Genomics Services

   11,415    47  7,755    4  7,435 
  

 

 

    

 

 

    

 

 

 
   171,325    17  146,421    11  131,479 

Animal Safety:

        

Life Sciences

   9,704    24  7,815    (10%)   8,715 

Veterinary Instruments & Disposables

   41,693    (1%)   42,028    1  41,740 

Animal Care & Other

   29,495    (19%)   36,494    32  27,606 

Rodenticides, Insecticides & Disinfectants

   69,825    31  53,490    17  45,857 

Genomics Services

   39,552    13  35,027    27  27,677 
  

 

 

    

 

 

    

 

 

 
   190,269    9  174,854    15  151,595 
  

 

 

    

 

 

    

 

 

 

Total Revenue

  $361,594    13 $321,275    13 $283,074 
  

 

 

    

 

 

    

 

 

 

Year Ended May 31, 2017 Compared to Year Ended May 31, 2016

The Company’s Food Safety segment revenues in fiscal 2017 were $171.3 million compared to $146.4 million in fiscal 2016, an increase of 17%. Organic growth for the segment was 9%, with the acquisitions of Lab M (August 2015), Deoxi (April 2016), Quat-Chem (December 2016) and Rogama (December 2016) contributing the remainder of the growth. Adverse currency conditions,Asia resulting from the strengthAfrican swine fever outbreak in that region increasing demand, and higher sales to a U.K.-based toll manufacturer.

Genomics Services –
Sales of the U.S. dollar, reduced overall growth and organic growth within the segment for the comparative period. In a neutral currency environment, overallgenomics services sold through our Food Safety growth for the year was 22% and organic growth was 14%.

Natural Toxins, Allergens & Drug Residues salesoperations increased by 12% to $70.9 million11% in fiscal 2017. Within this category, sales of natural toxin test kits increased 19%, led by sales of test kits and related equipment to detect the mycotoxin deoxynivalenol (DON), due to outbreaks of DON in corn crops in the midwest U.S., Canada and western Europe. Allergen test kit revenues rose 16% for the year, as increases in product recalls relating to allergenic contamination of food continued to expand the market. The largest increases in this product line were test kits to detect milk, gliadin, tree nut, hazelnut and peanut contamination. Partially offsetting these increases, sales of test kits to detect drug residues were down 4%, due primarily to market losses in Europe caused by delays in the launch of new products, and, to a lesser extent, currency translations, as this product is sold in euros, which declined 2% against the dollar in fiscal 2017. A number of new and improved drug residue detection products are expected to be available for sale in the first half of fiscal 2018.

Bacterial & General Sanitation revenues rose 2%, compared to the prior fiscal year, led by a 4% increase in sales of the Company’s line of automated equipment and consumable vials to detect spoilage microorganisms (e.g. yeast and mold), and an 11% increase in sales ofSalmonella test kits for the year as the Company gained market share with its ANSR product line. These increases were partially offset by lower sales of a distributed product that the Company discontinued in fiscal 2017. The Company’s line of AccuPoint readers and samplers to monitor environmental sanitation rose 4% for the year, with samplers increasing 7%, while equipment was flat compared to fiscal 2016. Dehydrated Culture Media & Other sales increased 9% in fiscal 2017, aided in part by the acquisition of Lab M; organic sales in this category increased 6%. Within this category, there was a significant increase in sales of forensic test kits through the Company’s Brazilian subsidiary. Demand for these kits from commercial labs located in Brazil has increased dramatically due to a new requirement for drug testing of commercial truck drivers. Partially offsetting this increase was an 11% decrease in sales of the Company’s Acumedia line of dehydrated culture media sold into traditional domestic markets; the first half of fiscal 2016 had strong sales resulting from a research project, which did not recur.

Rodenticides, Insecticides & Disinfectants sales into the Company’s Food Safety segment increased 223%, almost entirely due to the acquisitions of Rogama (Brazil), which reports through Neogen do Brasil, and Quat-Chem (U.K.), which reports through Neogen Europe; each was purchased in December 2016. Excluding these acquisitions, growth in this category was 3%, primarily from rodenticide and disinfectant sales into Mexico and Central America by the Company’s Mexican subsidiary. Genomics revenues into Food Safety increased 47%, primarily due to strong demand of genomics testing in Europe and expanded capabilities at the Company’s operation in Ayr, Scotland to better serve the growing European market; the Deoxi acquisition in April 2016 also contributed to the growth.

Revenues for the Company’s Animal Safety segment were $190.3 million in fiscal 2017, an increase of 9% compared to prior year revenues of $174.9 million. The revenue growth resulted from the acquisitions of Virbac (December 2015) and Preserve (May 2016). In the first quarter of fiscal 2017, the Company lost the ability to sell its popular canine thyroid replacement product after the FDA approved a new drug application for a competitor, which gave the competitor exclusive marketing rights to the product. The Company will be unable to sell this product, which had sales of $6.2 million in fiscal 2016, in the U.S. until similar regulatory approval is granted; this approval is currently expected to occur in fiscal 2019. Additionally, in January 2017, the Company’s agreement to distribute certain cleaners and disinfectants was canceled, resulting in the loss of $1.3 million of sales in the 4th quarter of fiscal 2017. Excluding these products, this segment had overall organic growth of 5% for the year. Currency translations had minimal effect on revenues in this segment.

Life Sciences sales increased 24% in fiscal 2017, compared to the prior year. This growth was primarily due to increased volume to U.S. commercial labs to meet new requirements for drug testing of commercial truck drivers in Brazil. Veterinary Instruments & Disposables revenues decreased 1%, due to lower sales of disposable syringes, which had increased sales in the prior year due to a competitor’s backorder situation, and marking products. Partially offsetting this were gains in the sales of the Company’s proprietary detectable needles and durable speed needles, with both gains due to strong demand from customers. Animal Care & Other sales decreased 19% due to the loss of the ability to sell the Company’s popular thyroid replacement product, mentioned above. Partially offsetting this was an increase in revenues for vitamin injectable products due to increased market share and price increases.

Rodenticides, Insecticides & Disinfectants revenues increased 31% for the current fiscal year, due to the acquisitions of Virbac (December 2015) and Preserve (May 2016); organic sales in this category were flat. The Preserve acquisition added $15.5 million of revenue in fiscal 2017, primarily to the domestic swine, poultry, dairy and food processing markets. Rodenticide sales increased 1% with strong sales in the custom solutions, retail and distribution markets offset by lower sales in the northwest U.S. after the prior year rodent outbreak subsided. Cleaners and disinfectant sales were 8% lower on an organic basis, due to the early termination of a distribution agreement for certain cleaners and disinfectants in the second half of the fiscal year; it is expected that there will be some offset of these lost revenues in fiscal 2018 by substitution of similar products from the planned transition to the Preserve product line.

Genomics Services revenues reported within the Animal Safety segment increased 13% in fiscal 2017, compared to fiscal 2016. The increase was due primarily to increased market share in the beef and dairy markets from new product offerings and focused sales efforts in these markets; also contributing to the increase was expanded business with a large customer in the poultry market.

Year Ended May 31, 2016 Compared to Year Ended May 31, 2015

The Company’s Food Safety segment revenues were $146.4 million in fiscal 2016, an 11% increase compared to the prior year. The increase, predominantly volume related, from organic sales was 6%, with revenues from the BioLumix (October 2014), Lab M (August 2015) and Deoxi (April 2016) acquisitions contributing the remainder of the growth. Sales of Natural Toxins, Allergens & Drug Residues increased 4% in fiscal 2016 compared to fiscal 2015. Natural toxin sales were flat with a 10% increase in aflatoxin sales offset by a 3% decrease in DON sales, due to outbreaks in the prior year which were not repeated in fiscal 2016. Allergen sales increased 20%, as increased consumer awareness continued to grow demand for these products, while sales of drug residue test kits decreased 5%, caused by currency conversions, as the majority of these sales are invoiced in euros.

Bacterial & General Sanitation revenues increased 15% in fiscal 2016, aided by $1.9 million in sales from the October 2014 BioLumix acquisition. Excluding BioLumix sales, the organic increase in these products was 9% over the prior year. The AccuPoint sanitation monitoring product line recorded an increase of 18% due to the continued successful introduction of an improved, next generation product line. Sales of the Soleris and BioLumix product lines, which detect spoilage organisms, increased 23% for the year (5% organic growth), with revenue increases in both equipment and disposable vials. Pathogen sales increased 4% in fiscal 2016 as2022 compared to the prior year, primarily due to an increaseincreased beef business in salesBrazil and higher sample volumes from a large customer in China.

30

Table ofListeria test kits to the commercial lab market.

Dehydrated Culture Media & Other sales increased 27% Contents

Animal Safety:
Life Sciences –
Sales in this category decreased 1% in fiscal 2016. This category includes $4.8 million of Lab M revenues, a business which was acquired in August 2015; excluding the impact of these revenues, the organic increase was 10%. Sales of Acumedia products into the food safety market increased 10% while sales into traditional domestic media markets increased 16%. Rodenticides, Insecticides & Disinfectants revenues decreased 8% in U.S. dollars, due to the strength of the dollar, poor economic conditions in a number of international markets and order timing from large distributors. Genomics service revenues in the Company’s international operations increased 4%.

The Company’s Animal Safety segment revenues were $174.9 million in fiscal 2016, a 15% increase, predominantly volume related, over fiscal 2015. Life Sciences sales decreased 10% in fiscal 2016 after a strong 16% increase in 2015. Sales of forensic kits to commercial labs declined as new testing requirements in Brazil for commercial drivers, originally anticipated to go into effect in late fiscal 2015, were delayed until the 4th quarter of fiscal 2016. Veterinary Instruments & Disposables increased 1%, as market share gains in disposable syringes, up 25%, and animal marking products, up 14%, were almost entirely offset by an 8% decrease in detectable needles, due to large orders in the prior year which did not recur, and an 11% decline in hoof and leg products, due to lower sales of these products to customers in the retail market.

Animal Care & Other product sales rose 32% in fiscal 2016, with the increase primarily the result of a new distribution agreement with a large manufacturer and supplier of dairy equipment, and strong sales of the Company’s line of thyroid replacement therapy for companion animals. Also contributing to growth in the Animal Care product category were increased sales of wound care products, as a key active ingredient which had been on backorder for much of fiscal 2015, became available in fiscal 2016, and veterinary antibiotics, due to a competitor exiting the business. During the fourth quarter of fiscal 2016, the Company was notified that a competitor had been granted approval on a new drug application for a competitive thyroid replacement product, effectively giving them exclusive rights to sell the product. As a result, the Company is unable to sell its product into the domestic market effective July 2016, until it is granted similar regulatory approval; this approval is expected in fiscal 2019. Sales of this product in fiscal 2016 were $6.2 million.

The Company’s line of Rodenticides, Insecticides & Disinfectants rose 17% in fiscal 2016, compared to the prior year, led by a 58% increase in sales of rodenticides. This increase was in large part the result of an expansion of the Company’s contract manufacturing business with a large marketer of rodenticides to the commercial and residential markets. Additionally, the Company successfully introduced a number of new products into the retail agricultural market, and also benefitted from the continued vole outbreak in the northwestern U.S. Cleaners and disinfectant revenues declined 9% compared to fiscal 2015, primarily due to lower sales to international customers as the strength of the U.S. dollar made the Company’s products less competitive internationally; poor economic conditions in a number of the Company’s key international markets also adversely impacted sales. The Company’s line of insecticides rose 3% in fiscal 2016, as incremental revenues from new product launches were almost entirely offset by lower sales of existing products due to timing of orders and backorders caused by a vendor issue.

Genomics Services revenues increased 27% in fiscal 20162022 compared to the same period in the prior year. Incrementalyear, primarily due to the loss of hair testing business with a large poultry producer, earnedU.S. commercial laboratory that moved to a different testing platform.

Veterinary Instruments
 & Disposables –
Revenues in this category increased 33% in fiscal 2015, was the primary driver2022 compared to fiscal 2021, led by a large increase in sales of the growth. The Company also continued to gain market shareveterinary instruments, including needles and syringes, resulting from recently won private label business.
Animal Care
 & Other –
Sales of these products increased 11% in fiscal 2016 with its proprietary chip technology, primarily2022 compared to cattlefiscal 2021; excluding the contribution of parasiticides from the September 2021 acquisition of CAPInnoVet, revenues in this category rose 6%. Growth in our biologics, small animal supplements and pig producers,wound care product lines were partially offset by a large decline in sales of dairy supplies due to the June 2020 termination of an agreement under which we distributed these types of products for a large manufacturer of dairy equipment.
Rodenticides, Insecticides
 & Disinfectants –
Sales in this category increased 8% in fiscal 2022, compared to the prior year. Insecticide sales increased 32%, led by strong demand in the farm and grew sample volume particularly with its largest customers. In addition, the canine testing service business grew 17% as the Company successfully commercialized new service offerings, developedhome channels, and cleaners and disinfectants sales rose 6%. These increases were partially offset by a 4% decline in rodenticide sales due to increased rodent pressure in the prior year, which resulted in a difficult comparison.
Genomics Services –
Sales in this category increased 11% in fiscal 2022 compared to fiscal 2021; excluding the December 2021 acquisition of Genetic Veterinary Sciences, the organic increase was 5%. The growth was led by increases in beef and sheep testing in Australia, due to improved market conditions, and higher sample volumes from domestic dairy and beef cattle and poultry customers. The increase was partially offset by a decline in domestic companion animal revenues due to a difficult comparison from strong prior year sales growth.
Year Ended May 31, 2021 Compared to Year Ended May 31, 2020
Food Safety:
The
COVID-19
pandemic, which began in the second half of fiscal 2020, continued to cause difficult operating conditions in many of our key market segments in fiscal 2021. Shelter in place orders across the U.S. and in most of our international markets, the closure or reduced output of businesses due to quarantine and/or local legislation, disruption in the supply chain resulting from reduction in
end-market
demand and shipping issues, and the inability of some markets to react quickly to these changes, each disrupted our revenues.
Natural Toxins, Allergens
 & Drug Residues –
Sales in this category increased 1% in fiscal 2021, with a 6% increase in sales of natural toxin test kits and a 5% increase in our allergens product line partially offset by a 30% decrease in sales of drug residue test kits. Sales of drug residue test kits have continued to decline as we ended an exclusive distributor agreement in Europe and faced competitive pressure and lower demand due to poor economic conditions.
Bacterial
 & General Sanitation –
Sales in this category increased 5% in fiscal 2021 compared to the prior year. Sales of products to detect spoilage organisms in processed foods increased 19% in fiscal 2021, resulting from sales of our new instrument (Soleris NG), which launched in the first quarter, and increased consumables sales from new instrument placements. Sales of our AccuPoint sanitation monitoring product line were flat as many customers were shut down or operating at reduced capacity for a portion of the year, resulting in use of less consumables. A next generation reader for this product line was launched late in the fourth quarter; there will be significant sales and marketing focus on this product line in fiscal 2022. Sales of test kits to detect pathogens decreased 2%, as lower sales of ANSR equipment were only partially offset by increases from our
Listeria
Right Now test kit, which grew 21% in fiscal 2021.
Culture Media
 & Other –
Sales in this category increased 28% in fiscal 2021 compared to fiscal 2020. Excluding sales from the December 2020 acquisition of Megazyme, sales increased 18%. This category includes sales of acquired inventory of
non-Neogen
manufactured products from our new businesses in Italy and the South American southern cone countries; these sales are not expected to continue long-term. This category also includes sales of veterinary instruments transferred to our U.K. sales team in fiscal 2021. Sales of Neogen Culture Media increased 1% as new business gained in the U.S. from a
COVID-19
vaccine manufacturer offset the loss of some business due to competitor pricing.
Rodenticides, Insecticides
 & Disinfectants –
Revenues of products in this category sold through our Food Safety operations increased 12% in fiscal 2021 compared to fiscal 2020, due primarily to continued strength in cleaners and disinfectant sales in China resulting from increased demand due to the African swine fever outbreak in that country and the
COVID-19
pandemic. We also benefitted from strong sales of hand and skin sanitizing products at our U.K.-based Quat-Chem location in the first quarter of this fiscal year.

31

Table of Contents
Genomics Services –
Sales of genomics services sold through our Food Safety operations increased 12% in fiscal 2021 compared to the prior year, primarily due to higher sales in the Chinese porcine and bovine markets.
Animal Safety:
Life Sciences –
Sales in this category decreased 10% in fiscal 2021 compared to the same period in the prior year, primarily the result of lower forensic drug test kit sales to large commercial labs in the U.S. as the
COVID-19
pandemic created less demand for testing; a reduction in sales of products to the U.S. horse racing industry in the U.S. also contributed to the decline, as racing activity was down.
Veterinary Instruments
 & Disposables –
Revenues in this category increased 12% in fiscal 2021 compared to fiscal 2020. Veterinary instruments sales increased 16% for the year, led by increases in detectable needles and syringes as we gained new customers and market share from a key competitor. Partially offsetting this increase was a 9% decline in protective wear sales, as gloves were on backorder for much of the current year due to COVID related demand.
Animal Care
 & Other –
Sales of these products increased 26% in fiscal 2021 compared to fiscal 2020; this category includes sales of food safety products sold through our Australian operation, the result of a February 2020 acquisition of a distributor. Excluding these sales, revenues in this category increased 21%. Sales of our small animal supplements, vitamin injectables, and joint pain products benefitted from growth in veterinary markets, as the
COVID-19
pandemic has led to an increase in pet ownership, particularly dogs and cats. Additionally, sales rose for our equine supplements and antibiotics, due to strong demand in these markets. This category also includes sales of our thyroid treatment for dogs, which became available for sale late in the fourth quarter. Partially offsetting these gains was a 49% decline in sales of dairy supplies due to the June 2020 termination of an agreement in which we distributed these products for a large manufacturer of dairy equipment.
Rodenticides, Insecticides
 & Disinfectants –
Sales in this category increased 13% in fiscal 2021, compared to the prior year. Rodenticide sales increased 42% as rodent pressure in certain areas of the U.S. increased significantly. Insecticide sales rose 15%, due in part to our acquisition of the StandGuard product line for fly control on July 31, 2020; organic sales in this category increased 7%. Cleaners and disinfectants sales decreased 15% resulting from lower sales of water treatment products and the transfer of a product line to our U.K. operation; additionally, opportunistic sales of sanitizing products in the fourth quarter of the prior year, due to extremely high demand early in the
COVID-19
pandemic, did not continue at those levels in fiscal 2021.
Genomics Services –
Sales in this category increased 14% in fiscal 2021 compared to fiscal 2020. The growth was led by strong increases to the U.S. and Australian companion animal markets, driven by increased pet adoption and higher consumer spending on pets during the
COVID-19
pandemic. Gains in the commercial beef and beef association markets in the U.S., Canada and Australia also contributed to the growth, as well as the recent launch of a new high-density chip for white leg shrimp.
COST OF REVENUES

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Cost of Revenues

  $189,626    13 $168,211    17 $143,389 

(in thousands)
  
2022
   
Change
  
2021
   
Change
  
2020
 
Cost of Revenues
  $ 284,146    12 $ 253,403    14 $ 221,891 
Cost of revenues increased 13%12% in fiscal 20172022 compared to fiscal 2021 and 17%increased 14% in fiscal 2016 in comparison with the prior years.2021 compared to fiscal 2020. This compares with revenue increases of 13% in both fiscal years.2022 and 12% in fiscal 2021. Expressed as a percentage of revenues,sales, cost of revenues was 52.4%53.9%, 52.4%54.1% and 50.7%53.1% in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively. InGross margins were 46.1%, 45.9%, and 46.9% for fiscal 2017, improvementsyears 2022, 2021, and 2020, respectively.
Fiscal 2022
– Our overall gross margin increased 20 basis points in fiscal 2022, primarily from a product mix shift to higher margin products in the Animal Safety gross margins, resulting from lowersegment. Partially offsetting this were higher raw material and freight costs within each segment, which resulted from continued supply chain disruptions, inflationary pressure, and ongoing issues related to
COVID-19
and its variants across most of our markets. The Company has taken pricing actions where appropriate in response to these cost increases.
Fiscal 2021
– Our overall gross margin declined 100 basis points in fiscal 2021 as pressure on the worldwide supply chain caused by the
COVID-19
pandemic resulted in increased overhead costs; in particular, freight costs on inventory purchases increased 53% in fiscal 2021 compared to the prior year. Additional cost increases resulted from personnel costs, in the genomics business and increased higher margin forensic kit sales into the commercial laboratory market, and strong growth in sales of higher margin mycotoxin and allergen test kits in the Food Safety segment, overcame the lower gross margins resultingpart from the Quat-Chemincreased volumes, but also due to labor
32

Table of Contents
shortages, contracted services primarily related to our recently launched instruments, and Rogama acquisitions. Forhigher health insurance costs domestically, as employees and their families utilized elective medical services postponed from the fourth quarter of fiscal 2016,2020 due to
COVID-19.
To a lesser extent, the strength of the U.S. dollar, which adversely impacted revenue with no corresponding declineshift in product cost, had the largest impact on the decline in gross margins compared to fiscal 2015. In addition, shifts in product mix within the Food Safety segment in part the result of acquisitions completed in fiscal years 2015 and 2016, towards products which havewith lower gross margins thannegatively impacted the segment average, and a shift in the proportion of Animalconsolidated gross margin percentage.
Food Safety revenues to the overall revenue of the Company, resulted in the decline in gross margins.

Gross Margins:

Food Safety gross margins were 55.3%50.2%, 56.7%49.2% and 59.7%51.4% in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively. During
Fiscal 2022 –
Food Safety margins increased 100 basis points in fiscal 2017,2022, due to a product mix shift within the Company purchasedsegment toward higher sales of diagnostic test kits in fiscal 2022; gross margin was also aided by a full year of sales of food quality products and enzymes from the Quat-ChemMegazyme acquisition.
Fiscal 2021 –
Food Safety margins decreased 220 basis points in fiscal 2021, primarily due to higher sales of equipment such as the Soleris NG, which was launched in the current year and Rogama businesses, which generatedhas lower gross margins lower than historical averages for this segment. These acquisitions,our diagnostic test kits, and the full year impact of the prior year acquisitions of Lab Mcleaners and Deoxi resulted in a 140 basis point decline indisinfectants sold through our China location, which reports through the Food Safety gross margins. In addition, gross marginssegment. We were also negatively impacted by the strength of the U.S. dollar relative to the international currencies in which the Company operates, primarily in Europe and Mexico, where the pound and peso declined in value against the U.S. dollar by 14% and 12%, respectively. These international operations report in through the Food Safety segment. Partially offsetting these negative impacts to gross margins were favorable shifts in product mix towards higher margin diagnostic test kits for mycotoxins and allergens. In fiscal 2016, lower gross margins resulted primarily from the strength in the U.S. dollar, which resulted in lower revenues and gross margins when international sales were converted from local currencies to the dollar. All currencies the Company operates in weakened against the dollar in fiscal 2016, pressuring margins in this segment. Additionally, revenues from the acquisition of Lab M, which were at lower average gross margins than the rest of the segment, standard cost adjustments at Neogen Latinoamerica,increased freight, labor and other product mix shifts withinoverhead costs throughout the segment, negatively impacted gross margins in Food Safety.

segment.

Animal Safety Gross Margins:
Animal Safety gross margins were 40.6%42.1%, 40.1%42.6% and 40.4%42.3% in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively. For
Fiscal 2022 –
Animal Safety gross margins decreased by 50 basis points in fiscal 2017, improvements in raw material costs2022, primarily due to significant product cost increases and favorable productinternational freight charges. Negative mix in the genomics businesseffects occurred from lower sales of higher margin rodenticide products and companion animal services.
Fiscal 2021 –
Animal Safety gross margins increased by 30 basis points, primarily from strong sales of forensic kitshigher margin rodenticide and companion animal products and cost efficiencies; somewhat offsetting these gains, gross margin in this segment was negatively impacted by higher freight costs as rates to commercial labs inbring product into inventory rose significantly during the U.S. more than offset the loss of high margin revenuesyear, from the thyroid replacement product for companion animals which the Company was required to stop selling at the end of fiscal 2016. For fiscal 2016, improved gross margins from the 58% increase in sales of rodenticides, which have higher than average gross margins within the segment, were somewhat offset by lower gross margins on revenues from the dairy distribution business initiated in August 2015, lower gross margins at GeneSeek due to the significant increase in poultry business, which has lower than average gross margins within the genomics product line,both domestic and other product mix shifts within the segment.

international sources.

OPERATING EXPENSES

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Sales and Marketing

  $62,424    8 $57,599    11 $51,757 

General and Administrative

   34,214    17  29,189    16  25,233 

Research and Development

   10,385    5  9,890    3  9,577 
  

 

 

    

 

 

    

 

 

 

Total Operating Expense

   107,023    11  96,678    12  86,567 
  

 

 

    

 

 

    

 

 

 

(dollars in thousands)
  
2022
   
Change
  
2021
   
Change
  
2020
 
Sales and Marketing
  $84,604    15 $73,443    5 $69,675 
General and Administrative
   82,742    62  51,197    15  44,331 
Research and Development
   17,049    5  16,247    10  14,750 
  
 
 
    
 
 
    
 
 
 
Total Operating Expense
  $ 184,395    31 $ 140,887    9 $ 128,756 
  
 
 
    
 
 
    
 
 
 
Overall operating expenses increased by 11%31% in fiscal 20172022 and 12%9% in fiscal 2016,2021, each compared to the prior year. These increases compareLegal, consulting and other professional fees totaling $25.6 million were incurred in conjunction with due diligence, negotiation of terms and integration planning for our proposed business combination with 3M’s Food Safety business, which was announced on December 14, 2021. Excluding costs related to revenue increasesthe 3M transaction, operating expenses were $158.8 million, an increase of 13% in each comparative period.

compared to the prior year.

Sales and Marketing:
Sales and marketing expenses increased by 8%15% in fiscal 20172022 compared to fiscal 2021 and 11%increased 5% in fiscal 2016, each2021 compared withto the prior year. As a percentage of sales, sales and marketing expense was 17.3%16.0%, 17.9%15.7% and 18.3%16.7% in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively. For fiscal 2017, salaries and commissions within the
Fiscal 2022
– The $11.2 million, or 15%, increase in sales and marketing function, which is also comprised of technical service, customer serviceexpenses in fiscal 2022 resulted primarily from increases in employee compensation expenses such as salaries, bonuses, and product management personnel, rose 10%, primarily due to increased staffingcommissions, and shipping expense, both reflecting the increase in revenue, while travelrevenues. Travel, meals and entertainment, and tradeshow expense were also higher, with customer-facing activities increasing significantly, the result of the easing of COVID-19 restrictions.
33

Table of Contents
Fiscal 2021
– The $3.8 million, or 5%, increase in sales and marketing expenses rose 7%. Other significant expensein fiscal 2021 resulted primarily from increases were domesticin employee compensation expenses such as salaries, bonuses, and commissions, reflecting the increase in sales for the year, as well as increased headcount as we returned to normal staffing levels. In addition, shipping expense, up 11% andcosts rose in line with the revenue increase,revenues, health insurance costs rose as employees and royalty expense,their families resumed receiving medical treatment and procedures which rose 35% due to increased sales in fiscal 2017 and aone-time credithad been deferred in the fourth quarter of the prior fiscal year. Advertising and outside services also increased to support the launch of a number of new products during the year, resulting from a retroactive rate reduction on a royalty agreement. Ofmost notably the $4.8Soleris NG and AccuPoint NG readers. Partially offsetting these increases was $3 million increase in expenses, approximately $2.2 million resulted fromdecreased spending for travel and meals and entertainment for the Company’s recent acquisitions. For fiscal 2016, salaries, commissionsyear, the result of travel restrictions and travel expenses rose 13%, primarily on increasesreductions in staffing and higher revenue. Other significant expense increases were
face-to-face
sales promotions and allowances, based on higher levelsactivities in most of sales toour markets for the Company’s largest distributors, shipping expense, up 13%majority of the year. Travel and in line withperson customer meetings did begin to pick up in some geographic areas in the revenue increase,second half of fiscal 2021 as
COVID-19
restrictions were eased.
General and shows and exhibits, which rose 22% on increased Company participation in trade shows.

Administrative:

General and administrative expenses rose 17%62% in fiscal 20172022 compared to fiscal 20162021 and by 16%15% in fiscal 20162021 compared to fiscal 2015. The increases2020. Legal, consulting and other professional fees totaling $25.6 million were incurred in conjunction with due diligence, negotiation of terms and integration planning for our proposed transaction to combine with 3M’s Food Safety business. Excluding costs related to the 3M transaction, general and administrative expenses increased 12% compared to the prior year. As a percentage of sales, general and administrative expense was 15.7% (10.8% excluding 3M transaction costs), 10.9% and 10.6% in fiscal years 20172022, 2021 and 2016, respectively, are primarily the result of higher salaries, due to additional headcount as well as compensation increases. Higher2020, respectively.
Fiscal 2022 –
In fiscal 2022, we spent $25.6 million on strategic consulting, legal and other professional fees related to due diligence, negotiation of terms and additional amortization of intangible assets, dueintegration planning for our proposed transaction to the Company’s recent acquisitions, also contributed tocombine with 3M’s Food Safety business. Excluding these costs, the increase in each comparative period.    

general and administrative expense in fiscal 2022 was 12%. Other increases in the current year included compensation related costs due to increased headcount and improved operating performance, incremental amortization expenses

(non-cash)
from recent acquisitions, higher levels of depreciation
(non-cash)
and related software and licensing costs from continued investments in information technology infrastructure and applications.
Fiscal 2021 –
In fiscal 2021, we spent $3.1 million on strategic consulting, legal and other professional fees related to acquisition activity for businesses which we were ultimately not successful in acquiring. Excluding these costs, the increase in general and administrative expense in fiscal 2021 was 8%. Other increases in the current year included compensation increases due to increased headcount, including the addition of a number of senior management positions, incremental amortization expenses
(non-cash)
resulting from recent acquisitions, and higher levels of depreciation
(non-cash)
and related software and licensing costs from continued investments in information technology infrastructure and applications. Increases in this cost category resulting from the Megazyme acquisition totaled $957,000.
Research and Development:
Research and development expenses increased 5% in fiscal 20172022 and 3%10% in fiscal 2016, each compared to the prior year. Higher salaries expense in each fiscal year, resulting from increased headcount, was partially offset by lower levels of consulting and other outside services. As a percentage of revenue, these expenses were 2.9% in fiscal year 2017, 3.1% in fiscal year 2016 and 3.4% in fiscal year 2015; the Company expects to spend 3% to 4% of total revenue on research and development annually.

OPERATING INCOME

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Operating Income

  $64,945    15 $56,386    6 $53,118 

The Company’s operating income increased by 15% in fiscal 2017 compared to fiscal 2016, and by 6% in fiscal 2016 compared to fiscal 2015. Expressed as a percentage of revenues, it was 18.0%, 17.6% and 18.8% in fiscal years 2017, 2016 and 2015, respectively.

The 15% increase in operating income for 2017 was due to the 13% increase in revenues and operating expense increases which were less than the revenue growth rate, combined with gross margins which, at 47.6% of sales, were the same as the prior year.

The 6% increase in operating income in fiscal 2016 was due primarily to the 13% increase in revenues and lower rates of increases in operating expenses, partially offset by the 170 basis point reduction in gross margin expressed as a percentage of revenues. The Company controlled its expense growth while incurring additional amortization and other expenses relating to its recent acquisitions.

OTHER INCOME (EXPENSE)

(dollars in thousands)

  2017   Increase   2016  Increase   2015 

Other Income (Expense)

  $1,728    n/a   $(873  n/a   $(1,042

Other Income (Expense) consists principally of royalty income, interest income from investing the Company’s excess cash balances, the impact of foreign currency transactions, adjustments to contingent consideration liabilities relating to acquisitions, and other

miscellaneous items.

Other Income of $1,728,000 in fiscal 2017 primarily consisted of net interest income of $838,000, a $660,000 gain recorded as the result of the settlement of a licensing agreement, $171,000 of royalty income, a net gain of $18,000 resulting from contingent consideration payments made during the year for prior year acquisitions, and a loss of $40,000 on foreign currency translations.

In fiscal 2016, Other Expense primarily consisted of losses on foreign currency translations of $1,338,000, the result of all foreign currencies in which we operate devaluing against the U.S. dollar. In addition, the Company recognized interest income of $322,000,

and royalty income of $217,000.

In fiscal 2015, Other Income (Expense) primarily consisted of losses on foreign currency translations of $1,124,000, the result of the stronger U.S. dollar during the year. In addition, the Company recognized interest income of $228,000, royalty income of $150,000 and net expense of $297,000 resulting from contingent consideration payments made during the year for prior year acquisitions. The contingent consideration adjustments consisted of $241,000 of income for SyrVet, $454,000 of expense for Prima Tech, and $84,000 of expense for Chem-Tech; these adjustments were the difference between the liability recorded at the initial purchase of each business and the actual payment made to the former owners, and were based on the achievement of sales goals for the first 12

months of the Company’s ownership.

PROVISION FOR INCOME TAXES

(dollars in thousands)

  2017   Increase  2016   Increase  2015 

Provision for Income Taxes

  $22,700    20 $18,975    3 $18,500 

The effective tax rate was 34.0% of pretax income in fiscal 2017, 34.2% in fiscal 2016 and 35.5% in fiscal 2015. Differences in the tax rate from the 35% U.S. statutory corporate rate were primarily due to increases from international taxes and the provision for state taxes, offset by tax deductions related to domestic manufacturing and credits related to research and development activities. The fiscal 2017 effective tax rate of 34.0% includes benefit from research and development credits, the Company’s domestic manufacturing deduction and reversal of a valuation allowance against net operating losses in Brazil, which the Company is utilizing. The Company is currently under audit by the Internal Revenue Service for fiscal years 2014-2016.

The effective tax rate declined in fiscal 2016 due primarily to amendments filed for the fiscal 2012, 2013 and 2014 federal income tax returns and an adjustment for fiscal 2015 relating to credits claimed for research and development activities. The Company engaged a third party in fiscal 2016 to perform a study of its research and development activities, and credits originally claimed thereon, for these prior annual periods. Based on the results of the study, the Company revised its calculations for its research and development activities for those periods,

resulting in higher tax credits.

NET INCOME AND INCOME PER SHARE

(dollars in thousands-except per share data)

  2017   Increase  2016   Increase  2015 

Net Income Attributable to Neogen

  $43,793    20 $36,564    9 $33,526 

Net Income Per Share-Basic

  $1.16    $0.98    $0.91 

Net Income Per Share-Diluted

  $1.14    $0.97    $0.90 

Net income increased by 20% in fiscal 2017 and increased by 9% in fiscal 2016,2021, each compared to the prior year. As a percentage of revenue, these expenses were 3.2% in fiscal year 2022, 3.5% in fiscal year 2021 and 3.5% in fiscal year 2020; we expect to spend between 3% and 4% of total revenue on research and development annually as we continue to make investments in our future growth.

Fiscal 2022 –
The 5% increase in research and development expenses in fiscal 2022 was primarily the result of increased compensation expense, resulting from scheduled annual increases and additional headcount, and increases in contracted services related to new product development. These increases were partially offset by a decrease in external reader development costs; these projects were completed in the prior fiscal year.
Fiscal 2021 –
The 10% increase in research and development expenses in fiscal 2021 was primarily the result of increased compensation expense, resulting from scheduled annual increases and additional headcount from the Megazyme acquisition, project expense relating to new product innovation, spending with outside partners on the new readers launched in this fiscal year, and testing and approval costs for new product development.
34

Table of Contents
OPERATING INCOME
(dollars in thousands)
  
2022
   
Change
  
2021
   
Change
  
2020
 
Operating Income
  $ 58,618    (21%)  $ 74,169    10 $ 67,523 
Operating income decreased 21% in fiscal 2022 compared to fiscal 2021 and increased by 10% in fiscal 2021 compared to fiscal 2020. Excluding the $25.6 million in transaction costs associated with 3M’s Food Safety business, operating income increased 13% in fiscal 2022 compared to the prior year. Expressed as a percentage of revenues, operating income was 11.1% (16.0% excluding 3M transaction costs), 15.8% and 16.1% in fiscal years 2022, 2021 and 2020, respectively. Gross margins rose by $28.0 million, or 13% in fiscal 2022 compared to the prior fiscal year; this was more than offset by a $43.5 million increase in operating expenses (including $25.6 million of 3M transaction costs).
In fiscal 2021, gross margins rose by $18.8 million, or 10%; this increase was partially offset by an increase of $12.1 million, or 9%, in operating expenses, resulting in a $6.6 million, or 10%, increase in operating income compared to fiscal 2020.
OTHER INCOME (EXPENSE)
Other Income (Expense) for the previous three fiscal years consisted of the following:
(dollars in thousands)
  
2022
   
2021
   
2020
 
Interest income (net of expense)
  $ 1,267   $ 1,614   $5,992 
Foreign currency transactions
   (40   (541   (1,178
Licenses and settlements
   —      9    (38
Magiar contingent consideration
   —      111    —   
Clarus contigent consideration
   356    —      —   
Livestock Genomics contingent consideration
   (136   37    —   
Other
   142    (131   6 
  
 
 
   
 
 
   
 
 
 
Total Other Income
  $1,589   $1,099   $4,782 
  
 
 
   
 
 
   
 
 
 
Interest income decreased by $347,000 in fiscal 2022 compared to fiscal 2021, due to lower interest rates in effect for most of the fiscal year. The loss from foreign currency translations in fiscal years 2022, 2021 and 2020 is the result of the changes in the value of foreign currencies relative to the U.S. dollar in countries in which we operate; the dollar strengthened against most of these currencies in all three years.
In fiscal 2022, we recorded adjustments totaling $220,000 for contingent consideration accruals related to acquisitions completed in prior years. In fiscal 2021, we received proceeds of $309,000 for a property loss settlement and recorded $300,000 of expense resulting from a legal settlement with a vendor. Additionally, adjustments to contingent consideration accruals in fiscal 2021 resulted in $148,000 of income. In fiscal 2020, we took a charge to expense and recorded a reserve of $600,000 to provide for potential fines or penalties resulting from an administrative subpoena issued by the U.S. Treasury Department’s Office of Foreign Asset Control. This was partially offset by a $483,000 gain resulting from a settlement with the Brazilian government related to sales taxes charged over several years, and proceeds received for a property loss settlement.
35

Table of Contents
PROVISION FOR INCOME TAXES
(dollars in thousands)
  
2022
   
Change
  
2021
   
Change
  
2020
 
Provision for Income Taxes
  $ 11,900    (17%)  $ 14,386    12 $ 12,830 
Income tax expense for fiscal 2022 was $11.9 million, an effective tax rate of 19.8%, compared to income tax expense of $14.4 million in 2021, an effective tax rate of 19.1%. For fiscal 2020, income tax expense of $12.8 million represented an effective tax rate of 17.7%.
Differences from the U. S. statutory rate of 21% to our effective rate are primarily due to provisions in the U.S. Tax Act and the exercise of stock options. Please refer to Note 6 to the consolidated financial statements for more information.
NET INCOME AND INCOME PER SHARE
(dollars in thousands, except per share data)
  
2022
   
Change
  
2021
   
Change
  
2020
 
Net Income
  $ 48,307    (21%)  $ 60,882    2 $ 59,475 
Net Income Per Share-Basic
  $0.45    $0.57    $0.57 
Net Income Per Share-Diluted
  $0.45    $0.57    $0.56 
Net income decreased 21% in fiscal 2022 compared to fiscal 2021, due to $25.6 million of professional fees related to the 3M transaction. Excluding these costs and adjusting the tax rate accordingly, net income was 12.1%would have been $67.9 million, an increase of 12% compared to fiscal 2021.
Net income increased 2% in fiscal 2017, 11.4%2021 compared to fiscal 2020, primarily due to the $6.7 million increase in operating income. The increase in operating income was partially offset by lower other income and higher tax expense for the year.
NON-GAAP
FINANCIAL MEASURES
This report includes certain financial information of Neogen that differs from what is reported in accordance with GAAP. These
non-GAAP
financial measures consist of EBITDA, Adjusted EBITDA and Adjusted EBITDA margin. These
non-GAAP
financial measures are included in this report because management believes that they provide investors with additional useful information to measure the performance of Neogen, and because these
non-GAAP
financial measures are frequently used by securities analysts, investors and other interested parties as common performance measures to compare results or estimate valuations across companies in Neogen’s industries.
EBITDA
We define EBITDA as net income before interest, income taxes, and depreciation and amortization. We present EBITDA as a performance measure because it may allow for a comparison of results across periods and results across companies in the industries in which Neogen operates on a consistent basis, by removing the effects on operating performance of (a) capital structure (such as the varying levels of interest expense and interest income), (b) asset base and capital investment cycle (such as depreciation and amortization) and (c) items largely outside the control of management (such as income taxes). EBITDA also forms the basis for the measurement of Adjusted EBITDA (discussed below).
Adjusted EBITDA
We define Adjusted EBITDA as EBITDA, adjusted for stock-based compensation and certain transaction fees and expenses. We present EBITDA because it provides an understanding of underlying business performance by excluding the following:
Stock-based compensation
. We believe it is useful to exclude stock-based compensation to better understand the long-term performance of the respective core businesses and to facilitate comparison with the results of peer companies.
Certain transaction fees and expenses.
We exclude fees and expenses related to certain transactions because they are outside of Neogen’s underlying core performance.
Adjusted EBITDA margin
We define Adjusted EBITDA margin as Adjusted EBITDA as a percentage of total revenues. We present Adjusted EBITDA margin as a performance measure to analyze the level of Adjusted EBITDA generated from total revenue.
These
non-GAAP
financial measures are presented for informational purposes only. EBITDA, Adjusted EBITDA and Adjusted EBITDA margin are not recognized terms under GAAP and should not be considered in isolation or as a substitute for, or superior to, net income (loss), operating income, cash flow from operating activities or other measures of financial performance. This information does not purport to represent the results Neogen would have achieved had any of the transactions for which an adjustment is made occurred at the beginning of the periods presented or as of the dates indicated. This information is inherently subject to risks and uncertainties. It may not give an accurate or complete picture of Neogen’s financial condition or results of operations for the periods presented and should not be relied upon when making an investment decision.
The use of the terms EBITDA, Adjusted EBITDA and Adjusted EBITDA margin may not be comparable to similarly titled measures used by other companies or persons due to potential differences in the method of calculation.
These
non-GAAP
financial measures have limitations as analytical tools. For example, for EBITDA-based metrics:
they do not reflect changes in, or cash requirements for, Neogen’s working capital needs;
they do not reflect Neogen’s tax expense or the cash requirements to pay taxes;
they do not reflect the historical cash expenditures or future requirements for capital expenditures or contractual commitments;
they do not reflect any cash requirements for future replacements of assets that are being depreciated and amortized; and
they may be calculated differently from other companies in Neogen’s industries limiting their usefulness as comparative measures.
You should compensate for these limitations by relying primarily on the financial statements of Neogen and using these
non-GAAP
financial measures only as a supplement to evaluate Neogen’s performance.
For each of these
non-GAAP
financial measures below, we are providing a reconciliation of the differences between the
non-GAAP
measure and the most directly comparable GAAP measure.
Reconciliation between net income and EBITDA and Adjusted EBITDA is as follows:
   
Year ended May 31
 
(in thousands)
  
2022
  
2021
  
2020
 
Net Income
  $48,307  $60,882  $59,475 
Net Income margin %
  
 
9.2
 
 
13.0
 
 
14.2
Provision for income taxes
   11,900   14,386   12,830 
Interest income, net
   (1,267  (1,614  (5,992
Depreciation and amortization
   23,694   21,041   18,396 
  
 
 
  
 
 
  
 
 
 
EBITDA
  
$
82,634
 
 
$
94,695
 
 
$
 84,709
 
Stock-based compensation
   7,154   6,437   6,468 
Certain transaction fees and expenses
   25,581   3,085   —   
  
 
 
  
 
 
  
 
 
 
Adjusted EBITDA
  
$
 115,369
 
 
$
 104,217
 
 
$
91,177
 
  
 
 
  
 
 
  
 
 
 
Adjusted EBITDA margin %
  
 
21.9
 
 
22.2
 
 
21.8
EBITDA, ADJUSTED EBITDA AND ADJUSTED EBITDA MARGIN %
(dollars in thousands)
  
2022
  
Change
  
2021
  
Change
  
2020
 
EBITDA
   82,634   (13%)   94,695   12  84,709 
Adjusted EBITDA
   115,369   11  104,217   14  91,177 
Adjusted EBITDA Margin %
   21.9   22.2   21.8
Adjusted EBITDA increased 11% in fiscal 20162022 compared to fiscal 2021, due to revenue growth and 11.8%improved gross margins. Adjusted EBITDA increased 14% in fiscal 2015.

2021 compared to fiscal 2020, the result of revenue growth and lower spending on travel and other customer-facing activities.

FUTURE OPERATING RESULTS

Neogen Corporation’s future operating results involve a number of risks and uncertainties. Actual events or results may differ materially from those discussed in this report. Factors that could cause or contribute to such differences include, but are not limited to, the factors discussed below as well as those discussed elsewhere in this report. Management’s ability to grow the business in the future depends upon itsour ability to successfully implement various strategies, including:

developing, manufacturing and marketing new products with new features and capabilities;capabilities, and having those new products successfully accepted in the marketplace;

expanding the Company’sour markets by fostering increased use of Companyour products by customers;

36

Table of Contents
maintaining or increasing gross and net operating margins in changing cost environments;

strengthening operations and sales and marketing activities in geographies outside of the U.S.;

developing and implementing new technology development strategies; and

identifying and completing acquisitions that enhance existing product categories or create new products or services.services, and successfully integrating completed acquisitions, including our previously announced proposed transaction to combine with 3M’s Food Safety business.

FINANCIAL CONDITION AND LIQUIDITY

On May 31, 2017, the Company2022, we had $77.6$44.5 million in cash and cash equivalents, $66.1$336.6 million in marketable securities, and net working capital of $257.0$549.0 million. For the year ended May 31, 2017,2022, cash generated from operating activities was $60.3$68.0 million, compared to $35.3$81.1 million generated in fiscal 2016;2021; proceeds from stock option exercises provided an additional $21.1$7.9 million of cash. For the same period, additions to property, equipment and equipmentother
non-current
assets were $24.4 million and business acquisitions used cash of $14.6 million and $34.0 million, respectively. The Company has$38.7 million. We have a financing agreement with a bank providing for an unsecured revolving line of credit of $15.0 million, which expires on SeptemberNovember 30, 2019.2023. Upon close of the 3M Food Safety transaction, this credit facility will terminate and be replaced with a larger, revolving facility. There were no advances against this line of credit during fiscal years 2017, 20162022, 2021 and 2015,2020, and no balance outstanding at May 31, 20172022 and 2016. The Company does have an outstanding borrowing of $1.2 million at its pesticide business in Brazil, which originated prior to the Company’s purchase of the business. The terms of the borrowing allow for repayment of the principal only upon export shipment of the associated inventory, which the Company believes will occur in the 2018 fiscal year.

Accounts2021.

Net accounts receivable at May 31, 20172022 were $68.6$99.7 million, compared to $67.6$91.8 million at May 31, 2016,2021; the increase is primarily due to the increaseincreased sales in revenues. Daysthe fourth quarter of fiscal 2022 compared to the corresponding period a year ago. Our days sales outstanding, a measurement of the time it takes to collect receivables, decreased from 61improved to 62 days at May 31, 20162022 compared to 6066 days at May 31, 2017. All customer accounts are actively managed and no losses in excess of amounts reserved are currently expected.

2021.

Inventory balances were $73.1$122.3 million at May 31, 2017,2022, an increase of $8.7$21.6 million, or 14%21%, compared to $64.4$100.7 million at May 31, 2016. Approximately $2.22021, In addition to adding $1.7 million of the increase was from the acquisitions of Quat-Chem and Rogama, completed duringacquired inventory in fiscal 2017. The Company2022, we also increased ordering quantities and inventory levels to overcome supply chain constraints and minimize delays to customers.
On December 13, 2021, Neogen, 3M, and Garden Spinco, a newly formed subsidiary of 3M created to carve out 3M’s Food Safety business announced that they had entered into a definitive agreement pursuant to which 3M would separate its Food Safety business and simultaneously combine it with Neogen in a Reverse Morris Trust transaction, which is intended to be tax-efficient to 3M and its shareholders for U.S. federal income tax purposes. Under the terms of the definitive agreements, at the completion of the transaction, Neogen will issue a number of shares to 3M shareholders such that 3M shareholders will receive approximately 50.1% of the combined company and existing Neogen shareholders will continue to own approximately 49.9% of the combined company. In connection with the transaction, 3M will also receive consideration valued at approximately $1 billion, subject to closing and other adjustments. The transaction is expected to close by the end of the third quarter calendar year 2022, subject to approval by Neogen shareholders and the satisfaction of other customary closing conditions.
On June 30, 2022, Garden Spinco entered into a credit agreement consisting of a five-year senior secured term loan facility in the amount of $650.0 million and a five-year senior secured revolving facility in the amount of $150.0 million (collectively, the “Credit Facilities”), which, subject to customary closing conditions, will be available in connection with the merger and related transactions. The Credit Facilities, together with the Notes below, when incurred, represent the financing contemplated in connection with the merger.
In July 2022 Garden SpinCo closed on an offering of $350.0 million aggregate principal amount of 8.625% senior notes due 2030 (the “Notes”) in a private placement at par. The Notes were initially issued by Garden SpinCo to 3M and were transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. Garden SpinCo did not receive any proceeds from the sale of the Notes by the selling securityholder. Prior to the distribution of the shares of Garden SpinCo’s common stock to 3M stockholders, the Notes will be guaranteed on a senior unsecured basis by 3M. Upon consummation of such distribution, 3M will be released from all obligations under its other operationsguarantee. Upon the effectiveness of the merger, the Notes will be guaranteed on a senior unsecured basis by Neogen and certain wholly-owned domestic subsidiaries of Neogen.
In addition to support the revenue growth and to ensure adequate safety stocks to minimize backorders. The Company continues to identify and rationalize redundant product offerings resulting from recent acquisitions.

Neogen has been consistently profitable and has generated strong cash flow from operations during fiscal years 2015, 2016 and 2017. However, the Company’s3M transaction described above, our future cash on hand and current borrowing capacity may not be sufficient to meet the Company’s cash requirements to commercialize products currently under development or its potentialexecute our future plans to acquire additional businesses, technology and products that fit within the Company’sour strategic plan. Accordingly, the Companywe may be required, or may choose, to issue additional equity securities or enter into other financing arrangements for a portion of itsour future capital needs.

The Company is

We are subject to certain legal and other proceedings in the normal course of business that have not had, and, in the opinion of management, are not expected to have, a material effect on itsour results of operations or financial position.

37

Table of Contents
CONTRACTUAL OBLIGATIONS

The Company has

As of May 31, 2022, we have the following contractual obligations due by period:

(dollars in thousands)

  Total   Less than
1 year
   1-3 years   3-5 years   More than
5 years
 

Long-Term Debt

  $1,195   $1,195   $—     $—     $—   

Operating Leases

   1,150    591    381    155    23 

Unconditional Purchase Obligations (1)

   48,831    43,402    5,429    —      —   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 
  $51,176   $45,188   $5,810   $155   $23 

       
Less than
           
More than
 
(dollars in thousands)
  
Total
   
1 year
   
1-3 years
   
3-5 years
   
5 years
 
Long-Term Debt
  $—     $—     $—     $ —     $ —   
Operating Leases
   3,316    1,458    1,324    534    —   
Unconditional Purchase Obligations (1)
   
85,781
 
   83,031    2,750    —      —   
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
  $ 89,097   $ 84,489   $ 4,074   $534   $—   
(1)
Unconditional purchase obligations are primarily purchase orders for future inventory and capital equipment purchases.

We continue to make investments in our business and operating facilities. Our preliminary estimate for capital expenditures related to our existing operations in fiscal 2023 is $20 to $25 million; we also expect to spend approximately $70 million over the next two fiscal years to construct a manufacturing facility and $50 million over the next two fiscal years to implement a new enterprise resource planning solution. In conjunction with our planned transaction with 3M’s food safety business, we will spend an additional $3 to $5 million on capital leases and capital improvements on leased facilities in fiscal 2023.
NEW ACCOUNTING PRONOUNCEMENTS

See discussion of any New Accounting Pronouncements in Note 1 to Consolidated Financial Statements.

consolidated financial statements.

ITEM 7A.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company has

We have interest rate and foreign exchange rate risk exposure but no long-term fixed rate investments or borrowings. The Company’sOur primary interest rate risk is due to potential fluctuations of interest rates for variable rate borrowings and short-term investments.

Foreign exchange risk exposure arises because the Company marketswe market and sells itssell our products throughout the world. Revenues in certain foreign countries, as well as certain expenses related to those revenues, are transacted in currencies other than the U.S. dollar. The Company’sOur operating results are exposed to changes in exchange rates between the U.S. dollar and the British pound sterling, the euro, the Mexican peso, the Brazilian real, the Chinese yuan, the Australian dollar and, to a lesser extent, the Indian rupee, the Canadian dollar, the Guatemalan quetzal, the Argentine peso, the Uruguayan peso and the Canadian dollar;Chilean peso; there is also exposure to a change in exchange rate between the British pound sterling and the euro. When the U.S. dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenuesinvoiced amounts can be positively or negatively affected by changes in exchange rates in the course of collection. The Company usesWe use derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the United States,U.S., located in the United Kingdom,Scotland, England, Ireland, Italy, Brazil, Mexico, Guatemala, Argentina, Uruguay, Chile, China, India, Canada and CanadaAustralia where the functional currency is the British pound sterling, euro, Brazilian real, Mexican peso, Guatemalan quetzal, Argentine peso, Uruguayan peso, Chilean peso, Chinese yuan, Indian rupee, Canadian dollar and CanadianAustralian dollar, respectively, and also transacts business throughout Europe in the euro. The Company’sOur investments in foreign subsidiaries are considered to be long-term.

As discussed in ITEM 1A. RISK FACTORS, our financial condition and results of operations could be adversely affected by currency fluctuations.
The following table sets forth the potential loss in future earnings or fair values, resulting from hypothetical changes in relevant market rates or prices:
Risk Category
Hypothetical Change
May 31, 2022
Impact
(dollars in thousands)
Foreign Currency — Revenue
10% Decrease in exchange rates$ 20,934Earnings
Foreign Currency — Hedges
10% Decrease in exchange rates442Earnings
Interest Income
10% Decrease in interest rates233Earnings
ITEM 8.
FINANCIAL STATEMENTS AND SUPPLEMENTALSUPPLEMENTARY DATA

The response to this item is submitted in a separate section of this report starting on page
F-1.

ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE—NONE

ITEM 9A.
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

An evaluation was performed under the supervision and with the participation of the Company’sour management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, of the effectiveness of the design and operation of the Company’sour disclosure controls and procedures (as defined in Rule
13a-15
(e) under the Securities Exchange Act of 1934) as of May 31, 2017.2022. Based on and as of the time of such evaluation, the Company’s management, including theour Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer concluded that the Company’sour disclosure controls and procedures were effective as of the end of the period covered by this report to ensure that information required to be disclosed in the reports that are filed or submitted under the Securities and Exchange Act of 1934 is appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure the information required to be disclosed in the reports that are filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

38

Table of Contents
Management’s Report on Internal Control over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules
13-a-15(f)
and
15d-15(f).
Under the supervision and with the participation of the Company’sour management, including the Chief Executive Chairman of the Board of DirectorsOfficer and Chief Financial Officer, an evaluation was conducted as to the effectiveness of internal control over financial reporting as of May 31, 2017,2022, based on the framework in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on that evaluation, management concluded that internal control over financial reporting was effective as of May 31, 2017.2022. The effectiveness of internal control over financial reporting as of May 31, 2017,2022 has been audited by BDO USA, LLP, an independent registered public accounting firm, as stated in its attestation report, which is included on the following page and is incorporated into this Item 9A by reference.

Changes in Internal Control over Financial Reporting

No changes in our internal control over financial reporting were identified as having occurred during the yearquarter ended May 31, 20172022 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

39

Table of Contents
Report of Independent Registered Public Accounting Firm

Shareholders and Board of Directors and Stockholders

Neogen Corporation and Subsidiaries

Lansing, Michigan

Opinion on Internal Control over Financial Reporting
We have audited Neogen Corporation and Subsidiaries’Corporation’s (the “Company’s”) internal control over financial reporting as of May 31, 2017,2022, based on criteria established inInternal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of May 31, 2022, based on the COSO criteria). Neogen Corporationcriteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company as of May 31, 2022 and Subsidiaries’2021, the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended May 31, 2022, and the related notes and schedules and our report dated July 27, 2022 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “ItemItem 9A, Management’s Report on Internal Control Overover Financial Reporting. Our responsibility is to express an opinion on the company’sCompany’s internal control over financial reporting based on our audit.

We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit of internal control over financial reporting in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, Neogen Corporation and Subsidiaries maintained, in all material respects, effective internal control over financial reporting as of May 31, 2017, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of Neogen Corporation and Subsidiaries as of May 31, 2017 and 2016, and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the three years in the period ended May 31, 2017, and our report dated July 28, 2017 expressed an unqualified opinion thereon.

/s/ BDO USA, LLP

Grand Rapids, Michigan

July 28, 2017

27, 2022

40

Table of Contents
ITEM 9B.
OTHER INFORMATION – INFORMATION—NONE

ITEM 9C.
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS—NOT APPLICABLE
41

Table of Contents
PART III

ITEM 10.
DIRECTORS, AND EXECUTIVE OFFICERS OF THE REGISTRANT AND CORPORATE GOVERNANCE

Information regarding the Company and certain corporate governance matters appearing under the captions “Election“Proposal 1 — Election of Directors”, “Audit Committee”,Directors,” “Information About the Board and “Miscellaneous-SectionCorporate Governance Matters,” and “Additional Information-Delinquent Section 16(a) Beneficial Ownership Reporting Compliance”Reports” is incorporated by reference to Neogen’s 20172022 proxy statement to be filed within 120 days of May 31, 2017.

The Company has2022.

We have adopted a Code of Conduct that applies to all of itsour directors, executive officers and employees. The Company has made a copy of thisThis Code of Conduct is available on itsour website at http:
https://www.neogen.com/pdf/CodeOfConduct.pdf.

OFFICERS AND OTHER KEY INDIVIDUALS OF THE REGISTRANT

www.Neogen.com/globalassets/pdfs/corporate-governance-sec-and-investor-information/codeofconduct.pdf

. We intend to satisfy the disclosure requirement regarding any amendment to, or a waiver from, a provision of the code of conduct for our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions, by posting such information on our website.
Information About Our Executive Officers
The officers of Neogen are elected by and serve at the discretion of the Board of Directors. The names and titles of the Company’sour officers as of May 31, 2022 are set forth below.

Name
  
Position with the Company
  
Year Joined

the Company
 

John E. Adent

  President & Chief Executive Officer   2017 

Stewart W. Bauck, D.V.M.,

Robert S. Donofrio, Ph.D.

  Vice President, AgrigenomicsResearch & Development   20122016 

Edward

Jerome L. Bradley

Hagedorn
  Vice President, Food SafetyNorth American Operations   19952018 

Richard

Douglas E. Calk

Jones
  Vice President & Chief Operating Officer   20142020 

Joseph A. Corbett

Jason W. Lilly, Ph.D.
  Vice President, Animal Safety Sales & Operations1993

James L. Herbert

Executive Chairman of the Board1982

Melissa K. Herbert

Vice President, Support ServicesInternational Business   2005 

Daniel D. Kephart, Ph.D.

Julie L. Mann
  Vice President & Chief ScienceHuman Resources Officer   2017 

Kenneth V. Kodilla

Vice President, Manufacturing2003

Jason W. Lilly, Ph.D., MBA

Vice President, Corporate Development2005

Terri A. Morrical

Vice President, Animal Safety1992

Steven J. Quinlan

  Vice President & Chief Financial Officer   2011 

Jennifer A. Rice, D.V.M.,

Amy M. Rocklin, Ph.D.

  Vice President, General Counsel & Senior Research DirectorCorporate Secretary   2008

Dwight E. Schroedter

Vice President, Animal Safety Manufacturing19952021 

Melissa K. Herbert, Vice President, Support Services, is the daughter of James L. Herbert, Executive Chairman of the Board.

Information concerning the officers of Neogen follows:

John E. Adent, age 49,54, joined Neogen as Chief Executive Officer on July 17, 2017 and was then named President on September 22, 2017. Prior to joining Neogen, Mr. Adent served as the Chief Executive Officer of Animal Health International, Inc., formerly known as Lextron, Inc., from 2004 to 2015, also serving as its President during that time. Animal Health International was sold to Patterson Companies, Inc. in 2015, and Mr. Adent served as the Chief Executive Officer of the $3.3 billion Animal Health Division of Patterson Animal Health from that period until his resignation on July 1, 2017. Mr. Adent began his career with management responsibilities for Ralston Purina Company, developing animal feed manufacturing and sales operations in China and the Philippines. When Ralston Purina spun off that business to Agribrands, he continued his management role in the European division in Spain and Hungary, serving as managing director of the Hungarian operations. He left Ralston Purina in 2004.

Dr. Stewart W. Bauck,Robert S. Donofrio, age 59,49, joined Neogen in 2012February 2016 as the Company’s Director of Beef Cattle Genomics,Microbiology Research and became General ManagerDevelopment, and was promoted to Director of Neogen’s GeneSeek subsidiaryFood Safety Research and Development in 2013.December 2016. In December 2016,April 2018, Dr. Bauck was named Neogen’s Vice President of Agrigenomics, responsible for GeneSeek’s operation and execution of the company’s genomics strategy. Prior to joining Neogen, Bauck spent 15 years with Merial Inc., where he created and launched the Igenity livestock production business. Igenity was acquired by Neogen from Merial in May 2012. Bauck’s experience also includes various responsibilities in technical services and management for Merck AgVet, and earlier in his career, he owned and operated his own private veterinary practice with a major emphasis on food-producing animals.

Edward L. Bradley, age 57, joined the Company in February 1995 as part of its acquisition of AMPCOR Diagnostics, Inc, where he served as Vice President of Sales and Marketing. In June 1996, he was named a Vice President of Neogen. In June 2006, Mr. BradleyDonofrio was named Vice President, Food Safety. He has responsibility for all of Food Safety with the exception of Neogen EuropeResearch and researchDevelopment and development. From 1988 to 1995, Mr. Bradley servedthen named Vice President, Research and Development in several sales and marketing capacities for Mallinckrodt Animal Health, including the position of National Sales Manager in its Food Animal Products Division.September 2018. Prior to joining Mallinckrodt, he held several sales and marketing positions for Stauffer Chemical Company.

Richard E. Calk Jr., age 54, joined the Company as President and Chief Operating Officer in December 2014. He is responsible for all of the operations of the Company. He joined the Company after gaining extensive experience in a variety of senior leadership positions at food ingredient companies CP Kelco, Roquette America, and DSM Food Specialties. Mr. Calk has specialized in leading the resurgence of various companies’ brands by helping to modify simple food commodities to become value-added specialty ingredients to be used in foods and other products, and then expanding the global reach of those value-added ingredients. His experience includes establishing new operations throughout Asia, Europe, North and South America.

Joseph A. Corbett, age 48, joined Neogen in December 1993 as a sales representative in the Animal Safety operation based in Lexington, Kentucky. Prior to Neogen, he worked for the Marriott Corporation in sales and operations. He has served15 years at NSF International in various sales, marketing and operational roles in the Neogen Animal Safety group. Most recently, Mr. Corbett was Seniorpositions of increasing responsibility, including Director of Sales & Operations, Animal Safety. HeMicrobiology and Molecular Biology and Director of Applied Research, where he led efforts in grant research and method development with partners in academia, industry and government. At Neogen, Dr. Donofrio is responsible for our worldwide food safety and animal safety research activities.

Jerome L. Hagedorn, age 56, joined Neogen in April 2018 as Vice President, Food Safety Operations; in 2020, he was named Vice President, Animal Safety Sales and Operations in October 2014,North American Operations. In the role, Mr. Hagedorn is responsible for all Animal Safety revenues excluding GeneSeek and Life Sciences and operations at the Lexington distribution centers.

James L. Herbert, age 77, is Executive Chairman of the Board of Directors of the Company. He had been the Chief Executive Officer and Chairman of the Board since 2006; he resigned as Chief Executive Officer on July 17, 2017, when John Adent was named to that role. Prior to 2006, he had been President and a Director since he founded the Company in June 1982. Mr. Herbert previously held the position of Corporate Vice President of DeKalb Ag Research, a major agricultural genetics and energy company. He has management experience in animal biologics, specialized chemical research, medical instruments, aquaculture, animal nutrition, and poultry and livestock breeding and production.

Melissa K. Herbert, age 53, joined the Company in August 2005 as a sales representative in the Company’s Food Safety Division in Lansing, Michigan. In 2011, Ms. Herbert was named Manager of Industry Affairs, with oversight of regulatory issues for both the Food and Animal Safety divisions, and in June 2013, Director of Industry Affairs. She was named Vice President, Support Services in October 2015. Support Services is comprised of Technical Service, Regulatory Affairs and Industry Affairs departments.

Dr. Daniel D. Kephart, age 53, joined Neogen in January 2017 as Chief Science Officer — a new position for the Company. Dr. Kephart’s experience and expertise in technology scouting, product design, and instrument integration will help broaden Neogen’s continued rapid growth in the development of solutions for both food and animal safety. Prior to joining Neogen, Kephart served as Research and Development Director for the Agribusiness unit of Thermo Fisher Scientific, as well as Animal Health and Food Safety Development at Life Technologies. His extensive industry experience also includes the management of a team focused on technical applications and customer-facing solutions for Promega Corporation.

Kenneth V. Kodilla, age 60, joined Neogen in November 2003 as Vice President of Manufacturing. He has responsibility for all manufacturing, inventory management,supply chain, shipping and warehousing, production engineering and quality system operationssystems for the Company’s Food Safety Division in Lansing, Michigan.Neogen’s North American operations. Prior to joining Neogen, Mr. KodillaHagedorn spent the past eight years as Vice President of Operations at Siemens Healthcare Diagnostics. At Siemens, he was responsible for multiple plant operations, including diagnostic instrument manufacturing and new product introduction. Prior to joining Siemens, Mr. Hagedorn held a variety of senior level positions over a 20 year career, including Director of Manufacturing at Bayer Healthcare in Indiana, Director of Lean Manufacturing at Invensys in Ohio, and Manager of Automated Manufacturing at Siemens Electronic Components in Mexico.

42

Table of Contents
Douglas E. Jones, age 52, joined Neogen as Vice President & Chief Commercial Officer on August 17, 2020; in 2022, he was named Vice President & Chief Operating Officer. Prior to joining Neogen, Mr. Jones served as plant managerthe President of the Companion Animal Division at Patterson Companies from 2016 to August 2020. Prior to joining Patterson, Mr. Jones served as the Head of Business Operations for Facet Technologiesthe North American Merial Animal Health Division of Sanofi. Mr. Jones began his career as a management consultant with the North Highland Company and PriceWaterhouseCoopers, focusing on commercial transformation and strategy projects in Atlanta, Georgia from 2001, as Manufacturing Manager for Becton Dickinsonthe pharmaceutical, healthcare distribution and Difco Laboratories from 1988, and as Quality Manager for Lee Laboratories from 1984. Mr. Kodilla’s manufacturing and regulatory experience includes FDA/ISO regulated Class and diagnostic reagents and devices, high volume automated assembly and packaging, materials management and plant operations.

high-tech industries.

Dr. Jason W. Lilly, age 43,48, joined the CompanyNeogen in June 2005 as Market Development Manager for Food Safety. In June 2009, he moved to the Corporate Development group. He was named Vice President of Corporate Development in December 2011, responsible for the identification and acquisition of new business opportunities for the Company. In January 2019, Dr. Lilly was named Vice President, International Business, responsible for Neogen’s operations outside of the U.S. and Canada; in April 2022, Dr. Lilly also assumed responsibility on an interim basis for the North American genomics business. Prior to joining Neogen, he served in various technical sales and marketing roles at Invitrogen Corporation. Dr. Lilly’s technical knowledge and business acumen provides the Company with a strong combination of merger and acquisition skills.

Terri A. Morrical,

Julie L. Mann, age 52,57, joined Neogen in September 19922017 as partDirector of the Company’s acquisitionHuman Resources and was promoted to Senior Director of WTT, Incorporated. SheHuman Resources in June 2019. In 2020, Ms. Mann was named Vice President & Chief Human Resources Officer, with responsibilities for people-focused programs and initiatives for Neogen’s worldwide employees. Ms. Mann has directed mostmore than 30 years of experience focused on all aspects of strategic human resources including talent acquisition, compensation and benefits, employee development and employee relations. Prior to joining Neogen, Ms. Mann held the Company’s Animal Safety operations since she joined Neogenpositions of Director, Talent Acquisition at Holland, a logistics company, and currently serves as Vice President in charge of all of the Company’s Animal Safety operations excluding GeneSeek. From 1986 to 1991, Ms. Morrical was Controller for Freeze Point Cold Storage Systems and concurrently served in the same capacity for Powercore, Inc. In 1990, she joined WTT, Incorporated as VP/CFO and then became President, the position she heldDirector, People Services Consulting at the time Neogen acquired the business.

Herman Miller.

Steven J. Quinlan, age 54,59, joined Neogen in January 2011 as Vice President and& Chief Financial Officer. HeOfficer and was namedalso Corporate Secretary in October 2011.until March 2021. He is responsible for all internal and external financial reporting for the Company,Neogen, and also manages the accounting, human resources, information technology, communicationscorporate purchasing, treasury and facilities departments.investor relations functions. Mr. Quinlan came to the CompanyNeogen following 19 years at Detrex Corporation (1992-2010), the last eight years serving as Vice President-Finance, CFO and Treasurer. He was on the audit staff at the public accounting firm Price Waterhouse (now PWC)PricewaterhouseCoopers) from 1985-1989.

Dr. Jennifer A. Rice,

Amy M. Rocklin, Ph.D., age 56,50, joined the CompanyNeogen in February 2009March 2021 as Senior Scientific Officer. In October 2010, she was named Vice President, General Counsel & Corporate Secretary. In this role, she is responsible for all legal and Senior Research Directorcompliance matters and had responsibility to manage and lead Neogen’s research and development team.serves as the Corporate Secretary. Prior to joining Neogen, Dr. Rice served as Animal Health Global Product Development LeaderRocklin was the Division Vice President, Corporate Law at Dow AgroSciences. From 1996 to 2004,Corning Incorporated, one of the world’s leading innovators in materials science. In her nearly ten years at Corning, she held Researchmultiple leadership positions within Corning’s Law Department, including Director Positionsof Law, M&A and Emerging Innovations. Before Corning, Dr. Rocklin held positions at Biocor Animal Health (2001-2004) and Merial Animal Health (1996-2001). Dr. Rice’s strong background in leading large global research and development teams brought a key management skill to Neogen. Dr. Rice retired from the Company effective November 11, 2016.

Dwight E. Schroedter, age 60, joined Neogen in January 1995 as the Research and Development Manager of the Animal Safety Division based in Lexington, Kentucky. He has served in a variety of technical, operational and sales roles as part of the Animal Safety DivisionSmiths Group plc and was named Vice President, Animal Safety Manufacturing in October 2014, overseeing manufacturing operationsprivate practice at the Company’s domestic Animal Safety manufacturing locations, excluding Lansing. Prior to joining Neogen, Mr. Schroedter managed the antibody development laboratory for the Ames Divisionlaw firm of Miles, Incorporated.

Foley & Lardner LLP.
43

Table of Contents
ITEM 11.
EXECUTIVE COMPENSATION

The information required by this Item, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the sections entitled “Compensation Discussion and Analysis”, “Compensation Committee Report”, “Executive Compensation”, “Information About the Board and Corporate Governance Matters-Compensation Committee Interlocks and Insider Participation”, “CEO Pay Ratio”, and “Compensation of Directors” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2022.
ITEM 12.
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT, AND RELATED STOCKHOLDER MATTERS

The information required by this Item, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the section entitled “Security Ownership of Certain Beneficial Owners, Directors and Management” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2022.
ITEM 13.
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

The information required by this Item, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the section entitled “Information about the Board and Corporate Governance Matters-Independent Directors,” “-Board Committees” and “-Certain Relationships and Related Party Transactions” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2022.
ITEM 14.
PRINCIPAL ACCOUNTANT FEES AND SERVICES

The information required by this itemItem, and pursuant to Regulation 14A of the Exchange Act, is incorporated by reference to Neogen’sfrom the section entitled “Proposal 3
Ratification of the Appointment of the Company’s Independent Registered Public Accounting Firm” in the Company’s definitive Proxy Statement to be filed within 120 days of May 31, 2017.

2022.

PART IV

ITEM 15.
EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

(a) (1) and (2) and (c). The response to this portion of ITEM 15 is submitted as a separate section of this report.

report starting on page

F-1.
(a) (3) and (b). The Exhibits, listed on the accompanying Exhibit Index on page 36,40, are incorporated herein by reference.

ITEM 16.
FORM
10-K
SUMMARY — NONE
44

Table of Contents
Neogen Corporation

Annual Report on Form
10-K

Year Ended May 31, 2017

2022

EXHIBIT INDEX

EXHIBIT NO.

  

DESCRIPTION

  3.12.1  ArticlesAgreement and Plan of Incorporation,Merger, dated as restatedof December 13, 2021, by and among 3M Company, Garden SpinCo Corporation, Neogen Corporation and Nova RMT Sub, Inc. (incorporated by reference to Exhibit 3(i)2.1 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).
2.2Separation and Distribution Agreement, dated as of December 13, 2021, by and among 3M Company, Garden SpinCo Corporation and Neogen Corporation (incorporated by reference to Exhibit 2.2 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).
2.3Asset Purchase Agreement, by and between 3M Company and Neogen Corporation, dated as of December 13, 2021 (incorporated by reference to Exhibit 2.3 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).
3.1Restated Articles of Incorporation, as amended on November 23, 2011 (incorporated by reference to Exhibit 3.1 filed with the Registrant’s Quarterly Report on Form10-Q dated November filed December 30, 2011).
3.2  Certificate of Amendment to Articles of Incorporation filed on October 11, 2010 (incorporated by reference to Exhibit 3.2 filed with the Registrant’s Annual Report on Form 10-K filed on July 30, 2020) .
3.3Certificate of Amendment to Articles of Incorporation filed on November 20, 2018 (incorporated by reference to Exhibit 3 filed with the Registrant’s Quarterly Report on Form 10-Q filed December 28, 2018).
3.4By-Laws, as amended (incorporated by reference to Exhibit 3.2 to the Registrant’s Quarterly Report on Form10-Q dated February 29, filed April 14, 2000).
3.5Certificate of Amendment to Articles of Incorporation of Neogen Corporation filed on March 14, 2022 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by Neogen Corporation on March 17, 2022).
10.1  Neogen Corporation 1997 Stock Option Plan, as amended (incorporated by reference to Exhibit 4.3 to the Registrant’s Registration Statement on FormS-8 (No.333-122110) filed January 18, 2005).
10.2Neogen Corporation 2007 Stock Option Plan as amended and restated (incorporated by reference to Exhibit A to the Registrant’s 2011 Proxy Statement August 31, 2011 filed September 1, 2011).
10.3Neogen Corporation 2015 Omnibus Incentive Plan (incorporated by reference to Appendix A to the Registrant’s 2015 Proxy Statement dated and filed August 29,25, 2015).
10.410.2  Neogen Corporation 2018 Omnibus Incentive Plan (incorporated by reference to Appendix A to the Registrant’s 2018 Proxy Statement dated and filed August 28, 2018).
10.3Amended and Restated Credit Agreement dated as of November 30, 2016 between Registrant and JPMorgan Chase N.A. (incorporated by reference to Exhibit 10.A to the registrant’sRegistrant’s Form8-K filed on December 6, 2016).
21.010.4  ListingFirst Amendment to Amended and Restated Credit Agreement dated as of SubsidiariesNovember 30, 2018 between Registrant and JPMorgan Chase N.A. (incorporated by reference to Exhibit 10.A to the Registrant’s Form 8-K filed on December 6, 2018).
23.110.5  Second Amendment to Amended and Restated Credit Agreement dated as of November 30, 2020 between Registrant and JPMorgan Chase N.A. (incorporated by reference to Exhibit 10.A to the Registrant’s Form 8-K filed on December 17, 2020).
10.6Employee Matters Agreement, dated as of December 13, 2021, by and among Neogen Corporation, Garden SpinCo Corporation and 3M Company (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by Neogen Corporation on December 15, 2021).
21Listing of Subsidiaries
23Consent of Independent Registered Public Accounting Firm BDO USA, LLP
24.124  Power of Attorney
31.1  Section 302 Certification of Principal Executive Officer
31.2  Section 302 Certification of Principal Financial Officer
32  Certification Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS  Inline XBRL Instance Document
101.SCH  Inline XBRL Taxonomy Extension Schema Document
101.CAL  Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF  Inline XBRL Taxonomy Extension Definition Document
101.LAB  Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE  Inline XBRL Taxonomy Extension Presentation Linkbase Document
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

45

Table of Contents
SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

  NEOGEN CORPORATION
By:  
/s/ James L. Herbert                            John E. Adent
  By:
/s/ Steven J. Quinlan
  

James L. Herbert, Executive Chairman

of the Board of Directors

John E. Adent, President & Chief
  Steven J. Quinlan, Vice President &
  Executive Officer  Chief Financial Officer
  (Principal Executive Officer)  (Principal Financial & Accounting Officer)

Dated: July 28, 2017

27, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

Signature

  
Title
  

Title

Date

/s/ James L. Herbert

James L. Herbert

Executive Chairman of the Board of Directors (Principal Executive Officer)July 28, 2017

/s/ Richard E. Calk

Richard E. Calk

  President & Chief OperatingExecutive Officer  
/s/ John E. Adent
(Principal Executive Officer)July 28, 201727, 2022
John E. Adent

/s/ Steven J. Quinlan

Steven J. Quinlan

  Vice President & Chief Financial Officer (Principal
/s/ Steven J. Quinlan
(Principal Financial & Accounting Officer)  July 28, 201727, 2022

*

Steven J. Quinlan    
William T. Boehm
*
Chairman of the Board of DirectorsJuly 27, 2022
James C. Borel    
*
DirectorJuly 27, 2022
William T. Boehm, Ph.D.
*
DirectorJuly 27, 2022
Ronald D. Green, Ph.D.
*
DirectorJuly 27, 2022
Ralph A. Rodriguez
*
DirectorJuly 27, 2022
James P. Tobin
*
DirectorJuly 27, 2022
Darci L. Vetter
*
DirectorJuly 27, 2022
Catherine E. Woteki, Ph.D.  

*

James C. Borel

By:
 Director

*

Ronald D. Green

Director

*

G. Bruce Papesh

Director

*

Jack C. Parnell

Director

*

Thomas H. Reed

Director

*

James P. TobinDirector

*By: 
/s/ James L. Herbert        
John E. Adent    
 James L. Herbert, John E. Adent,
Attorney-in-fact
    July 28, 201727, 2022

46

Table of Contents
ANNUAL REPORT ON FORM
10-K

ITEM 15 (a)(1)(a)(2) (3), (b) and (c)

LIST OF FINANCIAL STATEMENTS, EXHIBITS AND FINANCIAL STATEMENT SCHEDULES

YEAR ENDED MAY 31, 2017

NEOGEN CORPORATION

LANSING, MICHIGAN

FORM10-K—ITEM 15(a)(1) AND (2) AND 15(c)

LIST OF FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES

YEAR ENDED MAY 31, 2022
NEOGEN CORPORATION
LANSING, MICHIGAN
FORM
10-K—ITEM
15(a)(1) AND (2) AND 15(c)
LIST OF FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULES
The following consolidated financial statements of Neogen Corporation and subsidiaries are included below and incorporated in ITEM 8:

Report of Independent Registered Public Accounting Firm

, BDO USA, LLP, Grand Rapids, MI PCAOB ID# 243
  F-2

  F-4

  F-6

  F-7

  F-8

  F-9

  F-10

Schedules for which provision is made in the applicable accounting regulation of the United States Securities and Exchange Commission are not required under the related instructions or are inapplicable and, therefore, have been omitted.

FORM10-K – ITEM 15 (a) (3) AND (b)

A list

F-1

Table of Exhibits required to be filed as a part of this report is set forth in the Exhibit Index, which immediately follows the signature page, and is incorporated herein by reference.

Contents

Report of Independent Registered Public Accounting Firm

Shareholders and Board of Directors and Stockholders

Neogen Corporation and Subsidiaries

Lansing, Michigan

Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Neogen Corporation and Subsidiaries (the Company)“Company”) as of May 31, 20172022 and 2016, and2021, the related consolidated statements of income, comprehensive income, stockholders’ equity, and cash flows for each of the three years in the period ended May 31, 2017. These2022, and the related notes (collectively referred to as the “consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States)statements”). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Neogen Corporation and Subsidiariesthe Company at May 31, 20172022 and 2016,2021, and the results of its operations and its cash flows for each of the three years in the period ended May 31, 2017,2022, in conformity with accounting principles generally accepted in the United States of America.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), Neogen Corporation and Subsidiaries’the Company’s internal control over financial reporting as of May 31, 2017,2022, based on criteria established inInternal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)(“COSO”) and our report dated July 28, 20172
7
, 2022 expressed an unqualified opinion thereon.

Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.
Valuation of Contingent Consideration
As described in Note 3 to the Company’s consolidated financial statements, the Company has recorded a contingent consideration liability of approximately $6.5 million related to the acquisition of CAPInnoVet, Inc. A contingent consideration liability is recorded based on its estimated fair value as of the date of the acquisition and remeasured as of each balance sheet date.
We have identified the valuation of the contingent consideration liability as of the acquisition date as a critical audit matter. The contingent consideration liability is measured using a Monte-Carlo simulation utilizing significant unobservable inputs that considers the probability of achieving each of the potential milestones, including revenue volatility and an estimated discount rate associated with the risks of the expected cash flows. Due to the inherent uncertainty involved in estimating long-range revenue forecasts and the complexity of the Monte-Carlo simulation utilized by management, auditing the contingent consideration liability required increased auditor effort including the use of personnel with specialized knowledge and skills in valuation.
F-2

Table of Contents
The primary procedures we performed to address this critical audit matter included:
Testing the design and operating effectiveness of certain controls over the development of the significant assumptions used in the valuation model selected, including controls over assumptions related to: (i) long-range revenue forecasts and (ii) discount rates applied to the forecasts.
Assessing management’s estimated timing of milestone achievement and probabilities of success by corroborating with personnel knowledgeable of the current progression of the product candidates and reviewed filings with the applicable regulatory agencies.
Assessing management’s ability to forecast long-range revenue by
analyzing historical accuracy of management’s forecasts related to business combinations and comparing to industry data to validate the reasonableness of the growth assumption.
Utilizing professionals with specialized knowledge and skills in valuation to assist in evaluating the valuation methodology selected by management as well as assessing the reasonableness of key inputs including the discount rate and revenue volatility.
/s/ BDO USA, LLP

We have served as the Company’s auditor since 2014.
Grand Rapids, Michigan

July 28, 2017

2

7
, 2022
F-3

Table of Contents
Neogen Corporation and Subsidiaries

Consolidated Balance Sheets – Assets

(in thousands)

   May 31 
   2017   2016 

Assets

    

Current Assets

    

Cash and cash equivalents

  $77,567   $55,257 

Marketable securities

   66,068    52,539 

Accounts receivable, less allowance of $2,000 and $1,500 at May 31, 2017 and 2016, respectively

   68,576    67,652 

Inventories

   73,144    64,371 

Prepaid expenses and other current assets

   7,606    8,407 
  

 

 

   

 

 

 

Total Current Assets

   292,961    248,226 

Property and Equipment

    

Land and improvements

   3,094    2,659 

Building and improvements

   37,917    33,417 

Machinery and equipment

   64,867    56,470 

Furniture and fixtures

   3,333    3,068 

Construction in progress

   2,290    1,057 
  

 

 

   

 

 

 
   111,501    96,671 

Less accumulated depreciation

   49,753    41,988 
  

 

 

   

 

 

 

Net Property and Equipment

   61,748    54,683 

Other Assets

    

Goodwill

   104,759    88,506 

Othernon-amortizable intangible assets

   14,323    9,170 

Amortizable customer-based intangible assets, net of accumulated amortization of $20,846 and $17,277 at May 31, 2017 and 2016, respectively

   35,983    30,909 

Othernon-current assets, net of accumulated amortization of $9,931 and $7,530 at May 31, 2017 and 2016, respectively

   18,635    18,446 
  

 

 

   

 

 

 

Total Other Assets

   173,700    147,031 
  

 

 

   

 

 

 

Total Assets

  $528,409   $449,940 
  

 

 

   

 

 

 

   
May 31
 
   
2022
  
2021
 
Assets
   
Current Assets
   
Cash and cash equivalents
  
$

44,473  $75,602 
Marketable securities
   336,578   305,485 
Accounts receivable, net of allowance of $1,650
 
and $1,400 at May 31, 2022 and 2021, respectively
   99,674   91,823 
Inventories
   122,313   100,701 
Prepaid expenses and other current assets
   23,760   17,840 
   
 
 
   
 
 
 
Total Current Assets
   626,798   591,451 
Property and Equipment
         
Land and improvements
   9,485   7,783 
Building and improvements
   79,513   72,754 
Machinery and equipment
   114,180   108,194 
Furniture and fixtures
   6,307   6,270 
Construction in progress
   5,974   3,261 
   
 
 
   
 
 
 
    215,459   198,262 
Less accumulated depreciation
   (104,875)
 
  (97,809
   
 
 
   
 
 
 
Net Property and Equipment
   110,584   100,453 
Other Assets
         
Right of use assets
   3,184   2,477 
Goodwill
   142,704   131,476 
Other
non-amortizable
intangible assets
   15,397   15,545 
Amortizable intangible assets, net of accumulated amortization of $55,416
 
and $53,462 at May 31, 2022 and 2021, respectively
   92,106   76,771 
Other
non-current
assets
   2,156   2,019 
   
 
 
   
 
 
 
Total Other Assets
   255,547   228,288 
   
 
 
   
 
 
 
Total Assets
  $992,929  $920,192 
   
 
 
   
 
 
 
See accompanying notes to consolidated financial statements.

F-4

Table of Contents
Neogen Corporation and Subsidiaries

Consolidated Balance Sheets – Liabilities and Stockholders’ Equity

(in thousands, except shareshares and per share)

   May 31 
   2017  2016 

Liabilities and Equity

   

Current Liabilities

   

Accounts payable

  $16,244  $15,800 

Accruals

   

Accrued compensation

   5,002   4,986 

Income taxes

   936   —   

Other accruals

   13,820   7,812 
  

 

 

  

 

 

 

Total Current Liabilities

   36,002   28,598 

Deferred Income Taxes

   17,048   14,758 

OtherNon-Current Liabilities

   3,602   2,423 
  

 

 

  

 

 

 

Total Liabilities

   56,652   45,779 

Commitments and Contingencies (note 7)

   

Equity

   

Preferred stock, $1.00 par value - shares authorized 100,000; none issued and outstanding

   —     —   

Common stock, $0.16 par value - shares authorized 60,000,000; 38,199,367 and 37,567,689 shares issued and outstanding at May 31, 2017 and 2016, respectively

   6,112   6,011 

Additionalpaid-in capital

   176,779   150,000 

Accumulated other comprehensive loss

   (7,203  (3,946

Retained earnings

   295,926   252,133 
  

 

 

  

 

 

 

Total Neogen Corporation and Subsidiaries Stockholders’ Equity

   471,614   404,198 

Non-controlling interest

   143   (37
  

 

 

  

 

 

 

Total Equity

   471,757   404,161 
  

 

 

  

 

 

 
  $528,409   449,940 
  

 

 

  

 

 

 

   
May 31
 
   
2022
  
2021
 
Liabilities and Stockholders’ Equity
         
Current Liabilities
         
Accounts payable
  
$

34,614 
$23,900 
Accruals
     
   
Accrued compensation
   11,123 
 11,251 
Income
tax payable
   2,126 
 1,848 
Deferred revenue
   5,460 
 3,404 
Other accruals
   24,521 
 13,196 
   
 
 
   
 
 
 
Total Current Liabilities
   77,844 
 53,599 
Deferred Income
Tax Liability
   17,011 
 21,917 
Other
Non-Current
Liabilities
   10,700 
 4,299 
   
 
 
   
 
 
 
Total Liabilities
   105,555 
 79,815 
Commitments and Contingencies (note 7)
    
  
Stockholders’ Equity
     
   
Preferred stock, $1.00 par value — shares authorized 100,000; NaNissued and outstanding
    
 —   
Common stock, $0.16 par value — shares authorized 120,000,000; 107,801,094
 
a
nd 107,468,304 shares issued and outstanding at May 31, 2022 and 2021, respectively
   17,248 
 17,195 
Additional
paid-in
capital
   309,984 
 294,953 
Accumulated other comprehensive loss
   (27,769)
 

 (11,375
Retained earnings
   587,911 
 539,604 
   
 
 
   
 
 
 
Total Neogen Corporation and Subsidiaries Stockholders’ Equity
   887,374 
 840,377 
   
 
 
   
 
 
 
Total Liabilities and Stockholders’ Equity
  $992,929 
$ 920,192 
   
 
 
   
 
 
 
See accompanying notes to consolidated financial statements.

F-5

Table of Contents
Neogen Corporation and Subsidiaries

Consolidated Statements of Income

(in thousands, except per share)

   Year Ended May 31 
   2017  2016  2015 

Revenues

    

Product revenues

  $306,512  $273,570  $243,909 

Service revenues

   55,082   47,705   39,165 
  

 

 

  

 

 

  

 

 

 

Total Revenues

   361,594   321,275   283,074 
  

 

 

  

 

 

  

 

 

 

Cost of Revenues

    

Cost of product revenues

   156,568   137,766   120,377 

Cost of service revenues

   33,058   30,445   23,012 
  

 

 

  

 

 

  

 

 

 

Total Cost of Revenues

   189,626   168,211   143,389 
  

 

 

  

 

 

  

 

 

 

Gross Margin

   171,968   153,064   139,685 

Operating Expenses

    

Sales and marketing

   62,424   57,599   51,757 

General and administrative

   34,214   29,189   25,233 

Research and development

   10,385   9,890   9,577 
  

 

 

  

 

 

  

 

 

 
   107,023   96,678   86,567 
  

 

 

  

 

 

  

 

 

 

Operating Income

   64,945   56,386   53,118 

Other Income (Expense)

    

Interest income

   838   322   228 

Royalty income

   171   217   150 

Change in purchase consideration

   18   —     (297

Other, net

   701   (1,412  (1,123
  

 

 

  

 

 

  

 

 

 
   1,728   (873  (1,042
  

 

 

  

 

 

  

 

 

 

Income Before Income Taxes

   66,673   55,513   52,076 

Provision for Income Taxes

   22,700   18,975   18,500 
  

 

 

  

 

 

  

 

 

 

Net Income

   43,973   36,538   33,576 

Net (Income) Loss Attributable toNon-controlling Interest

   (180  26   (50
  

 

 

  

 

 

  

 

 

 

Net Income Attributable to Neogen

  $43,793  $36,564  $33,526 
  

 

 

  

 

 

  

 

 

 

Net Income Attributable to Neogen per Share

    

Basic

  $1.16  $0.98  $0.91 
  

 

 

  

 

 

  

 

 

 

Diluted

  $1.14  $0.97  $0.90 
  

 

 

  

 

 

  

 

 

 

   
Year Ended May 31
 
   
2022
   
2021
  
2020
 
Revenues
     
Product revenues
  
$

424,664   $376,302  $335,539 
Service revenues
   102,495    92,157   82,631 
   
 
 
   
 
 
  
 
 
 
Total Revenues
   527,159    468,459   418,170 
   
 
 
   
 
 
  
 
 
 
Cost of Revenues
              
Cost of product revenues
   228,017    201,348   173,566 
Cost of service revenues
   56,129    52,055   48,325 
   
 
 
   
 
 
  
 
 
 
Total Cost of Revenues
   284,146    253,403   221,891 
   
 
 
   
 
 
  
 
 
 
Gross Margin
   243,013    215,056   196,279 
Operating Expenses
              
Sales and marketing
   84,604    73,443   69,675 
General and administrative
   82,742    51,197   44,331 
Research and development
   17,049    16,247   14,750 
   
 
 
   
 
 
  
 
 
 
Total Operating Expenses
   184,395    140,887   128,756 
   
 
 
   
 
 
  
 
 
 
Operating Income
   58,618    74,169   67,523 
Other Income
              
Interest income, net
   1,267    1,614   5,992 
Royalty income
       —     —   
Other, net
   322    (515  (1,210
   
 
 
   
 
 
  
 
 
 
Total Other Income
   1,589    1,099   4,782 
   
 
 
   
 
 
  
 
 
 
Income Before Income Taxes
   60,207    75,268   72,305 
Provision for Income Taxes
   11,900    14,386   12,830 
   
 
 
   
 
 
  
 
 
 
Net Income
  $48,307   $60,882  $59,475 
   
 
 
   
 
 
  
 
 
 
Net Income per Share
              
Basic
  
$

0.45   $0.57  $0.57 
Diluted
  
$

0.45   $0.57  $0.56 
Weighted Average Shares Outstanding
              
Basic
   107,684    106,499   105,100 
Diluted
   108,020��   107,120   105,720 
See accompanying notes to consolidated financial statements.

F-6

Table of Contents
Neogen Corporation and Subsidiaries

Consolidated Statements of Comprehensive Income

(in thousands, except per share)

   Year Ended May 31 
   2017  2016  2015 

Net Income

Other comprehensive income (loss), net of tax:

  $43,973  $36,538  $33,576 

currency translations

   (3,257  (1,504  (2,813
  

 

 

  

 

 

  

 

 

 

Comprehensive income

   40,716   35,034   30,763 

Comprehensive (income) loss attributable tonon-controlling interest

   (180  26   (50
  

 

 

  

 

 

  

 

 

 

Comprehensive income attributable to Neogen

  $40,536  $35,060  $30,713 
  

 

 

  

 

 

  

 

 

 

thousands)

   
Year Ended May 31
 
   
2022
  
2021
  
2020
 
Net Income
  
$

48,307  $60,882  $59,475 
Other comprehensive income (loss):

            
Foreign currency translations   (13,955)  8,602   (8,495
Unrealized (loss) gain on marketable securities, net of tax 
of $(728), $(80) and $127
   (2,439)
 
  (268  426 
   
 
 
   
 
 
  
 
 
 
Comprehensive income  $31,913  $69,216  $51,406 
   
 
 
   
 
 
  
 
 
 
See accompanying notes to consolidated financial statements.

F-7

Table of Contents
Neogen Corporation and Subsidiaries

Consolidated Statements of Stockholders’ Equity

(in thousands, except shares)

              Accumulated           
           Additional  Other      Non-    
           Paid-in  Comprehensive  Retained   Controlling  Total 
   Shares   Amount   Capital  Income (Loss)  Earnings   Interest  Equity 

Balance, May 31, 2014

   36,732,313   $5,877   $118,070  $371  $182,043   $(61 $306,300 

Exercise of options, share-based compensation and $2,475 income tax benefit

   376,364    61    13,115       13,176 

Issuance of shares under employee stock purchase plan

   19,592    3    721       724 

Net income (loss) for 2015

         33,526    50   33,576 

Other comprehensive income (loss)

        (2,813     (2,813
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Balance, May 31, 2015

   37,128,269    5,941    131,906   (2,442  215,569    (11  350,963 

Exercise of options, share-based compensation and $2,945 income tax benefit

   421,143    67    17,311       17,378 

Issuance of shares under employee stock purchase plan

   18,277    3    783       786 

Net income (loss) for 2016

         36,564    (26  36,538 

Other comprehensive income (loss)

        (1,504     (1,504
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Balance, May 31, 2016

   37,567,689    6,011    150,000   (3,946  252,133    (37  404,161 

Exercise of options, share-based compensation and $3,922 income tax benefit

   612,963    98    26,621       26,719 

Issuance of shares under employee stock purchase plan

   18,715    3    922       925 

Purchase of minority interest

       (764      (764

Net income (loss) for 2017

         43,793    180   43,973 

Other comprehensive income (loss)

        (3,257     (3,257
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

Balance, May 31, 2017

   38,199,367   $6,112   $176,779  $(7,203 $295,926   $143  $471,757 
  

 

 

   

 

 

   

 

 

  

 

 

  

 

 

   

 

 

  

 

 

 

               
Accumulated
        
           
Additional
   
Other
        
   
Common Stock
   
Paid-in
   
Comprehensive
  
Retained
   
Total
 
   
Shares
   
Amount
   
Capital
   
Income (Loss)
  
Earnings
   
Equity
 
Balance, June 1, 2019
   104,433,178   $16,709   $213,583   $(11,640 $419,247   $637,899 
Exercise of options, RSUs and share-based compensation expense   1,415,348    227    34,452    —     —      34,679 
Issuance of shares under employee stock purchase plan
   43,156    7    1,186    —     —      1,193 
Net income for 2020
   —      —      —      —     59,475    59,475 
Other comprehensive loss
   —      —      —      (8,069  —      (8,069
   
 
 
   
 
 
   
 
 
   
 
 
  
 
 
   
 
 
 
Balance, May 31, 2020
   105,891,682   $16,943   $249,221   $(19,709 $478,722   $725,177 
Exercise of options, RSUs and share-based compensation expense   1,410,948    226    39,454    —     —      39,680 
Issuance of shares under employee stock purchase plan
   38,406    6    1,382    —     —      1,388 
Issuance of shares for Megazyme acquisition
   127,268    20    4,896    —     —      4,916 
Net income for 2021
   —      —      —      —     60,882    60,882 
Other comprehensive income   —      —      —      8,334   —      8,334 
   
 
 
   
 
 
   
 
 
   
 
 
  
 
 
   
 
 
 
Balance, May 31, 2021
   107,468,304   $17,195   $294,953   $(11,375 $539,604   $840,377 
Exercise of options, RSUs and share-based compensation expense   289,334    46    13,162           
13,208
 
Issuance of shares under employee stock purchase plan
   43,456    7    1,869           
1,876
 
Net income for 2022
   
—  
               48,307    
48,307
 
Other comprehensive
loss
   
—  
            (16,394)      
(16,394
)

   
 
 
   
 
 
   
 
 
   
 
 
  
 
 
   
 
 
 
Balance, May 31, 2022
   107,801,094   $17,248   $309,984   $(27,769 $587,911   $887,374 
  
 
 
   
 
 
   
 
 
   
 
 
  
 
 
   
 
 
 
See accompanying notes to consolidated financial statements.

F-8

Table of Contents
Neogen Corporation and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

   Year Ended May 31 
   2017  2016  2015 

Cash Flows From Operating Activities

    

Net income

  $43,973  $36,538  $33,576 

Adjustments to reconcile net income to net cash provided from operating activities:

    

Depreciation and amortization

   14,691   12,181   10,649 

Deferred income taxes

   (292  1,906   496 

Share-based compensation

   5,261   5,468   4,450 

Excess income tax benefit from exercise of stock options

   (3,922  (2,945  (2,475

Changes in operating assets and liabilities, net of business acquisitions:

    

Accounts receivable

   5,035   (6,002  (7,252

Inventories

   (6,970  (9,427  319 

Prepaid expenses and other assets

   812   (3,836  3,264 

Accounts payable

   (1,691  704   412 

Accruals and other changes

   3,377   744   353 
  

 

 

  

 

 

  

 

 

 

Net Cash From Operating Activities

   60,274   35,331   43,792 

Cash Flows Used in Investing Activities

    

Purchase of property, equipment and othernon-current intangible assets

   (14,578  (14,222  (9,619

Proceeds from the sales of marketable securities

   149,226   147,189   93,662 

Purchase of marketable securities

   (162,755  (151,625  (105,944

Business acquisitions, net of cash acquired

   (34,029  (42,491  (6,554
  

 

 

  

 

 

  

 

 

 

Net Cash Used in Investing Activities

   (62,136  (61,149  (28,455

Cash Flows From Financing Activities

    

Exercise of stock options

   21,148   12,363   8,558 

Excess income tax benefit from the exercise of stock options

   3,922   2,945   2,475 
  

 

 

  

 

 

  

 

 

 

Net Cash From Financing Activities

   25,070   15,308   11,033 

Effect of Exchange Rate on Cash

   (898  (294  (984
  

 

 

  

 

 

  

 

 

 

Net Increase (Decrease) in Cash and Cash Equivalents

   22,310   (10,804  25,386 

Cash and Cash Equivalents, Beginning of Year

   55,257   66,061   40,675 
  

 

 

  

 

 

  

 

 

 

Cash and Cash Equivalents, End of Year

  $77,567  $55,257  $66,061 
  

 

 

  

 

 

  

 

 

 

Supplementary Cash Flow Information

    

Income taxes paid, net of refunds

  $13,865  $13,413  $10,454 

   
Year Ended May 31
 
   
2022
  
2021
  
2020
 
Cash Flows From Operating Activities
             
Net income
  
$

48,307  $60,882  $59,475 
Adjustments to reconcile net income to net cash from operating activities:         
Depreciation and amortization
   23,694   21,041   18,396 
Deferred income taxes
   (4,695)  (640  1,601 
Share-based compensation
   7,154   6,437   6,468 
Changes in operating assets and liabilities, net of business acquisitions:
             
Accounts receivable
   (7,798)  (2,595  (2,881
Inventories
   (21,072)
 
  2,450   (10,011
Prepaid expenses and other assets
   (4,054)  (3,386  (1,017
Accounts payable
   10,215   (3,206  6,745 
Accruals and other changes
   16,287   106   7,102 
   
 
 
   
 
 
  
 
 
 
Net Cash From Operating Activities
   68,038   81,089   85,878 
Cash Flows for Investing Activities
             
Purchase of property, equipment and other
non-current
intangible assets
   (24,429)  (26,712  (24,052
Proceeds from the maturities of marketable securities
   381,839   764,597   406,731 
Purchase of marketable securities
   (415,894)  (792,678  (458,300
Business acquisitions, net of cash acquired
   (38,745)  (50,771  (13,164
   
 
 
   
 
 
  
 
 
 
Net Cash for Investing Activities
   (97,229)  (105,564  (88,785
Cash Flows From Financing Activities
             
Exercise of stock options and other
   7,933   34,631   29,405 
Payment of contingent consideration
   (1,120)  (1,087  —   
   
 
 
   
 
 
  
 
 
 
Net Cash From Financing Activities
   6,813   33,544   29,405 
Effects of Foreign Exchange Rate on Cash
   (8,751)  264   (1,917
   
 
 
   
 
 
  
 
 
 
Net (Decrease) Increase in Cash and Cash Equivalents   (31,129)  9,333   24,581 
Cash and Cash Equivalents, Beginning of Year
   75,602   66,269   41,688 
   
 
 
   
 
 
  
 
 
 
Cash and Cash Equivalents, End of Year
  $44,473  $75,602  $66,269 
   
 
 
  
 
 
  
 
 
 
Supplementary Cash Flow Information
             
Income taxes paid, net of refunds
  
$

17,242  $14,966  $7,364 
See accompanying notes to consolidated financial statements.

F-9

Table of Contents
Neogen Corporation and Subsidiaries

Notes to Consolidated Financial Statements

1.
Summary of Significant Accounting Policies

Nature of Operations

Neogen Corporation develops, manufactures and markets a diverse line of products and services dedicated to food and animal safety.

Basis of Consolidation

The consolidated financial statements include the accounts of Neogen Corporation and its subsidiaries, (collectively, the Company), all of which are wholly ownedwholly-owned as of May 31, 2017, with the exception of Neogen Latinoamerica. Neogen Latinoamerica was 90% owned as of May 31, 2017 and 2016. The Company made an additional capital contribution on December 31, 2013 which increased its ownership interest in Neogen Latinoamerica from 60% to 90%. Neogen do Brasil was 100% and 90% owned as of May 31, 2017 and 2016, respectively. The Company purchased all shares owned by the two minority interest owners on February 28, 2017, which increased its ownership interest in Neogen do Brasil to 100%.Non-controlling interest represents thenon-controlling owner’s proportionate share in the equity of these subsidiaries; thenon-controlling owner’s proportionate share in the income or losses of the subsidiaries is subtracted from, or added to, Company net income to calculate the net income attributable to Neogen Corporation.

2022.

All intercompany accounts and transactions have been eliminated in consolidation.

Use

Share and per share amounts reflect the June 4, 2021 2-for-1 stock split as if it took place at the beginning of Estimates

the periods presented.

Functional Currency
Our functional currency is the U.S. dollar. We translate our non-U.S. operations’ assets and liabilities denominated in foreign currencies into U.S. dollars at current rates of exchange as of the balance sheet date and income and expense items at the average exchange rate for the reporting period. Translation adjustments resulting from exchange rate fluctuations are recorded in other comprehensive income (loss). Gains or losses from foreign currency transactions are included in other income (expense) on our consolidated statement of income.
Recently Adopted Accounting Standards
Income Tax Simplification
On June 1, 2021, the Company adopted ASU 2019-12, Income Taxes (Topic 740). This guidance provides amendments to simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The preparationamendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The adoption of this guidance did not have a material impact on our consolidated financial statementsstatements.
Recent Accounting Pronouncements Not Yet Adopted
Reference Rate Reform
In March 2020, FASB issued Update
2020-04,
Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. This update provides temporary optional expedients to applying the reference rate reform guidance to contracts that reference LIBOR or another reference rate expected to be discontinued. Under this update, contract modifications resulting in conformity with U.S. generally accepted accounting principles requires managementa new reference rate may be accounted for as a continuation of the existing contract. This guidance is effective upon issuance of the update and applies to make estimates and assumptions that affectcontract modifications made through December 31, 2022. We will adopt this standard when our new credit agreement goes into effect on the amounts reporteddate of the 3M Food Safety business merger, currently expected to close in the third quarter of calendar year 2022. We are evaluating the impact the new standard will have on our consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates impacting the accompanying consolidated financial statements include the allowance for uncollectible accounts receivable, inventory valuation and intangible assets.

related disclosures, but do not anticipate a material impact.

Comprehensive Income

Comprehensive income represents net income and any revenues, expenses, gains and losses that, under U.S. generally accepted accounting principles, are excluded from net income and recognized directly as a component of stockholders’ equity. Accumulated other comprehensive income (loss) consists solely of foreign currency translation adjustments.

Accounts Receivableadjustments and Concentrationsunrealized gains and losses on our marketable securities.

F-10

Table of Credit Risk

Financial instruments which potentially subject the Company to concentrationsContents

Changes in our Accumulated Other Comprehensive Income (Loss) (“AOCI”) balances, net of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit history before extending credit and by monitoring credit exposure on a regular basis. An allowance for doubtful accounts on accounts receivable is established based upon factors surrounding the credit risk of specific customers, historical trends and other information. Collateral or other security is generally not required for accounts receivable. Once a receivable balance has been determined to be uncollectible, that amount is charged against the allowance for doubtful accounts. No customer accounted for more than 10% of accounts receivable at May 31, 2017 or 2016, respectively. The activity in the allowance for doubtful accounts wastax, were as follows:

   Year ended May 31 
(in thousands)  2017   2016   2015 

Beginning Balance

  $1,500   $1,300   $1,200 

Provision

   645    305    337 

Recoveries

   25    90    92 

Write-offs

   (170   (195   (329
  

 

 

   

 

 

   

 

 

 

Ending Balance

  $2,000   $1,500   $1,300 
  

 

 

   

 

 

   

 

 

 

(in thousands)
  
Foreign Currency
Translation Adjustments
   
Unrealized Gain (Loss) on
Marketable Securities
   
Total
AOCI
 
Balance, May 31, 2020
  $(20,135  $426   $(19,709
Other comprehensive income (loss)
   8,602    (268   8,334 
   
 
 
   
 
 
   
 
 
 
Balance, May 31, 2021
  $(11,533  $158   $(11,375
Other comprehensive loss
   
(13,955
)
   
(2,439
   (16,394)
   
 
 
   
 
 
   
 
 
 
Balance, May 31, 2022
  $(25,488  $(2,281)  $(27,769
   
 
 
   
 
 
   
 
 
 
Fair Value of Financial Instruments

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.

Fair Value Measurements


Fair value measurements are determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs. The Company utilizes a fair value hierarchy based upon the observability of inputs used in valuation techniques as follows:

Level 1:

  

Observable inputs such as quoted prices in active markets;

Level 2:

  

Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and

Level 3:

  Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.

The carrying amounts of the Company’s financial instruments other than cash equivalents and marketable securities, which include accounts receivable and accounts payable, approximate fair value based on either their short maturity or current terms for similar instruments.
Cash and Cash Equivalents

Cash and cash equivalents consist of bank demand accounts, savings deposits, certificates of deposit and commercial paper with original maturities of 90 days or less. Cash and cash equivalents were $77,567,000are maintained at financial institutions and, $55,257,000 at May 31, 2017times, balances may exceed federally insured limits. The Company has not experienced losses related to these balances and 2016, respectively.believes it is not exposed to significant credit risk regarding its cash and cash equivalents. The carrying value of these assets approximates fair value due to the short maturity of these instruments and meet theis classified as Level 1 criteria.in the fair value hierarchy. Cash held by foreign subsidiaries was $8,132,000$17,057,000 and $5,320,000$15,246,000 at May 31, 20172022 and 2016,2021, respectively.

Marketable Securities

The Company has marketable securities held by banks or broker-dealers at May 31, 2017,2022, consisting of short-term domestic certificates of deposit of $25,355,000commercial paper and commercial papercorporate bonds rated at leastA-2/P-2 A-1/P-1 (short-term) and A/A2 (long-term) with original maturities between 91 days and one yeartwo years
. Changes in market value are monitored and recorded on a monthly basis; in the event of $40,713,000. Total outstandinga downgrade in credit quality subsequent to purchase, the marketable security investment is evaluated to determine the appropriate action to take to minimize the overall risk to our marketable security portfolio. As these securities are highly rated and short-term in nature, they have very little credit risk; therefore, the Company does not believe a reserve for expected credit losses on marketable securities at May 31, 2017 were $66,068,000; there were $52,539,000 in marketable securities outstanding at May 31, 2016.is material. These securities are classified as available for sale. The primary objective of the Company’smanagement’s short-term investment activity is to preserve capital for the purpose of funding operations, capital expenditures and business acquisitions; short-term investments are not entered into for trading or speculative purposes. These securities are recorded at fair value (that approximates cost) based on recent trades or pricing models and therefore meet the Level 2 criteria. Interest income on these investments is recorded within Other Incomeother income on our consolidated statements of income. Adjustments in the fair value of these assets are recorded in other comprehensive income statement.

(loss).

F-11

Table of Contents
Marketable Securities as of May 31, 2022 and 2021 are listed below by classification and remaining maturities.
       
Year ended May 31
 
(in thousands)
  
Maturity
   
2022
   
2021
 
Commercial Paper & Corporate Bonds
   0 - 90 days   $106,497   $106,631 
    91 -180 days    61,373    78,727 
    181 days -1 year    91,706    87,590 
    1 - 2 years    77,002    26,752 
Certificates of Deposit
   0 - 90 days    —      3,262 
    91 - 180 days    —      1,260 
    181 days -1 year    —      1,263 
    1 - 2 years    —      —   
        
 
 
   
 
 
 
Total Marketable Securities
       $336,578   $305,485 
        
 
 
   
 
 
 
The components of marketable securities as of May 31, 2022 are as follows:
   
Amortized
   
Unrealized
   
Unrealized
     
(in thousands)
  
Cost
   
Gains
   
Losses
   
Fair Value
 
Commercial Paper & Corporate Bonds
  $339,540   $7   $(2,969  $336,578 
Certificates of Deposit
   —      —      —      —   
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Marketable Securities
  $339,540   $7   $(2,969  $336,578 
   
 
 
   
 
 
   
 
 
   
 
 
 
The components of marketable securities as of May 31, 2021 are as follows:
   
Amortized
   
Unrealized
   
Unrealized
     
(in thousands)
  
Cost
   
Gains
   
Losses
   
Fair Value
 
Commercial Paper & Corporate Bonds
  
$
299,524   $209   
$
(33  $299,700 
Certificates of Deposit
   5,755    30    —      5,785 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total Marketable Securities
  $305,279   $239   $(33  $305,485 
   
 
 
   
 
 
   
 
 
   
 
 
 
Use of Estimates
The preparation of these consolidated financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including, but not limited to, variable consideration related to revenue recognition, allowances for doubtful accounts, the market value of, and demand for, inventories, stock-based compensation, provision for income taxes and related balance sheet accounts, accruals, goodwill and other intangible assets. We believe that these estimates have the greatest potential impact on our financial statements, so we consider them to be our critical accounting policies and estimates. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Though the impact of the
COVID-19
pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates. Actual results may differ from these estimates under different assumptions or conditions.
F-12

Table of Contents
Accounts Receivable and Concentrations of Credit Risk
Financial instruments which potentially subject Neogen to concentrations of credit risk consist principally of accounts receivable. Management attempts to minimize credit risk by reviewing customers’ credit histories before extending credit and by monitoring credit exposure on a regular basis. Collateral or other security is generally not required for accounts receivable. We maintain an allowance for customer accounts that reduces receivables to amounts that are expected to be collected. In estimating the allowance for doubtful accounts, management considers relevant information about past events, current conditions and reasonable and supportable forecasts that affect the collectability of financial assets. Once a receivable balance has been determined to be uncollectible, generally after all collection efforts have been exhausted, that amount is charged against the allowance for doubtful accounts. No customer accounted for more than 10% of accounts receivable May 31, 2022 or 2021, respectively. The activity in the allowance for doubtful accounts was as follows:
   
Year ended May 31
 
(in thousands)
  
2022
   
2021
   
2020
 
Beginning Balance
  $1,400   $1,350   $1,700 
Provision
   332    239    393 
Recoveries
   98    139    49 
Write-offs
   (180)   (328   (792
   
 
 
   
 
 
   
 
 
 
Ending Balance
  $1,650   $1,400   $1,350 
   
 
 
   
 
 
   
 
 
 
Inventories

Inventories are stated at the lower of cost or net realizable value, determined on thefirst-in,first-out method, or market. method. The components of inventories were as follows:

   Year ended May 31 
(in thousands)  2017   2016 

Raw Materials

  $33,190   $29,501 

Work-in-process

   4,831    4,498 

Finished goods

   35,123    30,372 
  

 

 

   

 

 

 
  $73,144   $64,371 
  

 

 

   

 

 

 

   
Year ended May 31
 
(in thousands)
  
2022
   
2021
 
Raw Materials
  $58,667   $47,588 
Work-in-process
   6,388    6,412 
Finished goods
   57,258    46,701 
   
 
 
   
 
 
 
   $122,313   $100,701 
   
 
 
   
 
 
 
The Company’s inventories are analyzed for slow moving, expired and obsolete items no less frequently thanon a quarterly basis and the valuation allowance is adjusted as required.required within cost of
revenues
expense. The valuation allowance for inventory was $2,000,000$4,050,000 and $1,550,000$3,100,000 at May 31, 20172022 and 2016,2021, respectively.

Property and Equipment

Property and equipment is stated at cost. Expenditures for major improvements are capitalized while repairs and maintenance are charged to expense.expense as incurred. Depreciation is provided on the straight-line method over the estimated useful lives of the respective assets, which are generally seven to 39 years for buildings and improvements and three to ten10 years for furniture, fixtures, machinery and equipment. Depreciation expense was $8,783,000, $7,452,000$14,094,000, $13,288,000 and $6,318,000$11,907,000 in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively.

Goodwill and Other Intangible Assets

Goodwill represents the excess of purchase price over fair value of tangible net assets of acquired businesses after amounts are allocated to other identifiable intangible assets. Other intangible assets include customer relationships, trademarks, licenses, trade names, covenants
not-to-compete
and patents. Amortizable intangible assets are amortized on either an accelerated or a straight-line basis, generally over 5two to 25 years. The Companyremaining weighted average amortization period for intangibles was eight years and 10 years at May 31, 2022 and 2021, respectively. Management reviews the carrying amounts of goodwill and other
non-amortizable
intangible assets annually, or when indications of
impairment exist, to determine if such
F-13

Table of Contents
assets may be impaired by performingimpaired. Events that would indicate impairment and trigger an interim impairment assessment include, but are not limited to, current economic and market conditions, including a decline in the Company’s market capitalization, a significant adverse change in legal factors, business climate or operational performance of the business. In evaluating goodwill for impairment, we have the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis. If the qualitative assessment leads to a determination that the reporting unit’s fair value is less than its carrying value, or if we elect to bypass the qualitative assessment altogether, we are required to perform a quantitative assessment. Ifimpairment test by calculating the carrying amounts of these assets are deemed to be less than fair value based upon a discounted cash flow analysisof the reporting unit and comparison to comparable earnings multiples of peer companies, such assets are reduced to their estimatedcomparing the fair value with its associated carrying value. In the fourth quarter of fiscal 2022
, management performed our annual goodwill impairment analysis qualitatively.
In connection with our annual goodwill impairment assessment for 2022, 2021, and a charge is made to operations. The remaining weighted-average amortization period for customer-based intangibles and other intangibles are 11 and 12 years, respectively, at May 31, 2017 and May 31, 2016.

2020, we determined that 0 impairment adjustments were necessary.

Long-lived Assets

Management reviews the carrying values of its long-lived assets to be held and used, including definite-lived intangible assets, for possible impairment whenever events or changes in business conditions warrant such a review. The carrying value of a long-lived asset is considered impaired when the anticipated separately identifiable undiscounted cash flows over the remaining useful life of the asset are less than the carrying value of the asset. In such an event, fair value is determined using discounted cash flows, and if lower than the carrying value, impairment is recognized through a charge to operations.

NaN impairments of long-lived assets were identified during the years ended May 31, 2022, 2021 and 2020, respectively.

Business Combinations
We utilize the purchase method of accounting for business combinations. This method requires, among other things, that results of operations of acquired companies are included in Neogen’s results of operations beginning on the respective acquisition dates and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Any excess of the fair value of consideration transferred over the fair values of the net assets acquired is recognized as goodwill. Contingent consideration liabilities are recognized at the estimated fair value on the acquisition date; these are recorded in either other accruals within current liabilities (for expected payments in less than a year) or other non-current liabilities (for expected payments in greater than a year), both on our consolidated balance sheets. Subsequent changes to the fair value of contingent consideration liabilities are recognized in other income (expense) in the consolidated statements of income. Contingent consideration payments made soon after the acquisition date are classified as investing activities in the consolidated statements of cash flows. Contingent consideration payments not made soon after the acquisition date that are related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows, and amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of assets acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a period of time not to exceed 
12
months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all other business acquisition costs are expensed when incurred. 
Reclassifications

Certain immaterial amounts in the fiscal 20162021 and 20152020 consolidated financial statements have been reclassified to conform towith the fiscal 20172022 presentation.

See the Company’s discussion on Accounting Standards Update2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes, below for information on reclassifications related to the adoption of this standard as of May 31, 2017.

Stock Options

Equity Compensation Plans
At May 31, 2017,2022, the Company had stock option plans which are described more fully in Note 5.

5 to the consolidated financial statements.

We measure stock-based compensation at the grant date, based on the estimated fair value of the award, and recognize the cost (net of estimated forfeitures) as compensation expense on a straight-line basis over the requisite service period. Our stock-based compensation expense is reflected in general and administrative expense in our consolidated statements of income.
The weighted-average fair value per share of stock options granted during fiscal years 2017, 20162022, 2021 and 2015,2020, estimated on the date of grant using the Black-Scholes option pricing model, was $15.86, $13.11$8.49, $7.71 and $11.91,$7.78, respectively. The fair value of stock options granted was estimated using the following weighted-average assumptions:

   Year ended May 31 
   2017   2016   2015 

Risk-free interest rate

   1.2%    1.2%    1.2% 

Expected dividend yield

   0.0%    0.0%    0.0% 

Expected stock volatility

   35.2%    33.3%    36.2% 

Expected option life

   4.0 years        4.0 years        4.0 years     

   
Year ended May 31
 
   
2022
  
2021
  
2020
 
Risk-free interest rate
   0.4  0.2  1.9
Expected dividend yield
   0.0  0.0  0.0
Expected stock volatility
   32.8  31.3  29.4
Expected option life
   3.12 years   3.25 years   3.5 years 
The risk-free interest rate for periods within the expected life of options granted is based on the United States Treasury yield curve in effect at the time of grant. Expected stock price volatility is based on historical volatility of the Company’s stock. The expected option life, representing the period of time that options granted are expected to be outstanding, is based on historical option exercise and employee termination data. TheWe include recent historical experience in estimating our forfeitures. As employees terminate, grant tranches expire or as forfeitures are known, estimated expense is adjusted to actual. For options granted in fiscal years 2022, 2021 and 2020, the Company recognizesrecorded charges in general and administrative expense based on the fair value of stock options using the acceleratedstraight-line method over their requisite service periods which the Company has determined to be the vesting periods.

Revenue Recognition

Revenue from productsperiod of three to five years.

F-14

Table of Contents
The Company also issues restricted stock units (RSUs), which are described more fully in Note 5 to the consolidated financial statements. The RSUs generally vest over three to five years and services is recognized when the product has been shipped or the service performed, the sales price is fixed and determinable, and collectionhave a weighted average value of any receivable is probable. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred and later recognized in the period that all recognition criteria have been met. Customer credits for sales returns, pricing and other disputes, and other related matters (including volume rebates offered to certain distributors as marketing support) represent approximately 3% of reported net revenue$37.28 in fiscal years 2017, 20162022 and 2015.

Shipping and Handling Costs

Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by the Company are recorded in sales and marketing expense; these expenses totaled $10,185,000, $9,734,000 and $8,648,000$34.21 in fiscal years 2017, 2016 and 2015, respectively.

2021.

Income Taxes

The Company accounts

We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and for tax credit carry forwardscarryforwards and are measured using the enacted tax rates in effect for the years in which the differences are expected to reverse. Deferred income tax expense represents the change in net deferred income tax assets and liabilities during the year.

The Company’s policy is to recognize both accrued interest expense and penalties related to unrecognized tax benefits in income tax expense.

Our wholly-owned foreign subsidiaries are comprised of Neogen Europe, Lab M Holdings, Quat-Chem Ltd, Abbott Analytical Limited, Delf (UK) Limited, Delf-Chem Solutions Limited, Megazyme Ltd, Megazyme IP, Neogen Italia S.r.l., Neogen do Brasil, Rogama Industria e Comercio Ltda, Neogen Latinoamérica, Neogen Guatemala, Neogen Argentina, Neogen Uruguay, Neogen Chile SpA, Neogen
Bio-Scientific
Technology Co (Shanghai), Neogen Food and Animal Security (India), Neogen Canada Acumedia do Brasil, Deoxi Biotecnologia Ltda, and Rogama Industria e Comercio, Ltda; Neogen owns 90% of Neogen Latinoamerica.Australasia Pty Limited. Based on historical experience, as well as the Company’smanagement’s future plans, earnings from these subsidiaries are expected to be
re-invested
indefinitely for future expansion and working capital needs. Furthermore, the Company’sour domestic operations have historically produced sufficient operating cash flow to mitigate the need to remit foreign earnings. On an annual basis, the Company evaluateswe evaluate the current business environment and whether any new events or other external changes might require a
re-evaluation
of the decision to indefinitely
re-invest
foreign earnings. At May 31, 2017, unremittedIt is not practicable to determine the income tax liability that would be payable if such earnings of the foreign subsidiaries were $35,281,000.

not reinvested indefinitely.

Research and Development Costs

Research and development costs, which consist primarily of compensation costs, administrative expenses and new product development, among other items, are expensed as incurred.

Advertising Costs

Advertising costs are expensed within sales and marketing as incurred and totaled $1,643,000, $1,463,000$2,018,000, $1,687,000 and $1,371,000$1,454,000 in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively.

Net Income Attributable to Neogen per Share

Basic net income per share is based on the weighted average number of common shares outstanding during each year. Diluted earnings per share is based on the weighted average number of common shares and dilutive potential common shares outstanding. The Company’sOur dilutive potential common shares outstanding during the years result entirely from dilutive stock options.options and restricted stock units. The following table presents the net income per share calculations:

   Year ended May 31 
(in thousands, except per share)  2017   2016   2015 

Numerator for basic and diluted net income per share - Net Income attributable to Neogen

  $43,793   $36,564   $33,526 
  

 

 

   

 

 

   

 

 

 

Denominator for basic net income per share - Weighted average shares

   37,908    37,402    36,953 

Effect of dilutive stock options

   466    473    491 
  

 

 

   

 

 

   

 

 

 

Denominator for diluted net income per share

   38,374    37,875    37,444 

Net income attributable to Neogen per share

      

Basic

  $1.16   $0.98   $0.91 

Diluted

  $1.14   $0.97   $0.90 


   
Year ended May 31
 
(in thousands, except per share)
  
2022
   
2021
   
2020
 
Numerator for basic and diluted net income per share — Net Income
  
$

48,307   $60,882   $59,475 
Denominator for basic net income per share — Weighted average shares
   107,684    106,499    105,100 
Effect of dilutive stock options and restricted stock units   336    621    620 
   
 
 
   
 
 
   
 
 
 
Denominator for diluted net income per share
   108,020    107,120    105,720 
Net income attributable per share
               
Basic
  $0.45   $0.57   $0.57 
Diluted
  $0.45   $0.57   $0.56 
At May 31, 2017, 2016 and 2015,2022, 383,000 shares from option exercises were excluded from the computation of diluted net income per share, as the option exercise prices exceeded the average market price of the common stock exceeded the option exercise price for all outstanding options; therefore, noshares. At May 31, 2021, 0 potential shares were excluded from the diluted net income per share computation.

New Accounting Pronouncements

In At

May 2014,31, 2020, 56,000 potential shares were excluded from the FASB issued ASU No.2014-09—Revenue from Contracts with Customers. The new standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principlecomputation.
F-15

Leases
The Company has formed a team to evaluate the impact of the adoption of this standard on its consolidated financial statements.

In July 2015, the FASB issued ASU No.2015-11—Inventory: Simplifying the Measurement of Inventory. The update requires inventory not measured using either the last in, first out (LIFO) or the retail inventory methods to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. The update is effective for fiscal years beginning after December 15, 2016. Early adoption is permitted for financial statements that have not been previously issued. The Company will adopt this standard on June 1, 2017 and does not expect the adoption will have a material impact on its consolidated financial condition and results of operations.

In September 2015, the FASB issued ASU2015-16—Simplifying the Accounting for Measurement—Period Adjustments. Changes to the accounting for measurement-period adjustments relate to business combinations. Currently, an acquiring entity is required to retrospectively adjust the balance sheet amounts of the acquiree recognized at the acquisition date with a corresponding adjustment to goodwill as a result of changes made to the balance sheet amounts of the acquiree. The measurement period is the period after the acquisition date during which the acquirer may adjust the balance sheet amounts recognized for a business combination (generally up to one year from the date of acquisition). The changes eliminate the requirement to make such retrospective adjustments, and instead require the acquiring entity to record these adjustments in the reporting period they are determined. The new standard is effective for public companies for fiscal years beginning after December 15, 2015. The Company has adopted this standard; the adoption has not had a material impact on its consolidated financial condition and results of operations.

The FASB issued ASU No.2015-17—Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes as part of its Simplification Initiative. The amendments eliminate the guidance in Topic 740, Income Taxes, that required an entity to separate deferred tax assets and liabilities between current andnon-current amounts in a classified balance sheet. Rather, deferred taxes will be presented asnon-current under the new standard. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 for public companies. Early adoption is permitted. The Company retrospectively adopted ASU2015-17 as of May 31, 2017. On the May 31, 2016 balance sheet, the Company reclassified $1,775,000 of current deferred tax assets to Deferred Income Taxes, withinNon-current Liabilities. Total assets and total liabilities decreased by $1,775,000.

In February 2016, the FASB issued ASU No.2016-02—Leases to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. A lessee should recognizerecognizes in the statement of financial position a liability to make lease payments (the lease liability) and a

right-of-use
asset representing its right to use the underlying asset for the lease term. The recognition, measurementWe recognized all leases with terms greater than 12 months in duration on our consolidated balance sheets as
right-of-use
assets and presentation of expenses
 lease liabilities
.
Right-of-use
assets are recorded in other assets on our consolidated balance sheets. Current and cash flows arising from
non-current
lease liabilities are recorded in other accruals within current liabilities and other
non-current
liabilities, respectively, on our consolidated balance sheets.
We lease various manufacturing, laboratory, warehousing and distribution facilities, administrative and sales offices, equipment and vehicles under operating leases. We evaluate our contracts to determine if an arrangement is a lease byat inception and classify it as a lessor have not significantly changed from previous U.S. GAAP. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2018. Modified retrospective application is permitted with certain practical expedients. Early adoption is permitted. The Company is infinance or operating lease. Currently, all of our leases are classified as operating leases. Leased assets and corresponding liabilities are recognized based on the process of evaluating its lessee and lessor arrangements to determine the impact of this amendment on its consolidated financial condition and results of operations. This evaluation includes a review of revenue through leasing arrangements as well as lease expenses, which are primarily through operating lease arrangements at mostpresent value of the Company’s facilities.

In March 2016,lease payments over the FASB issued ASUNo. 2016-09—Compensation-Stock Compensation (Topic 718): Improvementslease term. Our lease terms may include options to Employee Share-Based Payment Accounting to provide guidance that changes the accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are settled, thus eliminating additionalpaid-in capital pools. The guidance also allows for the employer to repurchase more of an employee’s shares for tax withholding purposes without triggering liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. This ASU is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2016 with early adoption permitted. The Company will adopt this standard effective June 1, 2017 and currently believes that tax benefits related to share-based payments will result in a lower effective tax rate in fiscal 2018.

In June 2016, the FASB issued ASUNo. 2016-13—Measurement of Credit Losses on Financial Instruments, which changes how companies measure credit losses on most financial instruments measured at amortized cost and certain other instruments, such as loans, receivables andheld-to-maturity debt securities. Rather than generally recognizing credit lossesextend when it is probablereasonably certain that we will exercise that option.

We have made certain assumptions and judgments when accounting for leases, the loss has been incurred,most significant of which are:
We did not elect to use hindsight when considering judgments and estimates such as assessments of lessee options to extend or terminate a lease or purchase the revised guidance requires companiesunderlying asset.
For all asset classes, we elected to not recognize an allowancea right-of-use asset and lease liability for credit lossesshort-term leases (i.e. leases with a term of 12 months or less).
For all asset classes, we elected to not separate non-lease components from lease components to which they relate and have accounted for the difference between the amortized cost basis of a financial instrumentcombined lease and the amount of amortized cost that the company expects to collect over the instrument’s contractual life. ASU2016-13 is effective for fiscal periods beginning after December 15, 2019 and must be adoptednon-lease components as a cumulative effect adjustment to retained earnings. Early adoption is permitted. single lease component.
The Company does not believe the adoption of this guidance will have an impact on its consolidated financial statements.

In August 2016, the FASB issued ASUNo. 2016-15—Classification of Certain Cash Receipts and Cash Payments (a consensusdetermination of the Emerging Issues Task Force). discount rate used in a lease is our incremental borrowing rate that is based on our estimate of what we would normally pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments.

Supplemental balance sheet information related to operating leases was as follows:

   
Year ended May 31
 
(in thousands)
  
2022
   
2021
 
Rights of use - assets
  $3,184   $2,477 
Lease liabilities - current
   1,440    1,285 
Lease liabilities - non-current
   1,788    1,207 
The amendmentsweighted average remaining lease term and weighted average discount rate were as follows:
   
Year ended May 31
 
   
2022
  
2021
 
Weighted average remaining lease term
   3 years   2 years 
Weighted average discount rate
   1.7  2.0
F-16

Operating lease expenses are classified as cost of revenues or operating expenses on the consolidated statements of income. The components of lease expense were as follows:
   
Year ended May 31
 
(in thousands)
  
2022
   
2021
 
Operating leases
  $438   $1,352 
Short term leases
   277    134 
   
 
 
   
 
 
 
Total lease expense
  $715   $1,486 
Cash paid for amounts included in ASU2016-15 address eight specificthe measurement of lease liabilities for operating leases included in cash flow issues and apply to all entities that are required to present aflows from operations on the statement of cash flows was approximately $1,407,000, $1,397,000 and $1,178,000 for the years ended May 31, 2022, 2021 and 2020, respectively. There were 0 non-cash additions to right-of-use assets obtained from new operating lease liabilities for the year ended May 31, 2022.
Maturities of operating lease liabilities as of May 31, 2022 are as follows:
(in thousands)
  
Amount
 
Years ending May 31, 2023
  $1,458 
2024
   887 
2025
   436 
2026
   345 
2027 and thereafter
   190 
   
 
 
 
Total lease payments
  $3,316 
Less: imputed interest
   (88
   
 
 
 
Total lease liabilities
  $3,228 
   
 
 
 
Revenue Recognition
We determine the amount of revenue to be recognized through application of the following steps:
Identification of the contract with a customer;
Identification of the performance obligations in the contract;
Determination of the transaction price;
Allocation of the transaction price to the performance obligations in the contract; and
Recognition of revenue when or as the Company satisfies the performance obligations.
Essentially all of Neogen’s revenue is generated through contracts with its customers. A performance obligation is a promise in a contract to transfer a product or service to a customer. We generally recognized revenue at a point in time when all of our performance obligations under FASB Accounting Standards Codification (FASB ASC) 230, Statementthe terms of Cash Flows.a contract are satisfied. Revenue is recognized upon transfer of control of promised products or services in an amount that reflects the consideration we expect to receive in exchange for those products or services. The amendmentscollectability of consideration on the contract is reasonably assured before revenue is recognized. To the extent that customer payment has been received before all recognition criteria are met, these revenues are initially deferred in ASU2016-15other accruals on the balance sheet and the revenue is recognized in the period that all recognition criteria have been met.
F-17

Certain agreements with customers include discounts or rebates on the sale of products and services applied retrospectively, such as volume rebates achieved by purchasing a specified purchase threshold of goods and services. We account for these discounts as variable consideration and estimate the likelihood of a customer meeting the threshold in order to determine the transaction price using the most predictive approach. We typically use the most-likely-amount method, for incentives that are effectiveoffered to individual customers, and the expected-value method, for public business entitiesprograms that are offered to a broad group of customers. Variable consideration reduces the amount of revenue that is recognized. Rebate obligations related to customer incentive programs are recorded in accrued liabilities; the rebate estimates are adjusted at the end of each applicable measurement period based on information currently available.
The performance obligations in Neogen’s contracts are generally satisfied well within one year of contract inception. In such cases, management has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. Management has elected to utilize the practical expedient to recognize the incremental costs of obtaining a contract as an expense when incurred because the amortization period for the prepaid costs that would otherwise have been deferred and amortized is one year or less. We account for shipping and handling for products as a fulfillment activity when goods are shipped. Shipping and handling costs that are charged to and reimbursed by the customer are recognized as revenues, while the related expenses incurred by Neogen are recorded in sales and marketing expense; these expenses totaled $17,482,000, $15,180,000 and $13,514,000 in fiscal years beginning after December 15, 2017,2022, 2021 and interim periods within those fiscal years. Early adoption2020, respectively. Revenue is permitted, including adoption during an interim period. recognized net of any tax collected from customers; the taxes are subsequently remitted to governmental authorities. Our terms and conditions of sale generally do not provide for returns of product or reperformance of service except in the case of quality or warranty issues. These situations are infrequent; due to immateriality of the amount, warranty claims are recorded in the period incurred.
The Company derives revenue from two primary sources — product revenue and service revenue.
Product revenue consists primarily of shipments of:
Diagnostic test kits, culture media and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation;
Consumable products marketed to veterinarians, retailers, livestock producers and animal health product distributors; and
Rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.
Revenue for Neogen’s products are recognized and invoiced when the product is shipped to the customer.
Service revenue consists primarily of:
Genomic identification and related interpretive bioinformatic services; and
Other commercial laboratory services.
Revenues for Neogen’s genomics and commercial laboratory services are recognized and invoiced when the applicable laboratory service is performed and the results are conveyed to the customer.
Payment terms for products and services are generally 30 to 60 days.
The Company has not yet adopted this update0
contract assets
;
 contract liabilities represent deposits made by customers before the satisfaction of performance obligation(s) and recognition of revenue. Upon completion of the performance obligation(s) that the Company has with the customer, the liability for the customer deposit is currently evaluatingrelieved and revenue is recognized. These customer deposits are listed as Deferred revenue
o
n the impactconsolidated balance sheets.
F-18

Table of ASUNo. 2016-15 on itsContents
The following table presents disaggregated revenue by major product and service categories for the years ended May 31, 2022, 2021 and 2020:
   
Year Ended
(dollars in thousands)
  
May 31, 2022
   
May 31, 2021
   
May 31, 2020
 
Food Safety:
               
Natural Toxins, Allergens & Drug Residues
  $79,395   $76,614  $76,207 
Bacterial & General Sanitation
   47,282    44,009   41,780 
Culture Media & Other
   75,278    61,245   47,847 
Rodenticides, Insecticides & Disinfectants
   35,691    32,219   28,890 
Genomics Services
   22,333    20,157   17,967 
   
 
 
   
 
 
  
 
 
 
   $259,979   $234,244  $212,691 
Animal Safety:
              
Life Sciences
   5,685    5,715   6,322 
Veterinary Instruments & Disposables
   63,938    48,128   42,941 
Animal Care & Other
   39,805    35,897   28,389 
Rodenticides, Insecticides & Disinfectants
   83,610    77,458   68,815 
Genomics Services
   74,142    67,017   59,012 
   
 
 
   
 
 
  
 
 
 
   $267,180   $234,215  $205,479 
   
 
 
   
 
 
  
 
 
 
Total Revenue
  $527,159   $468,459  $418,170 
   
 
 
   
 
 
  
 
 
 
See Note
11
to the consolidated financial statements.

In January 2017, the FASB issued ASU2017-04—Intangibles—Goodwill and Other (Topic 350). ASU2017-04 simplifies the subsequent measurement of goodwillstatements for disaggregated revenues by removing the second step of thetwo-step impairment test. The amendment requires an entity to perform its annual, or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The amendment should be applied on a prospective basis. ASU2017-04 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company has adopted this amendment; the adoption has not had an impact on its consolidated financial statements.

geographical location.

2. Goodwill and Other Intangible Assets

Management has completed the annual impairment analysis of goodwill and intangible assets with indefinite lives using a quantitative
qualitative
assessment as of the first day of the fourth quarter of fiscal years 2017, 20162022, 2021 and 2015,2020, respectively, and determined that recorded amounts were not impaired and that no write-down was necessary.

The following table summarizes goodwill by reportable segment:

(in thousands)  Food Safety   Animal Safety   Total 

Balance, May 31, 2015

  $18,806   $51,313   $70,119 

Goodwill acquired and/or adjusted

   8,083    10,304    18,387 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2016

  $26,889   $61,617   $88,506 

Goodwill acquired and/or adjusted (1)

   19,031    (2,778   16,253 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2017

  $45,920   $58,839   $104,759 
  

 

 

   

 

 

   

 

 

 

(in thousands)
  
Food Safety
   
Animal Safety
   
Total
 
Balance, May 31, 2020  $47,215   $63,125   $110,340 
Goodwill acquired   18,775    —      18,775 
Goodwill and/or currency adjustments (1)   1,832    529    2,361 
                
Balance, May 31, 2021  $67,822   $63,654   $131,476 
                
Goodwill acquired   4,152    11,752    15,904 
Goodwill and/or currency adjustments (1)   (4,416   (260   (4,676
                
Balance, May 31, 2022  $67,558   $75,146   $142,704 
                
(1)Represents
Includes final purchase price allocation adjustmentadjustments and currency adjustments for goodwill recorded at international locations.

F-19

At May 31, 2017,2022, non-amortizable intangible assets included licenses of $569,000, trademarks of $12,530,000$13,604,000 and other intangibles of $1,224,000. At May 31, 2016,2021, non-amortizable intangible assets included licenses of $569,000, trademarks of $7,377,000$13,752,000 and other intangibles of $1,224,000.

Amortizable intangible assets consisted of the following and are included in customer-based intangibleintangibles and othernon-current assets within the consolidated balance sheets:

(in thousands)  Gross
Carrying
Amount
   Less
Accumulated
Amortization
   Net
Carrying
Amount
 

Licenses

  $5,989   $2,011   $3,978 

Covenants not to compete

   1,208    309    899 

Patents

   9,304    4,601    4,703 

Customer-based intangibles

   56,829    20,846    35,983 

Other products and service-related intangibles

   12,065    3,010    9,055 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2017

  $85,395   $30,777   $54,618 
  

 

 

   

 

 

   

 

 

 

Licenses

  $5,189   $1,782   $3,407 

Covenants not to compete

   491    193    298 

Patents

   8,040    3,631    4,409 

Customer-based intangibles

   48,186    17,277    30,909 

Other products and service-related intangibles

   12,256    1,924    10,332 
  

 

 

   

 

 

   

 

 

 

Balance, May 31, 2016

  $74,162   $24,807   $49,355 
  

 

 

   

 

 

   

 

 

 


   
Gross
   
Less
   
Net
 
   
Carrying
   
Accumulated
   
Carrying
 
(in thousands)
  
Amount
   
Amortization
   
Amount
 
Licenses
  
$

17,109   
$

5,682   $11,427 
Covenants not to compete
   846    671    175 
Patents
   8,347    4,583    3,764 
Customer-based intangibles
   75,000    33,662    41,338 
Other product and service-related intangibles
   46,220    10,818    35,402 
   
 
 
   
 
 
   
 
 
 
Balance, May 31, 2022
  $147,522   $55,416   $92,106 
   
 
 
   
 
 
   
 
 
 
Licenses
  $16,913   $4,580   $12,333 
Covenants not to compete
   1,006    571    435 
Patents
   8,363    4,243    4,120 
Customer-based intangibles
   76,384    35,209    41,175 
Other product and service-related intangibles
   27,567    8,859    18,708 
   
 
 
   
 
 
   
 
 
 
Balance, May 31, 2021
  $130,233   $53,462   $76,771 
   
 
 
   
 
 
   
 
 
 
Amortization expense for intangibles totaled $5,908,000, $4,730,000$9,600,000, $7,753,000 and $4,331,000$6,489,000 in fiscal years 2017, 2016,2022, 2021, and 2015,2020, respectively. The estimated amortization expense for each of the five succeeding fiscal years is as follows: $5,951,000$9,634,000 in 2018, $5,558,0002023, $9,189,000 in 2019, $5,253,0002024, $8,686,000 in 2020, $4,977,0002025, $8,585,000 in 20212026 and $4,646,000$8,097,000 in 2022. 2027
 and $47,915,000 thereafter.
The amortizable intangible assets useful lives are 2 to 20 years for licenses, 53 to 1310 years for covenants not to compete, 5 to 25 years for patents, 59 to 20 years for customer-based intangibles and 25 to 20 years for other product and service-related intangibles, which primarily consist of product formulations. All definite-lived intangibles are amortized on a straight linestraight-line basis with the exception of definite-lived customer-based intangibles and product and service-related intangibles, which are amortized on either a straight-line or an accelerated basis.

3.Business Combinations

basis

.
3. Business Combinations
The Consolidated Statements of Income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method. Goodwill recognized in the acquisitions described below relates primarily to enhancing the Company’s strategic platform for the expansion of available product offerings.

Fiscal 2015

2020

On OctoberJanuary 1, 2014,2020, the Company acquired all of the stock of BioLumix, Inc.,Productos Quimicos Magiar, a manufacturer and marketerdistributor of automated systemsNeogen’s Food Safety products for the detection of microbial contaminantspast 20 years, located in Ann Arbor, Michigan.Argentina. This acquisition gives Neogen a direct sales presence in Argentina. Consideration for the purchase was $4,514,000$3,776,000 in cash. The final purchase price allocation, based upon the fair value of these assetsnet cash, with $3,237,000 paid at closing and liabilities determined using the income approach, included accounts receivable of $499,000, other receivable of $178,000, inventory of $421,000 prepaid assets of $48,000, property and equipment of $159,000, current liabilities of $155,000,non-current liabilities of $780,000, intangible assets of $2,090,000 (with an estimated life of5-15 years) and the remainder$540,000 payable to goodwill(non-deductible for tax purposes). These values are Level 3 fair value measurements. This business has been relocated to Lansing, Michigan and integrated with the Company’s operations there, reporting within the Food Safety segment.

On December 8, 2014, the Company acquired the food safety and veterinary genomic assets of its Chinese distributor Beijing Anapure BioScientific Co., Ltd. Consideration for the purchase was $2,040,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $525,000, property and equipment of $64,000, intangible assets of $422,000 (with an estimated life of5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business has been integrated into the Company’s subsidiary in China and reports within the Food Safety segment.

Fiscal 2016

On June 1, 2015, the Company acquired the assets of Sterling Test House, a commercial food testing laboratory based in India.

Consideration for the purchase was $1,118,000 in cash and approximately $102,000 of a contingent consideration liability, due in installments on the first two anniversary dates, based on an excess sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $43,000, inventory of

$14,000, property and equipment of $141,000, contingent consideration accrual of $102,000, intangible assets of $345,000 (with an estimated life of5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Food Safety segment. In July 2016, the Company paid the former owner $70,000 for contingent consideration based on the achievement of sales targets, and reduced the recorded liability by a corresponding amount. In May 2016, the Company revised the remaining contingent consideration accrual to Other Income because sales targets for the applicable periods were not achieved.

On August 26, 2015, the Company acquired all of the stock of Lab M Holdings, a developer, manufacturer and supplier of microbiological culture media and diagnostic systems located in the United Kingdom. Consideration for the purchase was $12,436,000 in cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included cash of $285,000, accounts receivable of $975,000, inventory of $1,169,000, property and equipment of $3,337,000, other current assets of $309,000, current liabilities of $948,000,non-current deferred tax liability of $784,000, intangible assets of $3,611,000 (with an estimated life of5-15 years) and the remainder to goodwill(non-deductible for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and reports within the Food Safety segment.

On December 22, 2015, the Company acquired the rodenticide assets of Virbac Corporation, the North American affiliate of the France-based Virbac group, a global animal health company. The acquired assets include a rodenticide active ingredient that complements Neogen’s existing active ingredients, and more than 40 regulatory approvals for a variety of formulations in the United States, Canada and Mexico. The acquired assets also include a large retail and OEM customer base. Consideration for the purchase was $3,525,000 in cashJanuary 1, 2022, and up to $300,000 of contingent consideration. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $317,000, property and equipment of $60,000, current liabilities of $300,000, intangible assets of $1,759,000 (with an estimated life of5-15 years),non-amortizable trademarks of $200,000 and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The products are manufactured at the Company’s production facility in Randolph, Wisconsin, and report within the Animal Safety segment. In fiscal 2016, the Company paid the former owner $300,000$979,000 of contingent consideration, payable in one year, based on the achievement of specific objectives, and reduced the recorded liability by a corresponding amount.

On April 26, 2016, the Company acquired the stock of Deoxi Biotecnologia Ltda., an animal genomics laboratory located in Aracatuba, Brazil. This acquisition is intended to help accelerate the growth of Neogen’s animal genomics services in Brazil. Consideration for the purchase was $1,549,000 in cash and up to $2,552,000 of contingent consideration, due at the end of each of the first two years, based onupon an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $132,000,$603,000, inventory of $89,000,$446,000, machinery and equipment of $36,000, other current assets of $9,000, property and equipment$221,000, accounts payable of $232,000,$383,000, other current liabilities of $266,000,$312,000, contingent consideration accrual of $453,000,$640,000,
non-current
deferred tax liabilityliabilities of $184,000 non-amortizable trademarks of $193,000,$441,000, intangible assets of $350,000$1,471,000 (with an estimated life of5-10 years) and the remainder to goodwill (deductible
(non-deductible
for tax purposes). These values are Level 3 fair value measurements. This business continues to operate in its current location and is managed by Neogen do Brasil, reporting within the Food Safety segment. In June 2017, the Company paidFebruary 2021, the former owners $393,000 in owner was paid $530,000 of
contingent consideration based on the achievement of sales targets, and charged $14,000 totargets;

F-20

the remaining $110,000 accrued but not earned was recorded as a gain in Other Income; $60,000 remains accrued for contingent consideration atIncome in the endthird quarter of
 fiscal 2021. In January 2022
,
 the former owner was paid the remaining $540,000 of the second year.

purchase price. This operation continues to operate in Buenos Aires, Argentina, reporting within the Food Safety segment. It is managed through Neogen’s Latin America operation.

On MayJanuary 1, 2016,2020, the Company acquired all of the stock of Preserve International and its sister company, Tetradyne LLC, manufacturers and marketersProductos Quimicos Magiar, a distributor of cleaners, disinfectants and associatedNeogen’s Food Safety products tofor the swine, poultry, food processing and dairy markets. Preserve and Tetradyne have manufacturing locationspast 20 years, located in Memphis, Tennessee and Turlock, California.Uruguay. This acquisition gives Neogen a direct sales presence in Uruguay. Consideration for the purchase was $24,245,000$1,488,000 in net cash, with $1,278,000 paid at closing and $210,000 payable to the former owner on January 1, 2022, and up to $241,000 in contingent consideration, payable in one year, based upon an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $280,000, inventory of $174,000, machinery and equipment of $16,000, other current assets of $68,000, accounts payable of $204,000, other current liabilities of $11,000, contingent consideration accrual of $159,000, non-current deferred tax liabilities of $99,000, intangible assets of $398,000 (with an estimated life of 5-10 years) and the remainder to goodwill (non-deductible for tax purposes). These values are Level 3 fair value measurements. In February 2021, the former owner was paid $158,000 of contingent consideration based on the achievement of sales targets; the remaining $1,000 accrued but not earned was recorded as a gain in Other Income in the third quarter of fiscal 2021.
In January 2022,
 the former owner was paid $184,000, after deducting $26,000 from the final payment for uncollectable accounts receivable balances. This operation continues to operate in Montevideo, Uruguay, reporting within the Food Safety segment. It is managed through Neogen’s Latin America operation.
On January 9, 2020, the Company acquired all of the stock of Diessechem Srl, a distributor of food and feed diagnostics for the past 27 years, located in Italy. This acquisition gives Neogen a direct sales presence in Italy. Consideration for the purchase was $3,455,000 in net cash. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,629,000,$780,000, inventory of $1,964,000,$5,000, other current assets of $269,000, land, property and equipment$160,000, accounts payable of $1,625,000,$140,000, other current liabilities of $987,000,$305,000, non-current deferred tax liabilities of $660,000,$294,000, intangible assets of $11,950,000$1,225,000 (with an estimated life of5-15 5-10 years),non-amortizable trademarks of $2,600,000, and the remainder to goodwill (partially deductible(non-deductible for tax purposes). These values are Level 3 fair value measurements.
This businessoperation continues to operate in its current locations and reportsMilan, Italy, reporting within the AnimalFood Safety segment.

Fiscal 2017

It is managed through Neogen’s Scotland operation.

On December 1, 2016,January 31, 2020, the Company acquired all of the stock of Quat-Chem Ltd.,Abtek Biologicals Limited, a chemical company that manufactures biosecurity products, based in Rochdale, England.manufacturer and supplier of culture media supplements and microbiology technologies. This acquisition enhances the Company’s culture media product line offering for the worldwide industrial microbiology markets. Consideration for the purchase was $21,606,000$1,401,000 in net cash, with $1,282,000 paid at closing and up$119,000 payable to $3,778,000 of contingent consideration, due at the end of each of the first two years, basedformer owner on an excess net sales formula.January 31, 2021. The preliminaryfinal purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $4,684,000,$135,000, inventory of $1,243,000, land, property$207,000, machinery and equipment of $2,715,000,$105,000, prepayments of $6,000, accounts payable of $2,197,000, deferred tax liability of $1,133,000, contingent consideration accrual of $1,105,000,$118,000, other current liabilities of $604,000,non-amortizable$34,000, non-current deferred tax liabilities of $92,000, intangible assets of $1,637,000, intangible assets of $5,682,000$484,000 (with an estimated life of5-15 5-10 years) and the remainder to goodwill(non-deductible (non-deductible for tax purposes). These values are Level 3 fair value measurements. The final $119,000 owed was paid to the former owner in January 2021.
This manufacturing operation continues to operate in Liverpool, England, reporting within the Food Safety segment. It is managed through Neogen’s Scotland operation.
On February 28, 2020, the Company acquired the assets of Cell BioSciences, an Australian distributor of food safety and industrial microbiology products. This acquisition gives Neogen a direct sales presence across Australasia for its entire product portfolio. Consideration for the purchase was $3,768,000 in cash, with $3,596,000 paid at closing and $172,000 payable in one year. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $420,000, unearned revenue liability of $13,000, intangible assets of $1,338,000 (with an estimated life of 3 to 10 years) and the remainder to goodwill (non-deductible for tax purposes). These values are Level 3 fair value measurements. The final $172,000 owed was paid to the former owner in March 2021. The business operates in Gatton, Australia, reporting within the Australian operations in the Animal Safety segment.
On March 26, 2020, the Company acquired the assets of Chile-based Magiar Chilena, a distributor of food, animal and plant diagnostics, including Neogen products. This acquisition gives Neogen a direct sales presence in Chile. Consideration for the purchase was $400,000 in cash, with $350,000 paid at closing and $50,000 payable to the former owner on March 26, 2021. The final purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included inventory of $164,000, machinery and equipment of $53,000, and intangible assets of $183,000 (with an estimated life of 5-10 years).
In April 2021, the former owner was paid $33,000, after deducting $17,000 from the final payment for inventory adjustments. The business continues to operate in its current location and is managed by Neogen Europe,Santiago, Chile, reporting within the Food Safety segment.

It is managed through Neogen’s Latin America operation.

F-21

Fiscal 2021
On December 27, 2016,July 31, 2020, the Company acquired the stock of Rogama Industria e Comercio, Ltda., a company that developsU.S. (including territories) rights to Elanco’s StandGuard Pour-on for horn fly and manufactures rodenticideslice control in beef cattle, and insecticides, based near Sao Paulo, Brazil.related assets. This product line fits in well with Neogen’s existing agricultural insecticide portfolio and organizational capabilities. Consideration for the purchase was $12,423,000$2,351,000 in cash, all paid at closing. The final purchase price allocation, based upon the fair value of these assets determined using the income approach, included inventory of $51,000 and intangible assets of $2,300,000 (with an estimated life of 15 years). This product line is currently being toll manufactured for the Company but is eventually expected to be manufactured at Neogen’s operation in Iowa; the sales are reported within the Animal Safety segment.
On December 30, 2020, the Company acquired all of the stock of Megazyme, Ltd, an Ireland-based company, and its wholly-owned subsidiaries, U.S.-based Megazyme, Inc. and Ireland-based Megazyme IP. Megazyme is a manufacturer and supplier of diagnostic assay kits and enzymes to measure dietary fiber, complex carbohydrates and enzymes in food and beverages as well as animal feeds. This acquisition will allow Neogen to expand its commercial relationships across food, feed and beverage companies, and provide additional food quality diagnostic products to commercial labs and food science research institutions. Consideration for the purchase was net cash of $39.8 million paid at closing, $8.6 million of cash placed in escrow payable to the former owner in two installments in two and four years, $4.9 million of stock issued at closing, and up to $2,069,000$2.5 million of contingent consideration, due atpayable in two installments over the end of each of the first two years,next year, based onupon an excess net sales formula. The
final
purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,376,000, inventory of $5,595,000, net property, plant and equipment of $12,599,000, prepayments of $69,000, accounts payable of $4,000, other current liabilities of $1,815,000, contingent consideration accrual of $2,458,000, non-current liabilities of $319,000, non-current deferred tax liabilities of $3,306,000, intangible assets of $22,945,000 (with an estimated life of 15-20 years) and the remainder to goodwill (non-deductible for tax purposes). These values are Level 3 fair value measurements. In February 2021, the former owner was paid $1,229,000 for the first installment of contingent consideration, based upon the achievement of sales
targets. In January 2022, the former owner was paid $1,120,000 for the second installment of contingent consideration, also based upon the achievement of sales targets, less a deduction of $120,000 related to a prior period tax adjustment. The Irish companies continue to operate in Bray, Ireland, reporting within the Food Safety segment and are managed through Neogen’s Scotland operation. The Company’s U.S. business is managed by our Lansing-based Food Safety team.
Fiscal 2022
On September 17, 2021, the Company acquired
all of
the stock of CAPInnoVet, Inc., a companion animal health business that provides pet medications to the veterinary market. This acquisition provides entry into the retail parasiticide market and enhances the Company’s presence in companion animal markets. Consideration for the purchase was net cash of $17.9 million paid at closing, including $150,000 of cash placed in escrow payable to the former owners in twelve months. There is also the potential for performance milestone payments to the former owners of up to $6.5 million and the Company could incur up to $14.5 million in future royalty payments. The preliminary purchase allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $308,000, inventory of $531,000, prepayments of $296,000, accounts payable of $120,000, other current liabilities of $84,000, non-current liabilities of $6.5 million
 (contingent consideration accrual calculated using a Monte Carlo simulation utilizing inputs
such as probability and timing of milestone achievements, revenue forecasts
and volatility, and estimated discount rates relating to estimated future cash flows of the business),
intangible assets of $19.2 million (with an estimated life of 15-20 years)
and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. The business is operated from our location in Lexington, KY, reporting within the Animal Safety segment. 
On November 30, 2021, the Company acquired all of the stock of Delf (U.K.) Ltd., a United Kingdom-based manufacturer and supplier of animal hygiene and industrial cleaning products, and Abbott Analytical Ltd., a related service provider. This acquisition will expand the Company’s line of dairy hygiene products and will enhance our cleaner and disinfectant product portfolio. Consideration for the purchase was net cash o
f $9.5 million
paid
at closing, including $722,000 of cash placed in escrow payable to the former owner in one year. The preliminary purchase price allocation, based upon
the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $1,863,000, $1,059,000,
inventory of $1,026,000,$972,000,
net property, plant and equipment of $1,840,000, $152,000, prepayments of $31,000, accounts payable of $497,000, other
current liabilities of $2,177,000, contingent consideration accrual of $430,000,$378,000, non-current
deferred tax liabilityliabilities of $1,307,000,non-amortizable$780,000, intangible assets of $591,000, intangible assets of $3,252,000$3.1 million (with an estimated life of 10-15
years) and the remainder to goodwill
(non-deductible for tax purposes). These values are Level 3 fair value measurements. The companies continue
to operate in Liverpool, England,
reporting within the Food Safety segment and are managed through Neogen’s Scotland operation. 
F-22

On December 9, 2021, the Company acquired
all of
the stock of Genetic Veterinary Sciences, Inc., a companion animal genetic testing business providing genetic information for dogs, cats and birds to animal owners, breeders and veterinarians. This acquisition will further expand the Company’s presence in the companion animal market. Consideration for the purchase was $11.4 million in net cash. The preliminary purchase price allocation, based upon the fair value of these assets and liabilities determined using the income approach, included accounts receivable of $38,000, net inventory of $292,000, net property, plant and equipment of $399,000, prepayments of $54,000, accounts payable of $325,000, unearned revenue of $1.9 million, other current liabilities of $321,000, intangible assets of $5.5 million (with an estimated life of 5-15
years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This
The business continues to operate in its current locationSpokane, Washington, reporting within the Animal Safety segment.
Subsequent to the end of the fiscal year, on July 1, 2022, Neogen acquired all of the stock of
Thai-Neo
Biotech Co., Ltd., a longstanding distributor of Neogen’s food safety products to Thailand and is managed bySoutheast Asia. This acquisition gives Neogen do Brasil,a direct sales presence in Thailand. Consideration for the purchase was
$1,558,000, with $1,324,000 paid at closing and $234,000 payable on October 1, 2023. Due to the timing of the transaction, the details of the preliminary purchase price allocation are not available. The business continues to operate in Bangkok, Thailand, reporting within the Food Safety segment.

4.Long-Term Debt

For the acquisitions listed above, revenues in the aggregate were $38.0 million, $27.0 million a
nd $
6.1
million in fiscal years 2022, 2021 and 2020, respectively. Earnings in the aggregate were
$5.4 million, $4.2 million and $520,000
in fiscal years 2022, 2021 and 2020, respectively.
3M Food Safety transaction
On December 13, 2021, Neogen, 3M, and Garden Spinco, a newly formed subsidiary of 3M created to carve out 3M’s Food Safety business, entered into a number of agreements
, including the merger agreement,
pursuant to which, among other things, 3M’s Food Safety business will combine with Neogen in a Reverse Morris Trust transaction, intended to
be tax-efficient to
3M and its shareholders for U.S. federal income tax purposes. Immediately following the transaction, Garden SpinCo stockholders will own, in the aggregate, approximately 50.1% of the issued and outstanding shares of Neogen common stock and
pre-Merger
Neogen shareholders will own, in the aggregate, approximately 49.9% of the issued and outstanding shares of Neogen common stock. The transaction implies an enterprise value for 3M’s Food Safety business of approximately $3.4 billion 
based on Neogen’s stock price at July 22, 2022
,
including $1 billion in new debt to be incurred by 3M’s Food Safety business. 3M’s Food Safety business will fund to 3M consideration valued at approximately $1 billion, subject to closing and other adjustments.
On June 30, 2022, Garden Spinco entered into a credit agreement consisting of a five-year senior secured term loan facility in the amount of $650.0 million and a five-year senior secured revolving facility in the amount of $150.0 million (collectively, the “Credit Facilities”), which, subject to customary closing conditions, will be available in connection with the merger and related transactions. The Credit Facilities, together with the Notes below, when incurred, represent the financing contemplated in connection with the Merger.
In July 2022 Garden SpinCo closed on an offering of $350.0 million aggregate principal amount of 8.625% senior notes due 2030 (the “Notes”) in a private placement at par. The Notes will initially be issued by
Garden
SpinCo to 3M and are expected to be transferred and delivered by 3M to the selling securityholder in the offering, in satisfaction of certain of 3M’s existing debt. SpinCo will not receive any proceeds from the sale of the Notes by the selling securityholder. Prior to the distribution of the shares of SpinCo’s common stock to 3M stockholders, the Notes will be guaranteed on a senior unsecured basis by 3M. Upon consummation of such distribution, 3M will be released from all obligations under its guarantee. Upon the effectiveness of the Merger, the Notes will be guaranteed on a senior unsecured basis by Neogen and certain wholly-owned domestic subsidiaries of Neogen.
The transaction is expected to close by the end of the third calendar quarter in 2022, subject to approval by Neogen shareholders, receipt of required regulatory approvals and the satisfaction of other customary closing conditions.
4. Long-Term Debt
The Company has a financing agreement with a bank providing for ana $15,000,000 unsecured revolving line of credit, which was amended onin the second quarter to extend the expiration to November 30, 2016 to increase the line from $12,000,000 to $15,000,000, and extend the maturity from September 1, 2017 to September 30, 2019.2023. There were nowere0 advances against the line of credit during fiscal years 20162022 and 2017;2021; there was no0 balance outstanding at May 31, 2017.2022. Interest on any borrowings is at LIBOR plus 100 basis points (rate under the
terms of the agreement was 2.04% 2.06%
F-23

at
 May 31, 2017)2022). See Note 1, Recent Accounting Pronouncements Not Yet Adopted, for information on reference rate reform. Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of whichEBITDA; the Company believes it was in compliance with these covenants at May 31, 2017.

5.Equity Compensation Plans

Qualified2022.

5. Equity Compensation Plans
Incentive andnon-qualified options to purchase shares of common stock may behave been granted to directors, officers and employees of the CompanyNeogen under the terms of the Company’s stock option plans. These options arewere granted at an exercise price of not less than the fair market value of the stock on the date of grant. Remaining shares available for grant under stock option
share-based compensation
plans were 1,894,000, 2,457,0005,386,000, 6,355,000 and 306,0007,002,000 at May 31, 2017, 20162022, 2021 and 2015,2020, respectively. Options vest ratably over three
three
and five yearfive-year periods and the contractual terms are generally five
five
or ten years.

(options in thousands)  Options   Weighted-Average
Exercise Price
   Weighted-Average
Grant Date Fair  Value
 

Outstanding at May 31, 2014 (577 exercisable)

   1,869    25.69    7.62 

Granted

   536    39.79    11.91 

Exercised

   (380   16.69    5.17 

Forfeited

   (37   33.55    9.45 
  

 

 

     

Outstanding at May 31, 2015 (639 exercisable)

   1,988    31.04    9.20 

Granted

   549    46.98    13.11 

Exercised

   (427   23.47    7.15 

Forfeited

   (29   38.57    11.14 
  

 

 

     

Outstanding at May 31, 2016 (656 exercisable)

   2,081    36.71    10.63 

Granted

   621    54.24    15.86 

Exercised

   (620   30.42    9.03 

Forfeited

   (58   42.72    12.22 
  

 

 

     

Outstanding at May 31, 2017 (496 exercisable)

   2,024    43.84    12.68 
  

 

 

     


       
Weighted-Average
   
Weighted-Average
 
(options in thousands)
  
Options
   
Exercise Price
   
Grant Date Fair Value
 
Outstanding at May 31, 2019 (1,234 exercisable)
   4,770   $24.69   $6.35 
Granted
   1,124    31.96    7.78 
Exercised
   (1,438   20.12    5.53 
Forfeited
   (132   28.72    7.10 
   
 
 
           
Outstanding at May 31, 2020 (972 exercisable)
   4,324    27.98    6.98 
Granted
   403    34.23    7.71 
Exercised
   (1,389   24.38    6.31 
Forfeited
   (381   28.99    7.20 
   
 
 
           
Outstanding at May 31, 2021 (643 exercisable)
   2,957    30.38    7.36 
Granted
   615    36.42    8.49 
Exercised
   (281   22.79    6.29 
Forfeited
   (47   33.93    8.02 
   
 
 
           
Outstanding at May 31, 2022 (1,191 exercisable)
   3,244    32.13    7.66 
   
 
 
           
The following is a summary of stock options outstanding at May 31, 2017:

(options in thousands)        
   Options Outstanding   Options Exercisable 

Range of Exercise Price

  Number   Average
Contractual Life
(in years)
   Weighted-Average
Exercise Price
   Number   Weighted-Average
Exercise Price
 

$  11.02 - $36.26

   491    1.8   $31.22    268   $29.16 

$  36.27 - $40.87

   382    2.8    39.57    113    39.54 

$  40.88 - $49.68

   536    4.1    46.52    115    45.12 

$  49.69 - $54.55

   576    4.7    53.94    —      —   

$  54.56 - $65.71

   39    7.7    58.74    —      —   
  

 

 

       

 

 

   
   2,024    3.5    43.84    496    35.23 

2022:


   
Options Outstanding
   
Options Exercisable
 
       
Average
             
(options in thousands)
      
Contractual Life
   
Weighted-Average
       
Weighted-Average
 
Range of Exercise Price
  
Number
   
(in years)
   
Exercise Price
   
Number
   
Exercise Price
 
$10.75 - $20.00
   49    2.3   $15.43    49   $15.43 
$20.01 - $28.99
   344    3.8    26.80    83    23.08 
$29.00 - $30.99
   493    0.9    30.16    332    30.13 
$31.00- $31.99
   1,509    2.0    31.70    581    31.64 
$32.00- $42.45
   849    3.7    37.16    146    33.88 
   
 
 
             
 
 
      
    3,244    2.5    32.13    1,191    30.24 
The weighted average exercise price of shares subject to options that were exercisable at May 31, 20172021 and 20162020 was $35.23$28.10 and $29.69,$24.47, respectively.

F-24

Compensation expense related to share-based awards was $5,261,000, $5,468,000 $
7,154,000
, $
6,437,000
and $4,450,000 $
6,468,000
in fiscal years 2017, 2016
2022
,
2021
and 2015,
2020
, respectively. Remaining compensation cost to be expensed in future periods fornon-vested options was $10,999,000 $
10,927,000
at May 
31 2017,
,
2022
, with a weighted average expense recognition period of 3.3
2.9
years.

   
Year ended May 31
 
(in thousands)
  
2022
   
2021
   
2020
 
Aggregate intrinsic value of options outstanding
  $850   $46,667   $32,988 
Aggregate intrinsic value of options exercisable
  $817   $11,617   $10,814 
Aggregate intrinsic value of options exerised
  $5,507   $22,349   $19,597 
The aggregate intrinsic value of options outstandingCompany grants restricted stock units (RSUs) to directors, officers and options exercisable was $39,388,000 and $13,929,000, respectively, at May 31, 2017, $26,344,000 and $12,912,000 respectively, at May 31, 2016 and $31,204,000 and $14,201,000 respectively, at May 31, 2015. The aggregate intrinsic value of options exercised during the year was $18,067,000 in fiscal 2017, $12,980,000 in fiscal 2016 and $10,690,000 in fiscal 2015.

Common stock totaling 8,725 of the 337,500 originally authorized shares are reserved for issuanceemployees under the terms of the 2002 Employee Stock Purchase Plan. An additional 375,000 shares 2018 Omnibus Incentive Plan, which vest ratably over three and five year periods.

The
RSUs
are also reserved for issuance under
 expensed straight-line over the termsremaining weighted-average period of the 2011 Employee Stock Purchase Plan.
4.0
years. On May 31,
2022
,
there was $6,866,000 in unamortized compensation cost related to non-vested RSUs.
(RSU Grants in thousands)
  
RSUs
   
Weighted Average
Grant Date Fair
Value
 
Outstanding at May 31, 2020
   —     $—   
Granted
   122    34.21 
Released
   —      —   
Forfeited
   (1   34.21 
   
 
 
      
Outstanding at May 31, 2021
   121    34.21 
Granted
   169    37.28 
Released
   (25   34.24 
Forfeited
   (8   36.80 
   
 
 
      
Outstanding at May 31, 2022
   257    36.14 
The plans giveCompany offers eligible employees the option to purchase common stock at a 5% discount to the lower of the market value of the stock at the beginning or end of each participation period;period under the terms of the 2011 Employee Stock Purchase Plan; the discount is recorded in general and administrative expense. Total individual purchases in any year are limited to 10% of compensation. Shares purchased by employees through this program were 18,715, 18,277 and 19,59243,456 in fiscal years 2017, 20162022, 38,406 in fiscal 2021 and 2015, respectively.

6.Income Taxes

43,156 in fiscal 2020. As of May 31, 2022, common stock totaling 605,774 of the 1,425,000 authorized shares remained reserved for issuance under the plan.


6. Income Taxes
Income before income taxes by source consists of the following amounts:

   Year ended May 31 
(in thousands)  2017   2016   2015 

U.S.

  $55,171   $50,662   $45,156 

Foreign

   11,502    4,851    6,920 
  

 

 

   

 

 

   

 

 

 
  $66,673   $55,513   $52,076 
  

 

 

   

 

 

   

 

 

 


   
Year ended May 31
 
(in thousands)
  
2022
   
2021
   
2020
 
U.S.
  
$

38,554   $55,753   $62,329 
Foreign
   21,653    19,515    9,976 
   
 
 
   
 
 
   
 
 
 
   $60,207   $75,268   $72,305 
   
 
 
   
 
 
   
 
 
 
The provision for income taxes consistedconsists of the following:

   Year ended May 31 
(in thousands)  2017   2016   2015 

Current:

      

U.S. Taxes

  $20,259   $14,630   $15,269 

Foreign

   2,514    1,756    1,364 

Deferred

   (73   2,589    1,867 
  

 

 

   

 

 

   

 

 

 
  $22,700   $18,975   $18,500 
  

 

 

   

 

 

   

 

 

 


   
Year ended May 31
 
(in thousands)
  
2022
   
2021
   
2020
 
Current
               
Domestic
               
Federal
  
$

8,579   $6,981   $6,886 
Change in tax-related uncertainties
   3    (75   269 
State
   2,406    2,147    1,262 
Foreign
   5,140    4,875    2,475 
Total Current   16,128    13,928    10,892 
Deferred
               
Domestic
               
Federal
   (3,721)   479    1,964 
State
   (356)   44    195 
Foreign
   (151)   (65   (221
Total Deferred   (4,228   458    1,938 
   
 
 
   
 
 
   
 
 
 
Provision for Income Taxes
  $11,900   $14,386   $12,830 
   
 
 
   
 
 
   
 
 
 
F-25

Table of Contents
The reconciliation of income taxes computed at the U.S. federal statutory tax rate to income tax expense is as follows:

   Year ended May 31 
(in thousands)  2017   2016   2015 

Tax at U.S. statutory rate

  $23,336   $19,429   $18,227 

Section 199 domestic production deduction

   (1,057   (1,143   (1,067

Foreign rate differential

   (1,247   (699   (949

Subpart F income

   996    1,049    1,396 

Tax credits and other

   (300   337    39 

Provision for state income taxes, net of federal benefit

   972    779    854 

Amended U.S. Federal tax returns FY12, FY13 & FY14

   —      (777   —   
  

 

 

   

 

 

   

 

 

 
  $22,700   $18,975   $18,500 
  

 

 

   

 

 

   

 

 

 


   
Year ended May 31
 
(in thousands)
  
2022
   
2021
   
2020
 
Tax at U.S. statutory rate
  $12,643   $15,806   $15,184 
Permanent differences
   67    292    360 
Global intangible low-taxed income (GILTI)
   1,501    2,064    438 
Foreign derived intangible income deduction (FDII)
   (1,308)
 
   (1,210   (1,120
Foreign rate differential
   215    669    (182
Subpart F income
   397    628    634 
Tax benefits on stock-based compensation
   (462)   (2,651   (1,998
Provision for state income taxes, net of federal benefit
   1,517    1,601    1,412 
Tax Credits
   (2,527)   (3,298   (1,417
Impact of tax rate changes   583    —      —   
Other
   (726)   485    (481
   
 
 
   
 
 
   
 
 
 
Income Tax Expense
  $11,900   $14,386   $12,830 
   
 
 
   
 
 
   
 
 
 
Foreign tax credits, primarily offsetting taxes associated with Subpart F and GILTI income, were $1,747,000, $2,753,000 and $945,000 in fiscal years 2022, 2021 and 2020, respectively. The Company’s research and development credits were $780,000, $545,000 and $472,000 in fiscal years 2022, 2021 and 2020, respectively.
Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’sour deferred income tax liabilities and assets are as follows:

   Year ended May 31 
(in thousands)  2017   2016 

Deferred income tax liabilities

    

Indefinite and long-lived assets

  $(23,177  $(19,296

Prepaid expenses

   (640   (824

Brazil valuation allowance

   —      (542
  

 

 

   

 

 

 
   (23,817   (20,662

Deferred income tax assets

    

Stock Options

   2,604    2,786 

Inventories and accounts receivable

   2,603    2,076 

Tax loss carryforwards

   436    813 

Accrued expenses and other

   1,126    229 
  

 

 

   

 

 

 
   6,769    5,904 
  

 

 

   

 

 

 

Net deferred income tax liabilities

  $(17,048  $(14,758
  

 

 

   

 

 

 

   
Year ended May 31
 
(
i
n thousands)
  
2022
   
2021
 
Deferred income tax liabilities
          
Indefinite and long-lived assets
  $(22,709)  $(25,072
Right of use asset   (344   (213
Prepaid expenses
   (884)   (721
   
 
 
   
 
 
 
    (23,937)   (26,006
Deferred income tax assets
          
Stock options
   2,085    1,106 
Inventories and accounts receivable
   2,044    2,081 
Tax loss carryforwards
   561    662 
Lease
liability
   382    211 
Accrued expenses and other
   2,422    570 
Valuation allowance
   (568)   (541
   
 
 
   
 
 
 
    6,926    4,089 
   
 
 
   
 
 
 
Net deferred income tax liabilities
  $(17,011)  $(21,917
   
 
 
   
 
 
 

F-26

Table of Contents
The Company had no accrualhas the following net operating loss carryforwards:

(
i
n thousands)
  
As of
May 31, 2022
   
Expiry
U.S.
  $281   2037
Foreign
   2,831   2024 to 2032
   
 
 
    
   $3,112    
   
 
 
    
Valuation allowances against certain deferred tax assets are established based on management’s determination of a more likely than not standard that the tax benefits will not be realized.
We are subject to income taxes in the U.S. (federal and state) and in numerous foreign jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate. The
Company’s
policy is to recognize both accrued interest expense and penalties related to unrecognized tax benefits in income tax expense. The amount of interest and penalties included in the unrecognized tax benefits reserve was $69,321 at May 31, 2022 and $64,518 at May 31, 2021. Of the total unrecognized tax benefits at both May 31, 20172022 and 2016. Should the accrualMay 31, 2021, $808,186 and $805,316 respectively, comprise unrecognized tax positions that would, if recognized, affect our effective tax rate.
The reconciliation of any interest or penalties relative toour unrecognized tax benefits be necessary, such accruals will be reflected within income tax accounts. is as follows:

   
Year ended May 31
 
(in thousands)
  
2022
   
2021
   
2020
 
Beginning balance
  
$

 764   $762   $ 541 
Increase/(decrease) related to prior periods
   (75)   (182   48 
Increase related to current period
   147    184    173 
Lapses of applicable statute of limitations   (95   —      —   
   
 
 
   
 
 
   
 
 
 
Ending balance
  $741   $764   $762 
   
 
 
   
 
 
   
 
 
 
The Company is under auditno longer subject to examination by the Internal Revenue Service for tax years 2014-2016.

7.Commitments and Contingencies

fiscal year 201

8
and preceding years.
F-27

7. Commitments and Contingencies
The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for
related costs when such costs are determined to be probable and estimable. The Company expensescurrently utilizes a pump and treat remediation strategy,
which includes semi-annual monitoring and reporting, consulting, and maintenance of monitoring wells. We expense these
annual costs of remediation,
which have ranged from $38,000$63,000 to $57,000 $131,000
per year over the past five years. from fiscal 2018 to fiscal 2021.
The Company’s estimated remaining liability for these costs iswas $916,000 at both May 31, 20172022 and 2016,2021, measured on an undiscounted basis over an estimated period of 15 years; $54,000
years. In fiscal 2019, the Company performed an updated Corrective Measures Study on the site, per a request from the Wisconsin Department of Natural Resources (WDNR), and is currently in discussion with the WDNR regarding potential alternative remediation strategies going forward. The Company believes that the current pump and treat strategy is appropriate for the site. However, the Company has agreed to a pilot study in which chemical reagents are injected into the ground in an attempt to reduce
on-site
contamination; costs incurred in fiscal 2022 
totaled $305,000, which included the cost of this study
.
At this time, the outcome of the pilot study is unknown, but a change in the current remediation strategy, depending on the alternative selected, could result in an increase in future costs and ultimately, an increase in the currently recorded liability, with an offsetting charge to operations in the period recorded. The Company has recorded
 $100,000 as a current liability, and the remaining $816,000 is recorded within current liabilities and the remainder is recorded withinin othernon-current liabilities in the consolidated balance sheet.

sheet

 as of May
31
, 2022.
On March 6, 2020, the Company received an administrative subpoena from the U.S. Treasury Department’s Office of Foreign Assets Control (OFAC) regarding activities or transactions involving parties located in Iran. The Company subsequently conducted an internal
investigation under the direction of outside legal counsel and disclosed information concerning certain genomic testing services provided to an unrelated U.S.-based party engaged in veterinary activities involving an Iranian party. The Company continues to cooperate with OFAC’s investigation and is currently examining whether certain of these activities may be eligible for OFAC General Licenses authorizing agricultural and veterinary activities.
In addition to responding to the administrative subpoena, the Company has implemented additional compliance measures to prevent inadvertent dealings with restricted countries or parties. These measures further enhance the Company’s international trade compliance program, which is designed to assure that the Company does not conduct business directly or indirectly with any countries or parties subject to economic sanctions and export control laws of the U.S. and other applicable jurisdictions. Although it is too early to predict what action, if any, that OFAC will take, the Company does not currently have any reason to believe that OFAC’s pending investigation will have a material impact on its operations, the results of operations for any future period, or its overall financial condition. In fiscal 2020, the Company took a charge to expense and recorded a reserve of
$600,000 to provide for potential fines or penalties on this matter. At this time, the Company believes that it is adequately reserved for this issue.

The Company has agreements with unrelated third parties that provide for the payment of license fees and royalties on the sale of certain products. Royalty expense, recorded in sales and marketing, under the terms of these agreements was $2,659,000, $1,969,000$1,999,000, $2,129,000 and $2,189,000$2,524,000 for fiscal years 2017, 20162022, 2021 and 2015,2020, respectively. Some of these agreements provide for guaranteed minimum royalty payments to be paid each fiscal year by the Company for certain technologies. Future minimum royalty payments are as follows: 2018—2023—$625,000, 2019—100,000, 2024—$659,000, 2020—100,000, 2025—$666,000, 2021—100,000, 2026—$674,00075,000 and 2022—2027—$597,000.

75,000.

The Company leases officehas unconditional purchase obligations consisting primarily of purchase orders for future inventory and manufacturing facilities undernon-cancelable operating leases. Rent expensecapital equipment purchases, totaling $85.8 million, of which $83.1 million is scheduled to be spent within the next 12 months, and $2.7 million is scheduled to be spent between
one to three
 years in the future.
In conjunction with the 3M Food Safety transaction announced on December 13, 2021, Neogen has entered into a credit agreement with JPMorgan
Chase
for fiscal years 2017, 2016$650 million in term loans, and 2015 was $729,000, $662,000has incurred $9.8 million in debt issuance costs, which will be paid at close, and $736,000, respectively. Future fiscal year minimum rental payments for these leasesamortized over their remaining termsthe five-year
term of the loans.
The loans are as follows: 2018—$591,000, 2019—$292,000, 2020—$88,000, 2021 – $87,000 and 2022 later—$91,000.

expected to be funded in the third calendar quarter of 2022. Interest on the loans will be at the Secured Overnight
Financing Rate (SOFR) plus 225 basis points.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, shouldare not expected to have a material effect on its future results of operations or financial position.

8.Defined Contribution Benefit Plan

8. Defined Contribution Benefit Plan
The Company maintains a defined contribution 401(k) benefit plan covering substantially all domestic employees. Employees are permitted to defer compensation up to IRS limits, with the CompanyNeogen matching 100% of the first 3% of deferred compensation and 50% of the next 2% deferred.of deferred compensation. In the first quarter of fiscal 2021, the Company suspended the 401(k) match, while we assessed the potential financial impact of
COVID-19 on the Company.
The Company’smatch was restored in September 2020. Neogen’s expense under this plan was $1,259,000, $1,188,000,$1,834,000, $1,204,000, and $1,051,000
$1,535,000
in fiscal years 2017, 20162022, 2021 and 2015,2020, respectively.

9.Segment Information

9. Derivatives
We operate on a global basis and are exposed to the risk that our financial condition, results of operations and cash flows could be adversely affected by changes in foreign currency exchange rates. To reduce the potential effects of foreign currency exchange rate movements on net earnings, we enter into derivative financial instruments in the form of foreign currency exchange forward contracts with major financial institutions.
F-28

Derivatives Not Designated as Hedging Instruments
We forecast our net exposure in various receivables and payables to fluctuations in the value of various currencies, and we enter into approximately 11 foreign currency forward contracts each month to mitigate that exposure. These contracts are recorded net at fair value on our consolidated balance sheets
,
classified as Level 2 in the fair value hierarchy; gains and losses from these contracts were recognized in other income in our consolidated statements of income. The notional amount of foreign currency forward contracts was $4,424,000 and $19,984,000 as of May 31, 2022 and 2021, respectively.
(
i
n thousands)
           
Fair Value of Derivatives Not Designated as Hedging Instruments
  
Balance Sheet Location
  
May 31, 2022
   
May 31, 2021
 
Foreign currency forward contracts, net
  Prepaid and Other  $(78  $515 
The location and amount of gains from derivatives not designated as hedging instruments in our consolidated statements of income were as follows:
(
i
n thousands)
     
Year ended May 31,
 
Derivatives Not Designated as Hedging Instruments
  
Location in statements of income
  
2022
   
2021
   
2020
 
Foreign currency forward contracts
  Other income (expense)  $1,218   $2,651   $1,111 
10. Related Party Transactions
The Company has two partnered with Corvium to develop a
software-as-a-service
offering for use in conjunction with several food safety product lines. Ralph Rodriguez is a member of Neogen’s Board of Directors and also serves on the Board of Directors at Corvium. Neogen made payments to Corvium of $1,573,000, $788,000 and $1,833,000 in fiscal years 2022, 2021 and 2020, respectively.
11. Segment Information
The Company has
2
reportable segments: Food Safety and Animal Safety. The Food Safety segment is primarily engaged in the development, production and marketing of diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the development, production and marketing of products dedicated to animal safety, including a complete line of consumable products marketed to veterinarians and animal health product distributors; this segment also provides genomic identification and related interpretive bioinformatic services. Additionally, the Animal Safety segment produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents, insects and disease in and around agricultural, food production and other facilities.

Neogen’s international operations in the United Kingdom, Mexico, Guatemala, Brazil, Argentina, Uruguay, Chile, China and India originally focused on the Company’s Food Safetysales and marketing of our food safety products, and each of these units reports through the Food Safety segment. In recent years, these operations have expanded to offer the Company’s complete line of products and services, including those usually associated with the Animal Safety segment such as cleaners, disinfectants, rodenticides, insecticides, veterinary instruments and genomics services. These additional products and services are managed and directed by existing management and are reported through the Food Safety segment.

Neogen’s operation in Australia originally focused on providing genomics services and sales of animal safety products and reports through the Animal Safety segment. With the acquisition of Cell BioSciences in February 2020, this operation has expanded to offer our complete line of products and services, including those usually associated with the Food Safety segment. These additional products are managed and directed by existing management at Neogen Australasia and report through the Animal Safety segment.
The accounting policies of each of the segments are the same as those described in Note 1.

F-2
9

Table of Contents
Segment information is as follows:

(in thousands)  Food Safety   Animal Safety   Corporate and
Eliminations (1)
  Total 

Fiscal 2017

       

Product revenues to external customers

  $155,795   $150,717   $—    $306,512 

Service revenues to external customers

   15,530    39,552    —     55,082 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total revenues to external customers

   171,325    190,269    —     361,594 

Operating income (loss)

   33,971    34,841    (3,867  64,945 

Depreciation and amortization

   7,088    7,603    —     14,691 

Total Assets

   190,895    210,927    126,587   528,409 

Expenditures for long-lived assets

   10,332    4,246    —     14,578 

Fiscal 2016

       

Product revenues to external customers

  $133,743   $139,827   $—    $273,570 

Service revenues to external customers

   12,678    35,027    —     47,705 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total revenues to external customers

   146,421    174,854    —     321,275 

Operating income (loss)

   28,984    30,978    (3,576  56,386 

Depreciation and amortization

   5,609    6,572    —     12,181 

Total Assets

   143,303    215,374    91,263   449,940 

Expenditures for long-lived assets

   9,192    5,030    —     14,222 

Fiscal 2015

       

Product revenues to external customers

  $119,990   $123,919   $—    $243,909 

Service revenues to external customers

   11,489    27,676    —     39,165 
  

 

 

   

 

 

   

 

 

  

 

 

 

Total revenues to external customers

   131,479    151,595    —     283,074 

Operating income (loss)

   30,265    26,034    (3,181  53,118 

Depreciation and amortization

   4,620    6,029    —     10,649 

Total Assets

   110,655    179,082    102,444   392,181 

Expenditures for long-lived assets

   4,216    5,403    —     9,619 


(in thousands)
  
Food Safety
   
Animal Safety
   
Corporate and
Eliminations (1)
   
Total
 
Fiscal 2022
                    
Product revenues to external customers
  $231,626   $193,038   $—     $424,664 
Service revenues to external customers
   28,353    74,142    —      102,495 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total revenues to external customers
   259,979    267,180    —      527,159 
Operating income (loss)
   38,581    52,546    (32,509)   58,618 
Depreciation and amortization
   13,386    10,308    —      23,694 
Total assets
   304,461    307,417    381,051    992,929 
Expenditures for long-lived assets
   7,842    16,939    —      24,781 
Fiscal 2021
                    
Product revenues to external customers
  $209,104   $167,198   $—     $376,302 
Service revenues to external customers
   25,140    67,017    —      92,157 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total revenues to external customers
   234,244    234,215    —      468,459 
Operating income (loss)
   33,725    48,685    (8,241   74,169 
Depreciation and amortization
   11,575    9,466    —      21,041 
Total assets
   295,065    244,039    381,088    920,192 
Expenditures for long-lived assets
   13,730    12,982    —      26,712 
Fiscal 2020
                    
Product revenues to external customers
  $189,893   $145,646   $—     $335,539 
Service revenues to external customers
   22,798    59,833    —      82,631 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total revenues to external customers
   212,691    205,479    —      418,170 
Operating income (loss)
   33,526    39,051    (5,054   67,523 
Depreciation and amortization
   10,173    8,223    —      18,396 
Total assets
   222,331    231,178    343,673    797,182 
Expenditures for long-lived assets
   15,867    8,185    —      24,052 
(1)
Includes corporate assets, including cash and cash equivalents, marketable securities, current and deferred tax accounts, and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions andnon-controlling interests.

Revenues to customers located outside the United States amounted to $129,322,000 or 35.8% of consolidated revenues in fiscal 2017, $107,680,000 or 33.5% in fiscal 2016 and $103,867,000 or 36.7% in fiscal 2015 and were derived primarily in various countries throughout Europe, Canada, South and Central America and Asia. No customer represented revenues in excess of 10% of consolidated net sales in any of the three years.

The United States based operations represent 76% offollowing table presents the Company’s long-lived assets asrevenue disaggregated by geographical location:
   
Year ended May 31
 
(in thousands)
  
2022
   
2021
 
Domestic
  $317,820   $285,262 
International
   209,339    183,197 
   
 
 
   
 
 
 
Total revenue
  $527,159   $468,459 
   
 
 
   
 
 
 
F-
30

Table of May 31, 2017 and 89% as May 31, 2016.

10.Stock Repurchase

Contents

1
2
. Stock Repurchases
In December 2008,October 2018, the Company’s Board of Directors authorized a program to purchase, subject to market conditions, up to 1,125,000
 6,000,000 shares of the Company’s common stock. As of May 31, 2017, 112,026 cumulativeIn December 2018, the Company purchased 100,000 shares have been purchasedunder the new program in negotiated and open market transactions for a total price, including commissions, of approximately $923,000. There were no purchases in fiscal years 2017, 2016 or 2015.$3,134,727. Shares purchasedacquired under the program were retired.

11.Summary of Quarterly Data (Unaudited)

   Quarter Ended 
(in thousands, except per share)  August
2016
   November
2016
   February
2017
   May
2017
 

Total Revenue

  $83,645   $90,717   $88,385   $98,847 

Gross Margin

   40,479    43,591    40,880    47,018 

Net income

   9,934    11,171    10,377    12,491 

Net income attributable to Neogen

   9,881    11,151    10,287    12,474 

Basic net income per share

   0.26    0.29    0.27    0.34 

Diluted net income per share

   0.26    0.29    0.27    0.32 
   Quarter Ended 
(in thousands, except per share)  August
2015
   November
2015
   February
2016
   May
2016
 

Total Revenue

  $74,860   $79,610   $76,725   $90,080 

Gross Margin

   37,792    38,224    35,196    41,852 

Net income

   9,289    9,142    8,289    9,818 

Net income attributable to Neogen

   9,323    9,073    8,311    9,857 

Basic net income per share

   0.25    0.24    0.22    0.27 

Diluted net income per share

   0.25    0.24    0.22    0.26 

Quarterly net income per share is based on weighted-average A total of 5,900,000 shares outstanding and potentially dilutiveof common stock optionsremained available for the specific period, andrepurchase under this program as a result, will not necessarily aggregate to total net income per share as computed for the year as disclosed in the consolidated statements of income.

F-21

May 31, 2022.
F-3
1